Ryan White HIV/AIDS Program

Annual Client-Level Data Report

Ryan White HIV/AIDS Program Services Report (RSR) 2014



The Ryan White HIV/AIDS Program Annual Client-Level Data Report is published by the Division of Policy and Data, HIV/AIDS Bureau (HAB), Health Resources and Services Administration (HRSA), U.S. Department of Health and Human Services, Rockville, Maryland.

Data are presented for clients reported to the HRSA/HAB Ryan White Services Report (RSR; non-ADAP) data system for calendar years 2010 through 2014.

The Ryan White HIV/AIDS Program Annual Client-Level Data Report is not copyrighted and may be used and copied without permission. Citation of the source is, however, appreciated.

Suggested citation

Health Resources and Services Administration. *Ryan White HIV/AIDS Program Annual Client-Level Data Report* 2014. http://hab.hrsa.gov/data/servicesdelivered/2014RWHAPDataReport.pdf. Published December 2015. Accessed [date].

Health Resources and Services Administration James Macrae, MA, MPP
HIV/AIDS Bureau, Health Resources and Services Administration
Laura Cheever, MD, ScM
Letitia Robinson, PhD, RN
Antigone Dempsey, MEd
Tracy Matthews, MHA, RN CAPT, USPHS; Deputy Director, Division of Policy and Data
Steven R. Young, MSPH Director, Division of Metropolitan HIV/AIDS Programs
Heather Hauck, MSW, LICSW
Mahyar Mofidi, DMD, PhD
Harold J. Phillips, MRPDirector, Office of HIV Training & Capacity Development Programs

Information about the Ryan White HIV/AIDS Program: http://hab.hrsa.gov/

Educational and technical assistance materials about HIV infection and the Ryan White HIV/AIDS Program: https://careacttarget.org/

Acknowledgments

Publication of this report was made possible by the contributions of the Ryan White HIV/AIDS Program grant recipients and subrecipients that provided RSR data to HRSA.

The following HAB staff contributed to the development of this report: Stacy Cohen, Pamela Klein, Vimal Rao, Samuel Ndubuisi, John Milberg.

CONTENTS

Commer	ntary	5
Technica	al Notes	12
Tables		
1	Ryan White HIV/AIDS Program clients (non-ADAP), by year and selected characteristics, 2010–2014—United States and 3 territories	17
2	Ryan White HIV/AIDS Program clients (non-ADAP), by race/ethnicity and selected characteristics, 2014—United States and 3 territories	19
3	Ryan White HIV/AIDS Program clients (non-ADAP), by gender and selected characteristics, 2014—United States and 3 territories	20
4	Ryan White HIV/AIDS Program clients (non-ADAP), by transmission risk category and selected characteristics, 2014—United States and 3 territories	21
5	Ryan White HIV/AIDS Program clients (non-ADAP), by poverty level and selected characteristics, 2014—United States and 3 territories	22
6	Ryan White HIV/AIDS Program clients (non-ADAP), by housing status and selected characteristics, 2014—United States and 3 territories	24
7	Ryan White HIV/AIDS Program clients (non-ADAP), by health care coverage and selected characteristics, 2014—United States and 3 territories	26
8	Ryan White HIV/AIDS Program clients (non-ADAP), by HHS region and selected characteristics, 2014—United States and 3 territories	27
9	Ryan White HIV/AIDS Program clients (non-ADAP), by state, 2014—United States and 3 territories	29
10	Ryan White HIV/AIDS Program clients (non-ADAP), by race/ethnicity and state, 2014—United States and 3 territories	30
11	Ryan White HIV/AIDS Program clients (non-ADAP), by transmission risk category and state, 2014—United States and 3 territories	32
12a	Retention in care among Ryan White HIV/AIDS Program clients (non-ADAP), by year and selected characteristics, 2010–2014—United States and 3 territories	34
12b	Retention in care among Ryan White HIV/AIDS Program clients (non-ADAP), by year and state, 2010–2014—United States and 3 territories	36
13a	Viral suppression among Ryan White HIV/AIDS Program clients (non-ADAP), by year and selected characteristics, 2010–2014—United States and 3 territories	38
13b	Viral Suppression among Ryan White HIV/AIDS Program clients (non-ADAP), by race/ethnicity and state, 2010–2014—United States and 3 territories	40
14a	Retention in care among women (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2014—United States and 3 territories	42
14b	Viral suppression among women (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2014—United States and 3 territories	44
15a	Retention in care among men (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2014—United States and 3 territories	46

15b	Viral suppression among men (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2014—United States and 3 territories	48
16a	Retention in care among transgender adults and adolescents (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2014—United States and 3 territories	50
16b	Viral suppression among transgender adults and adolescents (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2014—United States and 3 territories	52
17a	Retention in care among youth and young adults aged 13–24 years, served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2014—United States and 3 territories	54
17b	Viral suppression among youth and young adults aged 13–24 years, served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2014—United States and 3 territories	55
18a	Retention in care among young men who have sex with men aged 13–24 years, served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2014—United States and 3 territories	56
18b	Viral suppression among young men who have sex with men aged 13–24 years, served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2014—United States and 3 territories	57
19a	Retention in care among young women aged 13–24 years, served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2014—United States and 3 territories	58
19b	Viral suppression among young women aged 13–24 years, served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2014—United States and 3 territories	59
20a	Retention in care among people who inject drugs (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2014—United States and 3 territories	60
20b	Viral suppression among people who inject drugs (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2014—United States and 3 territories	62

COMMENTARY

The Ryan White HIV/AIDS Program (RWHAP) supports a comprehensive system of care that ensures ongoing access to HIV care, treatment, and support. The RWHAP provides services to low income individuals living with HIV, as well as their families, who have no health care coverage (public or private), have insufficient health care coverage, or lack financial resources to get the care and treatment they need for their HIV disease.

The Legislation

In 1990, Congress passed the Ryan White Comprehensive AIDS Resources Emergency (CARE) Act to address the crisis of the HIV epidemic in the United States. This legislation has been amended and reauthorized four times: in 1996, 2000, 2006, and in 2009 as the Ryan White HIV/AIDS Treatment Extension Act of 2009.

The RWHAP was funded at \$2.32 billion in fiscal year 2015. It is the largest federal program focused exclusively on HIV care and support. The RWHAP is administered by the U.S. Department of Health and Human Services (HHS), Health Resources and Services Administration (HRSA), HIV/AIDS Bureau (HAB).

The majority of RWHAP funds support primary medical care, access to antiretroviral treatment, and essential support services. A smaller but equally critical portion funds technical assistance, clinical training, and research on innovative models of care. The RWHAP works dynamically to leverage other funding sources and health care coverage opportunities.

The RWHAP legislation has a number of programs, called Parts, to meet the needs of different communities and populations affected by HIV:

- Part A provides emergency assistance to Eligible Metropolitan Areas and Transitional Grant Areas that are most severely affected by the HIV epidemic
- Part B provides grants to all 50 States, the District of Columbia, Puerto Rico, Guam, the U.S. Virgin Islands, and 5 U.S. Pacific Territories or Associated Jurisdictions to improve the quality, availability, and organization of HIV health care and support services
 - The RWHAP Part B grants include funding for the AIDS Drug Assistance Programs (ADAP) as well as other statutory components
- Part C provides comprehensive primary health care and support services in an outpatient setting for people living with HIV (PLWH)
- Part D provides family-centered care involving primary medical care for women, infants, children, and youth with HIV, and affected family members
- Part F provides funds for a variety of programs:
 - The Special Projects of National Significance Program funds innovative models of care and supports the development of effective delivery systems for HIV care
 - The AIDS Education and Training Centers Program supports a network of 8 regional centers and several national centers that conduct targeted, multidisciplinary education and training programs for health care providers treating people living with HIV
 - The Dental Programs provide additional funding for oral health care for PLWH
 - The Minority AIDS Initiative provides funding to evaluate and address the disproportionate impact of HIV on African Americans and other minorities

Together, the Parts of the RWHAP provide the public health infrastructure needed to ensure access to a wide range of core medical and support services (e.g., case management; housing; transportation) aimed at early diagnosis of HIV, linkage to care, retention in care, medically appropriate treatment, and sustained viral load suppression.

Inaugural Client-Level Data Report

This report is the first annual publication of national RWHAP client-level data collected through the Ryan White HIV/AIDS Services Report (RSR). The RSR dataset is the HIV/AIDS Bureau's primary source of annual, client-level data collected from its nearly 2,000 funded grant recipients and subrecipients.

Since 2010, client-level RSR data have been used to assess the numbers and types of clients receiving services and their HIV outcomes. Project Officers at the HIV/AIDS Bureau share the data with grant recipients and subrecipients to monitor and support their progress at improving care and treatment for people living with HIV. It is through the hard work of these providers and the RWHAP community that clients are helped every day.

This report includes data reported to the RSR for all clients served by the RWHAP during calendar years 2010 through 2014. RSR data do not include information about ADAP; all ADAP-related information is collected through another data system. Although data presented in this report are "non-ADAP," this does not imply the clients did not receive ADAP services. ADAP data will be published separately, at later time.

The data presented highlight the state of the RWHAP and include the demographic composition of clients served; sociodemographic factors among clients such as federal poverty level (FPL), health care coverage, and housing status; and the results of focused analyses to measure progress toward achieving selected indicators of the *National HIV/AIDS Strategy for the United States: Updated to 2020* (NHAS 2020). The data are representative of the overall RWHAP client population and key priority populations identified by NHAS 2020. This report does not include the specific services that were rendered for individuals; these data will be presented in another report. In addition, the data included in this report are not Part-specific; that is, all tables include all clients served across Parts A, B, C, and D, regardless of the RWHAP funding stream.

Tables displaying demographic data (Tables 1–11) include all RWHAP clients regardless of HIV serostatus; that is, data include PLWH, as well as clients who are uninfected (e.g., families of PLWH served by the RWHAP; people who receive RWHAP counseling and testing services). Tables displaying NHAS measures (Tables 12a–20b) include only PLWH who meet the criteria for the specified analysis (see Technical Notes). All tables include data from all 50 states, the District of Columbia, Puerto Rico, the U.S. Virgin Islands, and Guam. Readers are encouraged to read carefully all table titles and footnotes to ensure a complete understanding of the data presented.

Ryan White HIV/AIDS Program and the National HIV/AIDS Strategy: Updated to 2020

In July 2015, the White House released NHAS 2020, which outlined 4 goals for a coordinated national response to HIV in the United States and incorporated the objectives and recommendations of both the HIV Care Continuum Initiative and the Federal Interagency Working Group on the Intersection of HIV/AIDS, Violence against Women and Girls, and Gender-Related Health Disparities. The 4 main goals of NHAS 2020 are (1) reduce the number of people who become infected with HIV, (2) increase access to care and improve health outcomes for people living with HIV, (3) reduce HIV-related health disparities, and (4) achieve a more coordinated national response to the HIV epidemic.

The HIV/AIDS Bureau collects data to monitor progress toward achieving select indicators of NHAS 2020. In this report, retention in HIV medical care and viral load suppression among RWHAP clients (related to goals 1–3) are reported. These data are displayed for the overall RWHAP client population by demographics and by state (Tables 12a through 13b).

The NHAS 2020 highlights several focus populations for enhancing efforts toward improved health outcomes. These populations include women; transgender individuals; gay, bisexual, and other men who have sex with men (MSM); blacks/African Americans; Hispanics/Latinos; youth; young, black/African American WSM; young, black/African American women; and people who inject drugs. Tables 14a through 20b display retention in care ("a" tables) and viral suppression ("b" tables) for these key populations.

HIGHLIGHTS OF ANALYSES

Ryan White HIV/AIDS Program Clients

The RWHAP serves over half a million people each year. In 2014, 512,214 clients received services through the RWHAP (Table 1); of these, 96% (492,240) were living with HIV (data not shown).

The majority of RWHAP clients are male. In 2014, 70.6% of clients were male, 28.3% were female, and 1.1% were transgender (Table 1).

Nearly three-quarters of RWHAP clients are from racial/ethnic minority populations. In 2014, 47.2% of clients self-identified as black/African American, 22.2% Hispanic/Latino, and less than 2% each American Indian/Alaska Native, Asian, Native Hawaiian/Pacific Islander, and persons of multiple races (Table 1). Whites accounted for 27.0% of clients. The percentage distribution has remained consistent since 2010.

The RWHAP client population is aging. In 2014, people aged 50 years and older accounted for 40.4% of all RWHAP clients, an increase from 31.7% of clients in 2010. In total, this amounts to an increase of over 30,000 clients aged 50 years and older during this time (Table 1; data not shown).

Socioeconomic Factors and Health Care Coverage

Nearly two-thirds of RWHAP clients are living at or below 100% of the federal poverty level (FPL) and over three-quarters live at or below 138% FPL. In 2014, 64.2% of clients were living ≤100% FPL and a total of 76.3% of clients were living ≤138% FPL, the qualification level for Medicaid eligibility under the Patient Protection and Affordable Care Act (Table 1; see Technical Notes for additional information about poverty level and the Patient Protection and Affordable Care Act).

A quarter of RWHAP clients continue to have no health care coverage. Despite changes in the health care landscape in recent years, the percentage of RWHAP clients who have no health care coverage has remained at approximately 25% since 2010 (Table 1).

Three-quarters of RWHAP clients are covered by some form of health care coverage; just over half of all clients are covered by Medicaid, Medicare, or both. Among all RWHAP clients, 51.2% were covered by Medicaid, Medicare, or both during 2014 (Table 1). Among clients living ≤100% FPL,

however, this percentage was higher: 58.7% had these coverages: 42.9% Medicaid, 7.5% Medicare, and 8.3% dually eligible for Medicare and Medicaid (Table 5). Among clients living 101–138% FPL, a relatively similar percentage of clients (54.7%) were covered by Medicaid, Medicare, or both; however, the distribution of coverage differed from those living ≤100% FPL: 24% Medicaid, 18.7% Medicare, and 12.0% dually eligible Medicare/Medicaid.

Female and transgender clients have lower incomes than male clients. Among the 133,609 females with poverty level information in 2014, 72.5% (96,885) were living ≤100% FPL; 83.1% (110,997) were living ≤138% FPL. Among the 5,041 transgender individuals with poverty level information in 2014, 79.5% (4,010) were living ≤100% FPL; 88.3% (4,449) were living ≤138% FPL (Table 5; percentages presented in table are column percentages, while those presented here are row percentages).

Over 16% of RWHAP clients have temporary or unstable housing situations. By age group, the highest percentages of temporary or unstable housing were among those aged 20–24 (18.1%, 5.9% respectively), 25–29 (16.3%, 5.9%), and 30–34 (14.6%, 5.5%) years. By transmission risk category, the highest percentages of temporary or unstable housing were among those with the following transmission risk categories: injection drug use (15.8%, 8.1%) and male-to-male sexual contact *and* injection drug use (17.3%, 10.3%). Among transgender individuals, 16.1% had temporary housing and 10.3% had unstable housing (Table 6; percentages presented in table are column percentages, while those presented here are row percentages).

NHAS 2020 OUTCOMES HIGHLIGHTS

Retention in HIV Medical Care

Retention in HIV medical care was based on data for PLWH who had at least 1 outpatient ambulatory medical care (OAMC) visit by September 1 of the measurement year, with a second visit at least 90 days after.

The percentages of people retained in care were relatively consistent across years during 2010 through 2014. During 2014, 80.4% of 272,193 clients were retained in HIV care (Table 12a).

Across subpopulations, retention in care was generally consistent with the overall average; however, a few subpopulations had lower retention percentages (by at least 5 percentage points), most notably: clients aged 20–24 years (73.4%) and 25–29 years (74.3%); Native Hawaiians/Pacific Islanders (74.4%); and people with unstable housing (72.9%).

Viral Suppression

Viral suppression was based on data for PLWH who had at least 1 OAMC visit and at least 1 viral load test during the measurement year, and whose most recent viral load test result was <200 copies/mL.

More than 81% of RWHAP clients achieved viral suppression in 2014. During 2014, 81.4% of 283,811 clients had a suppressed viral load at their most recent test (Table 13a). During 2010 through 2014, the overall percentage of clients with viral suppression increased by 12 percentage points, from 69.5% in 2010 to 81.4% in 2014.

Young people aged 15–24 continue to have the lowest percentages of viral suppression. In 2014, clients aged 15–19 years (64.3%) and 20–24 years (64.2%) had the lowest percentages of viral suppression by age group (Table 13a). However, these percentages reflect a 13 percentage point increase for clients aged 15–19 and a 20 percentage point increase for those aged 20–24 from 2010 through 2014. Although great increases have been achieved, disparities remain.

Clients with unstable housing have lower percentages of viral suppression than clients with stable or temporary housing. In 2014, 67.1% of clients with unstable housing achieved viral suppression, compared to 77.0% of clients with temporary housing and 82.8% of clients with stable housing (Table 13a).

Outcomes among Key Populations

This section highlights overall retention in care and viral suppression for each key population and highlights the subpopulations for which the most improvement is needed. Generally, this includes subpopulations with outcomes at least 5 percentage points lower than that of the overall key population. Data for subpopulations with very small numbers are not included in the highlights due to the variability in percentages resulting from such small numbers.

Black/African American women (Tables 14a/b): Overall, the percentages of black/African American women who were retained in care (81.8%) and virally suppressed (78.1%) were relatively consistent with the national RWHAP averages (80.4% and 81.4%, respectively).

Retention in care was lower for black/African American women aged 25–29 years (75.5%); those in HHS Regions 6, 7, and 9 (73.0%, 67.9%, and 68.5%, respectively; see Technical Notes for states included in each Region); and those with unstable housing (76.9%).

Percentages of viral suppression among black/African American women were lower among those in each 5-year age group from 15–34 years (range: 57.7%–70.7%); those who were perinatally infected (61.5%); those in Region 6 (72.9%); and those with unstable housing (64.7%).

Black/African American men (Tables 15a/b): The overall percentage of black/African American men who were retained in care (78.7%) was relatively consistent with the national RWHAP average (80.4%), while the percentage who achieved viral suppression was slightly lower (76.6%) than the average (81.4%).

Retention in care was lowest among black/African American men aged 20–24 years (72.1%) and 25–29 years (73.3%); those in Regions 6, 7, and 9 (71.1%, 57.9%, and 62.7%, respectively); and those with unstable housing (72.2%).

Viral suppression was lower among black/African American men in each 5-year age group from 15–29 years (range: 62.3%–67.5%); those who were perinatally infected (65.5%); those in Region 6 (71.4%); those with no health care coverage (71.0%); and those with unstable housing (65.3%).

Hispanic/Latino women (Tables 14a/b): Overall, Hispanic/Latino women had a higher retention in care percentage (86.3%) than the national RWHAP average (80.4%); viral suppression (82.6%) was relatively consistent with the national RWHAP average (81.4%).

Retention in care was lowest among clients aged 20–24 years (77.8%); and those living 251–400% FPL (78.0%).

The lowest percentages of viral suppression were among clients in each 5-year age group from 15–29 years (range: 64.7%–70.7%); those who were perinatally infected (66.6%); and those with unstable housing (71.1%).

Hispanic/Latino men (Tables 15a/b): Overall, for Hispanic/Latino men, retention in care (82.3%) was consistent with the national RWHAP average (80.4%); viral suppression (84.5%) was higher than the national RWHAP average (81.4%).

Retention in care was lowest among clients aged 15–19 years (77.3%), 20–24 years (74.2%), and 20–29 years (75.8%); MSM who also had injection drug use as a risk factor (77.2%); those in Region 7 (75.4%); those with private individual health care coverage (75.4%); and those with unstable housing (73.9%).

Lower percentages of viral suppression were among clients aged 15–19 years (64.4%), 20–24 years (70.1%), and 25–29 years (77.3%); those who were perinatally infected (67.2%); and those with unstable housing (68.9%).

Transgender adults and adolescents (Tables 16a/b): Overall, for transgender adults and adolescents, retention in care (78.4%) was consistent with the national RWHAP average (80.4%), while viral suppression (74.0%) was lower than the average (81.4%).

Retention in care was lower among those aged 20–24 years (69.0%) and 25–29 years (71.7%); and among those with unstable housing (66.5%). Generally, transgender blacks/African Americans had lower percentages of retention in care across all other demographic subpopulations compared to transgender individuals of other races/ethnicities.

Viral suppression was lower among blacks/African Americans (68.8%) and clients of multiple races (68.9%); clients aged 20–24 years (53.1%), 25–29 years (65.9%), and 30–34 years (68.3%); and for those with unstable housing (53.0%). Generally, transgender blacks/African Americans had lower percentages of viral suppression across all other demographic subpopulations compared to transgender individuals of other races/ethnicities.

Given the low numbers within the various subpopulations for transgender adults and adolescents, caution should be used in interpreting the percentages in Tables 16a/b.

Gay, bisexual, and other men who have sex with men (MSM; Tables 15a/b): Overall, retention in care for MSM (79.5%) and for MSM who also had injection drug use as a risk factor (77.7%) was consistent with the national RWHAP average; viral suppression was also consistent with the national RWHAP average for both subpopulations (82.9% and 79.7%, respectively).

For MSM, by race/ethnicity, retention in care was lowest among Native Hawaiians/Pacific Islanders (72.2%); among MSM who also had injection drug use as a risk factor, retention was lowest among Asians (63.6%) and American Indians/Alaska Natives (64.4%).

For MSM, the lowest percentage of viral suppression was among blacks/African Americans (75.3%); among MSM who also had injection drug use as a risk factor, viral suppression was lowest among Asians (73.2%) and clients of multiple races (74.4%).

Youth aged 13–24 years (Tables 17a/b): Among youth overall, retention in care was lower (75.1%) than the national RWHAP average and viral suppression was much lower (64.6%).

The lowest percentages of retention in care were among transgender youth (overall 69.7%); youth who also had injection drug use as a risk factor (overall 63.2%); youth with Medicare coverage (overall 63.0%); and youth with unstable housing (overall 66.3%).

Viral suppression was lowest among transgender youth (overall 51.8%); young MSM who also had injection drug use as a risk factor (overall 56.6%); youth with no health care coverage (overall 59.4%); and youth with unstable housing (overall 52.3%). Within each of the groups with the lowest percentages of viral suppression, the disparity was more pronounced for black/African American transgender youth (49.7%) and for unstably housed black/African American youth (50.7%).

Young, black/African American MSM, aged 13–24 years (YBMSM; Tables 18a/b): Overall, retention in care for YBMSM (72.0%) was lower than the national RWHAP average (80.4%), but consistent with the average for young MSM overall (72.4%). Viral suppression for YBMSM (62.1%) was lower than the national RWHAP average (81.4%), and slightly lower than the average for young MSM overall (65.5%).

The lowest percentages of retention in care for YBMSM were among those in Regions 6, 7, 9, and 10 (62.2%, 67.3%, 45.0%, and 55.6%, respectively); and among those with unstable housing (65.1%).

Viral suppression for YBMSM was lowest among those in Regions 6 (56.5%) and 9 (57.0%); and among those with unstable housing (50.3%).

Given the low numbers within the various subpopulations of young MSM and young, black MSM, caution should be used in interpreting the percentages in Tables 18a/b.

Young, black/African American women, aged 13–24 years (Tables 19a/b): Overall, retention in care for young, black/African American women (79.8%) was consistent with the national RWHAP average (80.4%) and with the average for young women overall (79.4%). Viral suppression for young, black/African American women (60.4%) was lower than the national RWHAP average (81.4%), and slightly lower than the average for young women overall (62.8%).

The lowest percentages of retention in care for young, black/African American women were among those in Regions 5 (74.9%), 6 (68.2%), and 9 (72.3%); and among those with individual health care coverage (74.1%) and no health care coverage (73.6%).

Viral suppression for young, black/African American women was lowest among those in Regions 7 and 9 (40.0% and 55.6%, respectively); those with no health care coverage (53.8%); and those with unstable housing (50.9%).

Given the low numbers within the various subpopulations of young women and young, black/African American women, caution should be used in interpreting the percentages in Tables 19a/b.

People who inject drugs (PWID; Tables 20a/b): Overall, for PWID, retention in care (82.0%) and viral suppression (81.1%) were consistent with the national RWHAP averages.

Across all races/ethnicities, retention in care was generally lower among the youngest age groups, with the exception of those aged 15–19 years, and increased as age group increased. Also across all races/ethnicities, those with the lowest percentages were PWID in Region 7 (overall 64.5%); those with no health care coverage (overall 72.3%); and those with unstable housing (overall 74.6%).

Viral suppression followed similar patterns to retention in care with the lowest percentages among the younger age groups, and increased as age group increased. In addition, the lowest percentages of viral suppression were among those in Region 6 (overall 75.4%); those with no health care coverage (overall 73.9%); and those with unstable housing (overall 66.4%).

PWID data are based on clients who reported "injection drug use" as their transmission risk category and may not be reflective of current behavior.

TECHNICAL NOTES

RYAN WHITE HIV/AIDS PROGRAM DATA

The Ryan White HIV/AIDS Services Report (RSR) is the HIV/AIDS Bureau's (HAB) primary source of annual, client-level data collected from its nearly 2,000 funded grant recipients and subrecipients. These data are used to assess the number and type of clients receiving services and their HIV outcomes. Client-level RSR data have been used since 2010. Each year, grant recipients and subrecipients that use Ryan White HIV/AIDS Program (RWHAP) funds to provide core medical or supportive services during the reporting period are required to submit data to HAB in a specified format.¹

This report includes data reported to the RSR for all clients served by the RWHAP Parts A–D during calendar years 2010 through 2014. RSR data do not include information about the AIDS Drug Assistance Program (ADAP); all ADAP-related information is collected through another data system. Although data presented in this report are "non-ADAP," this does not imply the clients did not receive ADAP services. ADAP data will be reported separately, at a later time.

After removal of personal identifying information, data were submitted to HAB. Data were reported by RWHAP grant recipients and subrecipients in 50 states, the District of Columbia, and 3 territories: Guam, Puerto Rico, and the U.S. Virgin Islands.

RSR data include de-identified client-level information about people who received RWHAP-funded services. Clients of the RWHAP include PLWH, as well as people who are not HIV-infected but are affected by HIV and received services such as HIV testing, counseling, or other services that are offered by the RWHAP. The families of PLWH are also able to receive certain services by some Parts of the RWHAP. The data presented in Tables 1-11 are inclusive of all RWHAP clients, regardless of HIV serostatus. Tables displaying retention in care and viral suppression (Tables 12a–20b) include only PLWH who meet the criteria for the specified analysis.

PRESENTATION OF DATA

The data in this report include information received by HAB for clients served during calendar years 2010 through 2014. Data are organized into 3 sections:

- Section 1 (Tables 1–8): numbers and percentages of clients served by the RWHAP (non-ADAP), presented by selected demographic stratifications
- Section 2 (Tables 9–11): numbers and percentages of clients served by the RWHAP (non-ADAP), presented by state
- Section 3 (Tables 12a–20b): retention in care and viral suppression among clients served by the RWHAP (non-ADAP), presented by selected demographics, by state, and by priority population as identified by the National HIV/AIDS Strategy 2020 (NHAS 2020).

Tables 1–3 and 5–8 display subtotals for each subpopulation, as well as the overall total. Subtotals are displayed to reflect the denominator used for the percentage calculation of each subpopulation. Due to missing data, the values in each column may not sum to the column total.

Age Group

RWHAP grant recipients and subrecipients report client birth year during the data collection process. This information is then used to calculate the client's age during the designated year as a discrete variable. For Tables 1–8, 12a, and 13a, client ages were categorized into groups that align with the Centers for Disease Control and Prevention's (CDC) National HIV Surveillance System (NHSS) age group delineations: <13 years, 13–14, 15–19, 20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54, 55–59, 60–64, and ≥65 years.

The designation "adults and adolescents" refers to clients aged 13 years and older. In Table 9, data are displayed separately for adults and adolescents and for children (aged less than 13 years).

Tables displaying NHAS measures for key populations (Tables 14a through 20b) include clients aged 13 years and older ("adults and adolescents") only. Tables 17a through 19b focus more narrowly on youth and young adults aged 13–24 years.

Race/Ethnicity

HAB collects race/ethnicity information on RWHAP clients according to Office of Management and Budget standards. Race and ethnicity are submitted as separate variables from RWHAP grant recipients and combined for analysis. The race/ethnicity variable is categorized as American Indian or Alaska Native, Asian, black or African American, Native Hawaiian or other Pacific Islander, white, multiple races (2 or more categories of race reported), and Hispanic or Latino.

In this report, clients categorized by race were not Hispanic or Latino; the number of clients reported in each race category may, however, include clients whose ethnicity was not reported.

RWHAP grant recipients and subrecipients are expected to make every effort to obtain and report race and ethnicity, based on each client's self-report. Self-identification is the preferred means of obtaining this information.

Gender

Client sex at birth and current gender identity are required reportable variables in the RSR since 2014 and are based on client self-report. Gender designations in this report are male, female, or transgender. Transgender is an umbrella term used to identify persons whose sex assigned at birth does not match current gender identity or expression. Transgender clients are subsequently classified as male-to-female (MTF), female-to-male (FTM), or unknown.

Transmission Risk Category

Transmission risk category is the term for the classification that summarizes a client's possible HIV risk factors; the summary classification results from selecting, from the presumed hierarchical order of probability, the single risk factor most likely to have been responsible for transmission. The definitions of transmission risk categories align with CDC's NHSS definitions for transmission categories. Clients with more than 1 reported risk factor are classified in the transmission risk category listed first in the hierarchy. The only exception is men who had sexual contact with other men and who injected drugs; this group makes up a separate transmission risk category. The risk categories are defined as follows:

- Male-to-male sexual contact. Male clients who report sexual contact with other men (i.e., homosexual contact) and males who report sexual contact with both men and women (i.e., bisexual contact)
- Injection drug use: Clients who report use of drugs intravenously or through skin-popping
- Male-to-male sexual contact and injection drug use: Male clients who report sexual contact with other men, or sexual contact with both men and women, and report the use of drugs intravenously or through skin-popping
- Heterosexual contact: Clients who report specific heterosexual contact with an individual with, or at increased risk for, HIV infection (e.g., a person who injects drugs)
- *Perinatal infection*: This category is exclusively for infants and children infected by mothers who are HIV positive or at risk (i.e., perinatal transmission/mother-to-child transmission)
- Other: Clients who report transmission from the receipt of transfusion of blood, blood components, or tissue; clients who report hemophilia/coagulation disorder; clients with unknown risk factor (not reported or not identified).

Tables 18a/b display retention in care and viral suppression among young men who have sex with men (MSM). These tables include "male-to-male sexual contact" as well as "male-to-male sexual contact and injection drug use." Tables 20a/b display retention in care and viral suppression among people who inject drugs (PWID). These tables include only those persons who reported "injection drug use"; they do not include "male-to-male sexual contact and injection drug use."

Poverty Level

Poverty level characterizes the client's income in terms of the percent of the Federal poverty level (FPL)ⁱⁱ at the end of the reporting period. For 2010–2013, poverty levels were categorized as 0–100% FPL, 101–200% FPL, 201–300% FPL, >300% FPL.

The categorization schema was changed in the 2014 RSR due to the introduction of the Patient Protection and Affordable Care Act. Under the Affordable Care Act, persons who earn less than 138% FPL and live in a state that expanded Medicaid may qualify for Medicaid or Children's Health Insurance Program (CHIP). Additionally, persons who earn 100–250% FPL may qualify for out-of-pocket cost assistance on certain health care plans purchased through State or Federal Health Insurance Marketplaces. Therefore, in 2014, poverty level was categorized as 0–100% FPL, 101–138% FPL, 139–250% FPL, 251–400% FPL, >400% FPL.

Health Care Coverage

RWHAP grant recipients and subrecipients are asked to report all sources of health care coverage that each client had for any part of the reporting period. These data are further categorized for analysis. In 2010 through 2013, health care coverage was categorized as private only, Medicare only, Medicaid only, other public, other private, multiple coverages, and no coverage (uninsured).

The categorization schema was changed in the 2014 RSR due to the introduction of the Affordable Care Act and a desire for more granular classification of health care coverage in the changing health care landscape. In 2014, health care coverage was categorized as private employer, private individual, Medicare, Medicaid, Medicare and Medicaid, Veterans Administration, Indian Health Service, other plan, multiple coverages, and no coverage. The Medicaid classification also includes CHIP and other public state health care coverage programs.

Housing Status

The housing status variable captures the client's housing status at the end of the reporting period and is categorized as stable permanent housing, temporary housing, or unstable housing. The definitions for each of these categories is based on the Housing Opportunities for Persons with AIDS (HOPWA) Program, Annual Progress Report (APR), Measuring Performance Outcomes, form HUD-40110-C and the McKinney-Vento Act, Title 42 US Code, Sec. 11302, General definition of homeless individual.

Region

The U.S. Department of Health and Human Services (HHS) utilizes 10 geographic designations for classifying regions of the United States, which encompass all states and territories. The classification of states and territories within these regions is as follows:

- Region 1: Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont
- Region 2: New Jersey, New York, Puerto Rico, U.S. Virgin Islands
- Region 3: Delaware, District of Columbia, Maryland, Pennsylvania, Virginia, West Virginia
- Region 4: Alabama, Georgia, Florida, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee
- Region 5: Illinois, Indiana, Michigan, Minnesota, Ohio, Wisconsin
- Region 6: Arkansas, Louisiana, New Mexico, Oklahoma, Texas
- Region 7: Iowa, Missouri, Nebraska, Kansas
- Region 8: Colorado, Montana, North Dakota, South Dakota, Utah, Wyoming
- Region 9: Arizona, California, Hawaii, Nevada, Guam
- Region 10: Alaska, Idaho, Oregon, Washington

State

State data are displayed in Tables 9 through 11, 12b, and 13b. State level analyses include data submitted across all Parts of the RWHAP. In addition, state delineation of data is based on **provider** location, rather than client location. Clients receiving services in multiple states were not included in state-specific totals; these clients make up less than 2% of the total RWHAP population.

Retention in Care and Viral Suppression

Retention in care and viral suppression were calculated among RWHAP clients who were HIV-positive and received at least 1 RWHAP-funded outpatient ambulatory medical care visit in the measurement year.

Retention in HIV medical care was defined as those clients who had at least 2 medical visit dates that were at least 90 days apart in the measurement year. Because the datasets are restricted to 1 calendar year of data each, the first of these HIV medical care visits in the year must have occurred before September 1, thus giving the client an opportunity to meet the retention criteria by December 31.

Viral suppression was defined as the most recent reported HIV RNA level <200 copies/mL in the calendar year and was calculated among HIV-positive clients who received RWHAP-funded HIV medical care and had at least 1 viral load test during the year.

National HIV/AIDS Strategy 2020 Key Populations

Goal 1 of NHAS 2020 is to reduce new infections. While anyone can become infected with HIV, all people and communities are not impacted equally. NHAS 2020 calls for continued effort to focus on communities where HIV is most concentrated.

These populations include women; transgender individuals; gay, bisexual, and other men who have sex with men; blacks/African Americans; Hispanics/Latinos; youth; young, black/African American MSM; young, black/African American women; and people who inject drugs. Tables 14a through 20b display retention in care ("a" tables) and viral suppression ("b" tables) for these key populations.

Data presented for young MSM (Tables 18a/b) include clients who reported male-to-male sexual contact or male-to-male sexual contact and injection drug use as their transmission risk category. Data presented for people who inject drugs (Tables 20a/b) are based on clients who reported injection drug use as their transmission risk category; these data may not be reflective of current injection drug use behavior.

ADDITIONAL RESOURCES

Health Resources and Services Administration, HIV/AIDS Programs http://hab.hrsa.gov/

TARGET Center, tools for the Ryan White Community https://careacttarget.org/

National HIV/AIDS Strategy for the United States, Updated to 2020. https://www.aids.gov/federal-resources/national-hiv-aids-strategy/nhas-update.pdf

AIDS.gov, the Nation's source for timely and relevant Federal HIV policies, programs, and resources

Centers for Disease Control and Prevention, HIV prevention resources http://www.cdc.gov/hiv

https://www.federalregister.gov/articles/2015/01/22/2015-01120/annual-update-of-the-hhs-poverty-guidelines

See http://hab.hrsa.gov/manageyourgrant/reportingrequirements.html

[&]quot;See: http://aspe.hhs.gov/2015-poverty-guidelines#guidelines or

Table 1. Ryan White HIV/AIDS Program clients (non-ADAP), by year and selected characteristics, 2010–2014—United States and 3 territories

	2010		2011		2012		2013		2014	
	No.	%								
Age group (yr)										
<13	11,495	2.1	10,824	2.0	8,481	1.6	6,515	1.2	6,571	1.3
13–14	1,672	0.3	1,540	0.3	1,254	0.2	1,035	0.2	863	0.2
15–19	9,090	1.6	7,979	1.4	6,411	1.2	5,853	1.1	5,443	1.1
20–24	26,127	4.7	26,002	4.7	24,800	4.6	24,701	4.7	23,260	4.5
25–29	36,415	6.6	37,539	6.8	37,504	7.0	39,014	7.4	39,761	7.8
30-34	46,753	8.4	47,243	8.5	46,111	8.6	45,498	8.7	43,915	8.6
35–39	57,613	10.4	54,537	9.8	51,008	9.5	49,327	9.4	47,682	9.3
40–44	85,602	15.4	80,113	14.4	72,407	13.5	65,287	12.4	58,589	11.4
45–49	105,153	18.9	102,460	18.5	95,254	17.8	88,035	16.8	79,175	15.5
50-54	83,429	15.0	86,190	15.5	86,599	16.2	87,265	16.6	86,807	17.0
55-59	51,376	9.2	55,391	10.0	57,434	10.7	59,501	11.3	61,645	12.0
60–64	24,880	4.5	27,587	5.0	29,991	5.6	31,948	6.1	34,944	6.8
≥65	16,350	2.9	17,226	3.1	18,946	3.5	20,693	3.9	23,361	4.6
Subtotal	555,955	100.0	554,631	100.0	536,200	100.0	524,672	100.0	512,016	100.0
Race/ethnicity										
American Indian/Alaska Native	2,922	0.5	2,796	0.5	2,645	0.5	2,629	0.5	2,375	0.5
Asian	5,238	1.0	5,341	1.0	5,687	1.1	5,868	1.1	5,873	1.2
Black/African American	256,136	47.2	255,645	47.3	245,828	46.7	242,593	46.8	239,537	47.2
Hispanic/Latino ^a	119,840	22.1	118,800	22.0	119,676	22.7	116,862	22.6	112,833	22.2
Native Hawaiian/Pacific Islander	1,105	0.2	1,143	0.2	941	0.2	935	0.2	852	0.2
White	152,115	28.0	150,466	27.8	144,245	27.4	140,810	27.2	136,949	27.0
Multiple races	5,719	1.1	6,591	1.2	7,224	1.4	8,211	1.6	9,143	1.8
Subtotal	543,075	100.0	540,782	100.0	526,246	100.0	517,908	100.0	507,562	100.0
Gender										
Male	380,893	68.5	382,984	69.1	375,267	70.0	370,140	70.6	361,323	70.6
Female	170,543	30.7	166,711	30.1	155,752	29.1	149,152	28.4	144,982	28.3
Transgender	4,326	0.8	4,718	0.9	5,027	0.9	5,172	1.0	5,467	1.1
Subtotal	555,762	100.0	554,413	100.0	536,046	100.0	524,464	100.0	511,772	100.0
Transmission risk category										
Male-to-male sexual contact	186,451	39.3	194,780	39.9	200,631	41.9	207,236	42.7	207,383	44.9
Injection drug use	47,537	10.0	45,179	9.3	41,757	8.7	40,491	8.3	36,679	8.0
Male-to-male sexual contact and injection drug use	10,967	2.3	11,041	2.3	11,349	2.4	11,091	2.3	11,270	2.4
Heterosexual contact ^b	187,935	39.6	194,736	39.9	191,051	39.9	190,563	39.2	189,591	41.1
Perinatal infection	13,722	2.9	14,507	3.0	12,780	2.7	11,861	2.4	11,975	2.6
Other ^c	28,369	6.0	27,808	5.7	21,382	4.5	24,368	5.0	4,688	1.0
Subtotal	474,981	100.0	488,051	100.0	478,950	100.0	485,610	100.0	461,586	100.0

Table 1. Ryan White HIV/AIDS Program clients (non-ADAP), by year and selected characteristics, 2010–2014—United States and 3 territories (cont)

	2010		2011		2012		2013		2014	
	No.	%								
Poverty level ^d										
0–100%	292,427	67.1	321,865	67.2	322,347	66.7	332,247	67.6	_	_
101–200%	92,869	21.3	102,499	21.4	105,421	21.8	107,631	21.9	_	_
201–300%	27,871	6.4	31,106	6.5	32,398	6.7	33,183	6.8	_	_
>300%	22,465	5.2	23,466	4.9	22,885	4.7	18,738	3.8	_	_
Subtotal	435,632	100.0	478,936	100.0	483,051	100.0	491,799	100.0	_	_
0–100%	_	_	_	_	_	_	_	_	304,168	64.2
101–138%	_	_	_	_	_	_	_	_	57,396	12.1
139–250%	_	_	_	_	_	_	_	_	69,999	14.8
251–400%	_	_	_	_	_	_	_	_	26,420	5.6
>400%	_	_	_	_	_	_	_	_	15,500	3.3
Subtotal	_	_	_	_	_	_	_	_	473,483	100.0
Health care coverage ^d										
Private only	58,248	12.8	64,269	13.1	64,947	13.0	61,934	12.4		_
Medicare only	42,279	9.3	44,932	9.2	44,293	8.9	44,341	8.9	_	_
Medicaid only	130,123	28.5	137,114	27.9	130,062	26.0	127,096	25.5	_	_
Other public	35,821	7.9	34,347	7.0	41,381	8.3	41,473	8.3		_
Other private	17,163	3.8	13,427	2.7	9,100	1.8	6,609	1.3	_	_
No coverage	115,171	25.3	133,341	27.2	137,761	27.6	138,447	27.8	_	_
Multiple coverages	57,061	12.5	63,389	12.9	72,173	14.4	78,346	15.7	_	_
Subtotal	455,866	100.0	490,819	100.0	499,717	100.0	498,246	100.0	_	_
Private employer	_	_	_	_	_	_	_	_	30,410	6.3
Private individual	_	_	_	_	_	_	_	_	25,762	5.3
Medicare	_	_	_	_	_	_	_	_	48,750	10.0
Medicaid	_	_	_	_	_	_	_	_	162,372	33.4
Medicare and Medicaid	_	_	_	_	_	_	_	_	37,617	7.7
Veterans Administration	_	_	_	_	_	_	_	_	1,302	0.3
Indian Health Service	_	_	_	_	_	_	_	_	115	0.0
Other plan	_	_	_	_	_	_	_	_	19,425	4.0
No coverage	_	_	_	_	_	_	_	_	123,273	25.4
Multiple coverages	_	_	_	_	_	_	_	_	37,036	7.6
Subtotal	_	_	_	_	_	_	_	_	486,062	100.0
Housing status										
Stable	378,842	82.0	400,930	82.4	403,976	83.1	404,743	83.3	402,175	83.5
Temporary	65,833	14.2	66,727	13.7	62,468	12.9	60,233	12.4	56,868	11.8
Unstable	17,617	3.8	18,657	3.8	19,702	4.1	21,001	4.3	22,702	4.7
Subtotal	462,292	100.0	486,314	100.0	486,146	100.0	485,977	100.0	481,745	100.0
Total ^e	556,175	_	554,646	_	536,219	_	524,675	_	512,214	_

^a Hispanics/Latinos can be of any race.

^b Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^c Includes hemophilia, blood transfusion, and unknown risk factor.

^d Data collected in 2014 used different categories than previous years. See Technical Notes for additional details.

^e Subtotals for each subpopulation are displayed to reflect the denominator used for the percentage calculation of each subpopulation; due to missing data, the values in each column may not sum to the column total.

Table 2. Ryan White HIV/AIDS Program clients (non-ADAP), by race/ethnicity and selected characteristics, 2014—United States and 3 territories

	America				Black/Af				Native Ha					
	Alaska		Asi		Ameri		Hispanic/l		Pacific Is		White		Multiple	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Age group (yr)														
<13	27	1.1	79	1.4	4,678	2.0	1,059	0.9	11	1.3	580	0.4	99	1.1
13–14	2	0.1	10	0.2	607	0.3	150	0.1	1	0.1	65	0.1	15	0.2
15–19	16	0.7	48	8.0	3,550	1.5	1,049	0.9	2	0.2	617	0.5	104	1.1
20–24	80	3.4	269	4.6	14,285	6.0	4,499	4.0	51	6.0	3,313	2.4	509	5.6
25–29	167	7.0	533	9.1	22,253	9.3	8,173	7.2	67	7.9	7,375	5.4	806	8.8
30–34	224	9.4	683	11.6	20,959	8.8	10,903	9.7	107	12.6	9,800	7.2	813	8.9
35–39	242	10.2	821	14.0	21,086	8.8	12,908	11.4	99	11.6	11,237	8.2	847	9.3
40–44	315	13.3	1,035	17.6	25,077	10.5	15,221	13.5	105	12.3	15,225	11.1	1,023	11.2
45–49	402	16.9	842	14.3	33,885	14.2	18,602	16.5	129	15.1	23,225	17.0	1,386	15.2
50-54	407	17.1	658	11.2	37,693	15.8	17,660	15.7	130	15.3	27,956	20.4	1,571	17.2
55-59	285	12.0	399	6.8	28,784	12.0	11,415	10.1	85	10.0	19,103	14.0	1,057	11.6
60–64	132	5.6	288	4.9	16,443	6.9	6,350	5.6	39	4.6	10,814	7.9	593	6.5
≥65	76	3.2	208	3.5	10,064	4.2	4,841	4.3	26	3.1	7,639	5.6	300	3.3
Subtotal	2,375	100.0	5,873	100.0	239,364	100.0	112,830	100.0	852	100.0	136,949	100.0	9,123	100.0
Gender														
Male	1,675	70.6	4,529	77.1	148,627	62.1	83,208	73.8	653	76.7	113,279	82.7	6,136	67.2
Female	655	27.6	1,251	21.3	87,691	36.7	28,019	24.8	175	20.6	23,010	16.8	2,862	31.4
Transgender	43	1.8	91	1.6	2,878	1.2	1,595	1.4	23	2.7	628	0.5	132	1.5
Subtotal	2,373	100.0	5,871	100.0	239,196	100.0	112,822	100.0	851	100.0	136,917	100.0	9,130	100.0
Transmission risk category														
Male-to-male sexual contact	1,040	47.3	2,724	53.1	70,220	33.1	46,916	45.3	472	62.2	80,813	63.9	3,841	44.0
Injection drug use	242	11.0	169	3.3	15,293	7.2	9,485	9.2	39	5.1	10,483	8.3	815	9.3
Male-to-male sexual contact and injection drug use	139	6.3	75	1.5	2,500	1.2	1,935	1.9	26	3.4	6,167	4.9	350	4.0
Heterosexual contact ^b	697	31.7	1,900	37.1	114,060	53.8	41,904	40.5	193	25.4	26,469	20.9	3,374	38.6
Perinatal infection	39	1.8	122	2.4	7,964	3.8	2,383	2.3	19	2.5	1,150	0.9	248	2.8
Other ^c	41	1.9	138	2.7	2,026	1.0	984	1.0	10	1.3	1,347	1.1	111	1.3
Subtotal	2,198	100.0	5,128	100.0	212,063	100.0	103,607	100.0	759	100.0	126,429	100.0	8,739	100.0
Total ^d	2,375	_	5,873	_	239,537	_	112,833	_	852	_	136,949	_	9,143	_

^a Hispanics/Latinos can be of any race.

^b Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^c Includes hemophilia, blood transfusion, and unknown risk factor.

^d Subtotals for each subpopulation are displayed to reflect the denominator used for the percentage calculation of each subpopulation; due to missing data, the values in each column may not sum to the column total.

Table 3. Ryan White HIV/AIDS Program clients (non-ADAP), by gender and selected characteristics, 2014—United States and 3 territories

	Male		Female	e	Transgende	r MTF	Transgende	r FTM	Transgender unknown	
	No.	%	No.	%	No.	%	No.	%	No.	%
Age group (yr)										
<13	3,250	0.9	3,315	2.3	_	_	_	_	_	_
13–14	403	0.1	457	0.3	_		_	_	_	_
15–19	2,920	0.8	2,487	1.7	25	0.5	3	1.4	3	0.9
20–24	17,217	4.8	5,647	3.9	333	6.8	20	9.6	31	8.9
25–29	30,466	8.4	8,396	5.8	773	15.8	48	23.0	48	13.8
30–34	31,361	8.7	11,747	8.1	711	14.5	27	12.9	46	13.2
35–39	31,792	8.8	15,120	10.4	671	13.7	23	11.0	50	14.3
40–44	39,124	10.8	18,631	12.9	718	14.6	31	14.8	44	12.6
45–49	56,108	15.5	22,247	15.4	681	13.9	25	12.0	50	14.3
50-54	62,795	17.4	23,367	16.1	519	10.6	16	7.7	38	10.9
55–59	44,041	12.2	17,231	11.9	281	5.7	8	3.8	25	7.2
60–64	25,194	7.0	9,580	6.6	130	2.7	6	2.9	10	2.9
≥65	16,569	4.6	6,709	4.6	60	1.2	2	1.0	4	1.1
Subtotal	361,240	100.0	144,934	100.0	4,902	100.0	209	100.0	349	100.0
Race/ethnicity										
American Indian/Alaska Native	1,675	0.5	655	0.5	37	0.8	3	1.5	3	0.9
Asian	4,529	1.3	1,251	0.9	81	1.7	2	1.0	8	2.4
Black/African American	148,627	41.5	87,691	61.0	2,584	53.2	97	49.0	197	58.3
Hispanic/Latino ^a	83,208	23.2	28,019	19.5	1,473	30.4	36	18.2	86	25.4
Native Hawaiian/Pacific Islander	653	0.2	175	0.1	17	0.4	3	1.5	3	0.9
White	113,279	31.6	23,010	16.0	550	11.3	56	28.3	22	6.5
Multiple races	6,136	1.7	2,862	2.0	112	2.3	1	0.5	19	5.6
Subtotal	358,107	100.0	143,663	100.0	4,854	100.0	198	100.0	338	100.0
Transmission risk category										
Male-to-male sexual contact	203,305	61.9	_	_	3,771	85.8	56	39.2	200	84.0
Injection drug use	24,178	7.4	12,381	9.7	75	1.7	6	4.2	7	2.9
Male-to-male sexual contact and injection drug use	11,022	3.4	_	_	233	5.3	6	4.2	5	2.1
Heterosexual contact ^b	81,786	24.9	107,362	83.8	289	6.6	67	46.9	25	10.5
Perinatal infection	5,570	1.7	6,382	5.0	9	0.2	6	4.2	1	0.4
Other ^c	2,616	0.8	2,049	1.6	20	0.5	2	1.4	0	0.0
Subtotal	328,477	100.0	128,174	100.0	4,397	100.0	143	100.0	238	100.0
Total ^d	361,323	_	144,982	_	4,906	_	209	_	352	_

Abbreviations: MTF, male-to-female; FTM, female-to-male.

Note. Data were not included for 4 clients due to unverified gender.

^a Hispanics/Latinos can be of any race.

^b Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^c Includes hemophilia, blood transfusion, and unknown risk factor.

^d Subtotals for each subpopulation are displayed to reflect the denominator used for the percentage calculation of each subpopulation; due to missing data, the values in each column may not sum to the column total.

Table 4. Ryan White HIV/AIDS Program clients (non-ADAP), by transmission risk category and selected characteristics, 2014—United States and 3 territories

	Male-to-m	nale			Male-to-male sexua	contact	Heterose	xual				
	sexual cor		Injection dr	ug use	and injection dr		contac	t ^a	Perinatal ir	nfection	Othe	r ^b
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Age group (yr)												
<13	_	_	_	_	-	_	_	_	5,361	45.4	13	0.3
13–14	6	0.0	1	0.0	0	0.0	48	0.0	493	4.2	6	0.1
15–19	1,006	0.5	27	0.1	8	0.1	931	0.5	1,905	16.1	20	0.4
20–24	12,781	6.2	195	0.5	220	2.0	4,609	2.4	2,662	22.5	76	1.6
25–29	23,862	11.5	595	1.6	626	5.6	9,551	5.0	1,163	9.8	132	2.8
30–34	22,236	10.7	1,246	3.4	954	8.5	14,786	7.8	229	1.9	268	5.7
35–39	20,289	9.8	1,854	5.1	1,087	9.6	19,618	10.4	_	_	334	7.1
40–44	23,046	11.1	3,036	8.3	1,427	12.7	25,160	13.3	_	_	498	10.6
45–49	32,096	15.5	5,566	15.2	2,042	18.1	31,589	16.7	_	_	722	15.4
50-54	33,237	16.0	8,536	23.3	2,292	20.3	33,866	17.9	_	_	880	18.8
55–59	20,421	9.8	8,236	22.5	1,538	13.7	24,815	13.1	_	_	763	16.3
60–64	11,062	5.3	5,227	14.3	756	6.7	13,945	7.4	_	_	452	9.6
≥65	7,291	3.5	2,127	5.8	317	2.8	10,558	5.6	_	_	522	11.1
Total	207,333	100.0	36,646	100.0	11,267	100.0	189,476	100.0	11,813	100.0	4,686	100.0

Note. Data were not included for 245 clients due to unverified transmission risk category.

^a Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^b Includes hemophilia, blood transfusion, and unknown risk factor.

Table 5. Ryan White HIV/AIDS Program clients (non-ADAP), by poverty level and selected characteristics, 2014—United States and 3 territories

	0–100% F	PL	101–138%	FPL	139–250%	FPL	251–400%	FPL	>400% F	PL
	No.	%	No.	%	No.	%	No.	%	No.	%
Age group (yr)										
<13	4,703	1.6	492	0.9	404	0.6	205	0.8	100	0.7
13–14	547	0.2	76	0.1	66	0.1	29	0.1	9	0.1
15–19	3,476	1.1	377	0.7	316	0.5	112	0.4	76	0.5
20–24	15,640	5.1	1,946	3.4	2,159	3.1	578	2.2	465	3.0
25-29	24,560	8.1	3,609	6.3	5,320	7.6	1,742	6.6	1,035	6.7
30-34	26,855	8.8	4,092	7.1	5,628	8.0	2,330	8.8	1,364	8.8
35–39	29,355	9.7	4,715	8.2	6,174	8.8	2,348	8.9	1,575	10.2
40–44	35,173	11.6	6,239	10.9	7,852	11.2	3,213	12.2	1,961	12.7
45–49	47,182	15.5	8,936	15.6	10,823	15.5	4,388	16.6	2,587	16.7
50-54	51,079	16.8	10,403	18.1	12,117	17.3	4,728	17.9	2,605	16.8
55–59	35,345	11.6	7,863	13.7	9,071	13.0	3,385	12.8	1,779	11.5
60-64	18,692	6.2	5,051	8.8	5,591	8.0	2,024	7.7	1,114	7.2
≥65	11,425	3.8	3,583	6.2	4,447	6.4	1,336	5.1	830	5.4
Subtotal	304,032	100.0	57,382	100.0	69,968	100.0	26,418	100.0	15,500	100.0
Race/ethnicity										
American Indian/Alaska Native	1,542	0.5	260	0.5	281	0.4	80	0.3	62	0.4
Asian	3,012	1.0	735	1.3	967	1.4	376	1.4	381	2.5
Black/African American	152,767	50.6	24,549	43.0	27,595	39.7	10,668	40.6	5,125	33.7
Hispanic/Latino ^a	72,006	23.9	11,870	20.8	13,255	19.1	4,575	17.4	3,778	24.9
Native Hawaiian/Pacific Islander	457	0.2	107	0.2	132	0.2	57	0.2	36	0.2
White	66,402	22.0	18,402	32.3	26,029	37.4	10,134	38.6	5,653	37.2
Multiple races	5,749	1.9	1,140	2.0	1,289	1.9	387	1.5	163	1.1
Subtotal	301,935	100.0	57,063	100.0	69,548	100.0	26,277	100.0	15,198	100.0
Gender										
Male	203,112	66.8	42,778	74.6	55,135	78.9	21,000	79.5	12,409	80.1
Female	96,885	31.9	14,092	24.6	14,362	20.6	5,307	20.1	2,963	19.1
Transgender	4,010	1.3	439	8.0	355	0.5	110	0.4	127	0.8
Subtotal	304,007	100.0	57,309	100.0	69,852	100.0	26,417	100.0	15,499	100.0
Transmission risk category										
Male-to-male sexual contact	107,714	38.7	26,905	50.5	37,502	57.8	14,193	58.7	8,147	60.5
Injection drug use	27,282	9.8	3,129	5.9	2,604	4.0	1,262	5.2	452	3.4
Male-to-male sexual contact and injection drug use	7,479	2.7	1,325	2.5	1,268	2.0	373	1.5	160	1.2
Heterosexual contact ^b	124,974	44.8	20,303	38.1	21,882	33.7	7,655	31.6	4,363	32.4
Perinatal infection	8,394	3.0	1,135	2.1	1,006	1.6	416	1.7	231	1.7
Other ^c	2,860	1.0	538	1.0	615	1.0	293	1.2	115	0.9
	278,703	100.0	53,335	100.0	64,877	100.0	293 24,192	100.0		100.0
Subtotal	210,703	100.0	55,535	100.0	04,077	100.0	24, 192	100.0	13,468	100.0

Table 5. Ryan White HIV/AIDS Program clients (non-ADAP), by poverty level and selected characteristics, 2014—United States and 3 territories (cont)

	0–100% F	PL	101–138%	FPL	139–250%	FPL	251-400%	FPL	>400% F	PL
	No.	%	No.	%	No.	%	No.	%	No.	%
Housing status										
Stable	234,858	79.0	51,207	90.6	64,051	93.0	23,758	91.4	14,063	91.5
Temporary	43,982	14.8	3,794	6.7	3,651	5.3	1,615	6.2	897	5.8
Unstable	18,418	6.2	1,547	2.7	1,137	1.7	634	2.4	414	2.7
Subtotal	297,258	100.0	56,548	100.0	68,839	100.0	26,007	100.0	15,374	100.0
Health care coverage										
Private employer	7,170	2.4	2,637	4.7	9,075	13.3	6,849	26.7	3,492	23.1
Private individual	9,376	3.2	3,010	5.3	7,461	10.9	3,316	13.0	1,538	10.2
Medicare	22,414	7.5	10,560	18.7	10,035	14.7	2,077	8.1	843	5.6
Medicaid	127,578	42.9	13,547	24.0	9,850	14.4	3,825	14.9	1,992	13.2
Medicare and Medicaid	24,680	8.3	6,779	12.0	3,906	5.7	1,096	4.3	388	2.6
Veterans Administration	573	0.2	312	0.6	268	0.4	101	0.4	26	0.2
Indian Health Service	101	0.0	1	0.0	9	0.0	1	0.0	2	0.0
Other plan	10,384	3.5	1,497	2.7	2,484	3.6	902	3.5	425	2.8
No coverage	77,781	26.1	12,544	22.2	17,325	25.3	5,011	19.6	4,425	29.2
Multiple coverages	17,667	5.9	5,579	9.9	8,063	11.8	2,438	9.5	2,004	13.2
Subtotal	297,724	100.0	56,466	100.0	68,476	100.0	25,616	100.0	15,135	100.0
Total ^d	304,168	_	57,396	_	69,999	_	26,420	_	15,500	_

Abbreviation: FPL, federal poverty level.

^a Hispanics/Latinos can be of any race.

^b Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^c Includes hemophilia, blood transfusion, and unknown risk factor.

^d Subtotals for each subpopulation are displayed to reflect the denominator used for the percentage calculation of each subpopulation; due to missing data, the values in each column may not sum to the column total.

Table 6. Ryan White HIV/AIDS Program clients (non-ADAP), by housing status and selected characteristics, 2014—United States and 3 territories

	Stable		Tempora	ary	Unstab	le
	No.	%	No.	%	No.	%
Age group (yr)						
<13	5,579	1.4	638	1.1	53	0.2
13–14	658	0.2	65	0.1	4	0.0
15–19	3,641	0.9	609	1.1	136	0.6
20–24	15,993	4.0	3,801	6.7	1,240	5.5
25–29	28,729	7.2	6,013	10.6	2,173	9.6
30–34	32,780	8.2	6,001	10.6	2,238	9.9
35–39	36,594	9.1	6,030	10.6	2,353	10.4
40–44	45,773	11.4	6,884	12.1	2,823	12.5
45–49	62,472	15.5	8,887	15.6	3,766	16.6
50-54	69,701	17.3	8,591	15.1	4,034	17.8
55-59	50,639	12.6	5,353	9.4	2,350	10.4
60–64	29,337	7.3	2,625	4.6	1,036	4.6
≥65	20,150	5.0	1,353	2.4	453	2.0
Subtotal	402,046	100.0	56,850	100.0	22,659	100.0
Race/ethnicity						
American Indian/Alaska Native	1,788	0.5	267	0.5	179	0.8
Asian	4,742	1.2	711	1.3	152	0.7
Black/African American	184,935	46.3	25,883	46.0	11,946	52.9
Hispanic/Latino ^a	88,320	22.1	15,439	27.4	4,180	18.5
Native Hawaiian/Pacific Islander	690	0.2	82	0.2	37	0.2
White	112,051	28.1	12,679	22.5	5,413	24.0
Multiple races	6,879	1.7	1,227	2.2	680	3.0
Subtotal	399,405	100.0	56,288	100.0	22,587	100.0
Gender						
Male	281,803	70.1	42,455	74.8	16,971	74.8
Female	116,340	29.0	13,489	23.8	5,178	22.8
Transgender	3,754	0.9	822	1.5	527	2.3
Subtotal	401,897	100.0	56,766	100.0	22,676	100.0
Transmission risk category						
Male-to-male sexual contact	168,516	45.3	23,685	45.9	7,766	38.8
Injection drug use	26,863	7.2	5,566	10.8	2,864	14.3
Male-to-male sexual contact and injection drug use	7,923	2.1	1,893	3.7	1,125	5.6
Heterosexual contact ^b	155,362	41.7	18,477	35.8	7,827	39.1
Perinatal infection	9,952	2.7	1,477	2.9	253	1.3
Other ^c	3,828	1.0	465	0.9	207	1.0
	·					
Subtotal	372,444	100.0	51,563	100.0	20,042	100.0

Table 6. Ryan White HIV/AIDS Program clients (non-ADAP), by housing status and selected characteristics, 2014—United States and 3 territories (cont)

	Stable		Tempora	ary	Unstab	le
	No.	%	No.	%	No.	%
Health care coverage						
Private employer	28,340	7.2	1,056	1.9	328	1.5
Private individual	23,329	5.9	1,297	2.3	562	2.5
Medicare	42,772	10.8	3,271	5.8	1,218	5.5
Medicaid	127,927	32.4	20,137	35.8	10,186	46.1
Medicare and Medicaid	31,886	8.1	3,440	6.1	1,757	8.0
Veterans Administration	1,097	0.3	131	0.2	54	0.2
Indian Health Service	75	0.0	12	0.0	25	0.1
Other plan	13,857	3.5	4,254	7.6	713	3.2
No coverage	94,341	23.9	18,330	32.6	5,737	26.0
Multiple coverages	30,780	7.8	4,266	7.6	1,523	6.9
Subtotal	394,404	100.0	56,194	100.0	22,103	100.0
Total ^d	402,175	_	56,868	_	22,702	_

^a Hispanics/Latinos can be of any race.

^b Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^c Includes hemophilia, blood transfusion, and unknown risk factor.

^d Subtotals for each subpopulation are displayed to reflect the denominator used for the percentage calculation of each subpopulation; due to missing data, the values in each column may not sum to the column total.

Table 7. Ryan White HIV/AIDS Program clients (non-ADAP), by health care coverage and selected characteristics, 2014—United States and 3 territories

	Priva emplo		Priva individ		Medica	are	Medica	aid	Medica:		Vetera Administ		Indian He		Other i	olan	No cove	rage	Multip	
-	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Age group (yr)																				
<13	339	1.1	158	0.6	20	0.0	5,116	3.2	39	0.1	7	0.5	0	0.0	66	0.3	318	0.3	159	0.4
13–14	36	0.1	10	0.0	9	0.0	577	0.4	1	0.0	2	0.2	0	0.0	39	0.2	43	0.0	37	0.1
15–19	219	0.7	112	0.4	31	0.1	2,992	1.8	18	0.1	7	0.5	0	0.0	154	0.8	666	0.5	169	0.5
20-24	1,357	4.5	1,246	4.8	178	0.4	7,824	4.8	298	0.8	34	2.6	4	3.5	895	4.6	7,994	6.5	1,378	3.7
25–29	2,423	8.0	2,246	8.7	597	1.2	12,121	7.5	708	1.9	37	2.8	6	5.2	1,848	9.5	15,036	12.2	2,380	6.4
30-34	2,715	8.9	2,450	9.5	1,242	2.6	13,555	8.4	1,238	3.3	61	4.7	12	10.4	2,099	10.8	15,312	12.4	2,794	7.6
35–39	2,979	9.8	2,706	10.5	2,095	4.3	14,439	8.9	1,919	5.1	70	5.4	16	13.9	2,186	11.3	15,811	12.8	3,212	8.7
40-44	3,867	12.7	3,245	12.6	3,802	7.8	17,857	11.0	3,324	8.8	107	8.2	22	19.1	2,585	13.3	17,001	13.8	4,101	11.1
45-49	5,146	16.9	4,132	16.0	7,112	14.6	25,308	15.6	6,384	17.0	152	11.7	16	13.9	3,034	15.6	18,620	15.1	5,819	15.7
50-54	5,286	17.4	4,476	17.4	10,257	21.1	27,935	17.2	8,646	23.0	229	17.6	15	13.0	3,007	15.5	16,501	13.4	6,656	18.0
55–59	3,589	11.8	2,795	10.9	8,947	18.4	20,196	12.5	6,684	17.8	271	20.8	18	15.7	1,995	10.3	9,560	7.8	4,863	13.1
60–64	1,879	6.2	1,705	6.6	5,943	12.2	10,879	6.7	3,898	10.4	203	15.6	5	4.4	1,081	5.6	4,730	3.8	2,978	8.0
≥65	573	1.9	477	1.9	8,500	17.4	3,455	2.1	4,439	11.8	122	9.4	1	0.9	436	2.2	1,669	1.4	2,476	6.7
Subtotal	30,408	100.0	25,758	100.0	48,733	100.0	162,254	100.0	37,596	100.0	1,302	100.0	115	100.0	19,425	100.0	123,261	100.0	37,022	100.0
Race/ethnicity																				
American Indian/Alaska Native	115	0.4	116	0.5	192	0.4	799	0.5	256	0.7	13	1.0	102	88.7	103	0.5	317	0.3	246	0.7
Asian	398	1.3	458	1.8	243	0.5	1,776	1.1	230	0.6	6	0.5	2	1.7	352	1.8	1,573	1.3	537	1.5
Black/African American	12,853	42.5	9,964	39.1	22,000	45.5	83,545	51.8	16,427	43.8	567	43.7	0	0.0	6,682	34.6	60,396	49.4	13,499	36.9
Hispanic/Latino ^a	4,147	13.7	3,968	15.6	6,174	12.8	40,134	24.9	6,512	17.4	139	10.7	6	5.2	6,234	32.3	34,298	28.1	7,154	19.6
Native Hawaiian/Pacific Islander	64	0.2	57	0.2	59	0.1	272	0.2	68	0.2	4	0.3	0	0.0	53	0.3	146	0.1	63	0.2
White	12,220	40.4	10,435	40.9	18,807	38.9	31,731	19.7	13,020	34.7	533	41.1	3	2.6	5,619	29.1	23,949	19.6	14,056	38.4
Multiple races	418	1.4	510	2.0	881	1.8	3,094	1.9	976	2.6	35	2.7	2	1.7	245	1.3	1,615	1.3	1,044	2.9
Subtotal	30,215	100.0	25,508	100.0	48,356	100.0	161,351	100.0	37,489	100.0	1,297	100.0	115	100.0	19,288	100.0	122,294	100.0	36,599	100.0
Gender																				
Male	23,249	76.5	20,439	79.4	37,201	76.4	99,177	61.1	26,643	70.9	1,157	89.0	79	68.7	14,898	76.7	93,797	76.2	27,579	74.5
Female	7,062	23.2	5,114	19.9	11,243	23.1	60,745	37.5	10,606	28.2	136		35	30.4	4,320	22.3	27,943	22.7	9,114	
Transgender	88	0.3	206	0.8	275	0.6	2,287	1.4	345	0.9	7	0.5	1	0.9	201	1.0	1,391	1.1	329	0.9
Subtotal	30,399	100.0	25,759	100.0	48,719	100.0	162,209	100.0	37,594	100.0	1,300	100.0	115	100.0	19,419	100.0	123,131	100.0	37,022	100.0
Transmission risk category																				
Male-to-male sexual contact	16,819	58.2	14,250	60.6	21,046	47.2	47,433	32.1	15,376	42.8	676		47	42.3	10,065	55.6	56,220	50.4	18,434	
Injection drug use	852	3.0	786	3.3	3,895	8.7	18,078	12.2	4,067	11.3	114	9.1	16	14.4	824	4.6	4,662	4.2	2,348	6.7
Male-to-male sexual contact and injection drug use	358	1.2	383	1.6	1,225	2.7	3,799	2.6	1,476	4.1	41	3.3	8	7.2	486	2.7	1,980	1.8	1,224	3.5
Heterosexual contact ^b	9,991	34.6	7,584	32.3	17,600	39.4	68,542	46.4	14,215	39.6	376	30.2	40	36.0	6,334	35.0	46,762	41.9	11,993	34.4
Perinatal infection	598	2.1	285	1.2	152	0.3	8,338	5.7	294	8.0	23	1.8	0	0.0	218	1.2	1,205	1.1	527	1.5
Other ^c	292	1.0	211	0.9	723	1.6	1,469	1.0	497	1.4	17	1.4	0	0.0	171	0.9	812	0.7	343	1.0
Subtotal	28,910	100.0	23,499	100.0	44,641	100.0	147,659	100.0	35,925	100.0	1,247	100.0	111	100.0	18,098	100.0	111,641	100.0	34,869	100.0
Total ^d	30,410	_	25,762	_	48,750	_	162,372	_	37,617	_	1,302	_	115	_	19,425	_	123,273	_	37,036	_

^a Hispanics/Latinos can be of any race.

^b Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^c Includes hemophilia, blood transfusion, and unknown risk factor.

^d Subtotals for each subpopulation are displayed to reflect the denominator used for the percentage calculation of each subpopulation; due to missing data, the values in each column may not sum to the column total.

Table 8. Ryan White HIV/AIDS Program clients (non-ADAP), by HHS region and selected characteristics, 2014—United States and 3 territories

13-14		Regio	n 1	Regio	n 2	Regio	n 3	Regior	ո 4	Regio	n 5	Regio	n 6	Regio	on 7	Regio	on 8	Regio	n 9	Regio	n 10
13-14 13-1		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
13-14 3 0 0 1 98 0 1 79 0 1 538 0 3 0 1 539 0 1 79 0 1 538 0 3 137 0 3 65 0 1 8 0 1 20 0 2 0 71 0 1 1 51-51 51-51 0 1 51	Age group (yr)																				
15-19 175 0.8 1.139 1.3 1.475 0.8 1.139 1.3 1.475 0.8 1.139 1.3 1.475 0.8 1.139 1.4 2. 61.4 5.3 1.769 1.4 5.1 1.09 6.2 0.6 6.9 0.8 3.08 3.08 0.5 3 25-29 1992 4.4 5.974 6.6 4.289 7.6 10.505 8.2 5.66 8.9 4.6 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	<13	179	0.8	670	0.7	611	1.1	2,565	2.0	785	1.4	643	1.1	99	1.0	217	2.4	695	1.1	73	0.7
20-24 599 26 3,789 3.1 4.2 6,724 5.3 2,976 5.3 3,199 5.5 5.58 5.8 260 2.9 1,871 3.1 25 25 25 25 3.0	13–14	30	0.1	98	0.1	79	0.1	335	0.3	137	0.3	65	0.1	8	0.1	20	0.2	71	0.1	10	0.1
25-29 992 4.4 5.974 6.6 4.289 7.6 10.505 8.2 5.168 9.3 5.547 9.5 8.28 8.5 95 6.6 4.012 6.5 5.66 9.3 0.0-44 1.310 5.8 6.65 8.7 0.3 4.489 7.9 10.967 8.6 5.388 9.4 6.10 10.5 10.5 10.5 10.5 11.5 10.5 11.5 10.5 11.5 10.5 11.5 10.5 11.5 10.5 11.5 10.5 11.5 10.5 11.5 11	15–19	175	0.8	1,139	1.3	475	0.8	1,838	1.4	769	1.4	511	0.9	62	0.6	69	0.8	308	0.5	36	0.3
39–94 1,310 5,8 6,658 7,3 4,458 7,9 10,967 8,6 5,228 9,4 6,109 10,5 9,80 10,1 10,29 9,1 5,265 8,6 8,9 4,444 10,4	20–24	579	2.6	3,769	4.1	2,381	4.2	6,724	5.3	2,976	5.3	3,199	5.5	558	5.8	260	2.9	1,871	3.1	259	2.4
35-39	25-29	992	4.4	5,974	6.6	4,289	7.6	10,505	8.2	5,166	9.3	5,547	9.5	828	8.5	595	6.6	4,012	6.5	618	5.
40-44 46-49 3.86 i 1.72 14.01 15.4 8.75 15.5 19.70 11.4 8.53 11.7 7.257 12.5 1.23 12.7 1.198 13.2 7.356 12.0 1.46-49 13.66 i 1.72 14.01 15.4 8.757 15.5 19.20 15.1 8.390 16.0 8.866 15.2 1.658 17.1 1.556 17.2 10.83 10.175 16.6 1.78 15.5 19.5 19.00 16.0 8.86 15.2 1.658 17.1 1.556 17.2 10.83 10.175 16.6 1.78 15.5 19.00 16.0 8.66 15.2 1.658 17.1 1.556 17.2 10.83 10.175 16.6 1.78 15.5 19.00 16.0 8.66 15.2 1.658 17.1 1.556 17.2 10.83 10.175 16.6 1.78 15.5 19.00 16.0 10.3 10.00 10.00 10.3 10.00 10.3 10.00 10.3 10.00 10.3 10.00 10.3 10.00 10.3 10.00 10.3 10.00 10.3 10.00 10.3 10.00 10.3 10.00 10.3 10.00 10.0 10.	30-34	1,310	5.8	6,658	7.3	4,458	7.9	10,967	8.6	5,228	9.4	6,109	10.5	980	10.1	829	9.1	5,265	8.6	940	8.
45-49	35–39	1,621	7.2	7,414	8.1	4,802	8.5	11,825	9.3	5,386	9.7	6,514	11.2	1,046	10.8	925	10.2	5,911	9.6	1,154	10.
50-54	40-44	2,414	10.8	9,514	10.5	5,957	10.5	14,570	11.4	6,531	11.7	7,257	12.5	1,232	12.7	1,198	13.2	7,356	12.0	1,408	13.
55-59 3,552 15.8 12,462 13.7 7,529 13.3 14,639 11.5 6,076 10.9 6,009 10.3 1,000 10.3 956 10.5 7,375 12.0 1,275 12.5 1,308 1.5 1	45-49	3,866	17.2	14,041	15.4	8,775	15.5	19,240	15.1	8,336	15.0	8,640	14.8	1,457	15.0	1,483	16.3	10,175	16.6	1,786	16.
60-64	50-54	4,522	20.1	16,054	17.6	10,170	18.0	20,862	16.4	8,909	16.0	8,866	15.2	1,658	17.1	1,556	17.2	10,834	17.7	1,989	18.
Subtotal 1,308 5,8 5,630 6,2 2,721 4,8 5,424 4,3 1,978 3,6 1,864 3,2 284 2,9 362 4,0 3,091 5,0 49 Subtotal 22,454 100,0 91,03 100,0 56,590 100,0 127,459 100,0 55,709 100,0 58,262 100,0 9,701 100,0 9,704 100,0 61,380 100,0 10,79 Race/ethnicity Race	55-59	3,552	15.8	12,462	13.7	7,529	13.3	14,639	11.5	6,076	10.9	6,009	10.3	1,000	10.3	956	10.5	7,375	12.0	1,270	11.
Subtotal	60-64	1,906	8.5	7,610	8.4	4,343	7.7	7,965	6.3	3,432	6.2	3,038	5.2	489	5.0	604	6.7	4,416	7.2	764	7.
Race/ethnicity American Indian/Alaska Native American Americ	≥65	1,308	5.8	5,630	6.2	2,721	4.8	5,424	4.3	1,978	3.6	1,864	3.2	284	2.9	362	4.0	3,091	5.0	492	4.
American Indian/Alaska Native 69 0.3 172 0.2 69 0.1 271 0.2 282 0.5 386 0.7 51 0.5 159 1.8 561 0.9 31 Asian Maian Marican 6,753 30.3 38,784 43.0 36,354 66.0 77,843 61.4 29,404 53.2 27,478 47.2 4.345 44.8 1,583 17.8 11,590 3.2 25 Black/African American 6,291 28.3 36,829 40.9 5,319 9.7 14,662 11.6 6,542 11.8 14,189 24.4 62.9 6.5 2,055 23.1 23,045 37.9 1,54 Native Hawaiian/Pacific Islander 18 0.1 778 0.1 44 0.1 55 0.0 37 0.1 44 0.1 12 0.1 17 0.2 22,175 32.4 Multiple races 32.9 1.5 959 1.1 1.483 2.7 2.256 1.8 996 1.8 966 1.0 55,282 10.0 58,184 10.0 9,700 10.0 8,892 10.0 60,889 10.0 10.73 Cendar	Subtotal	22,454	100.0	91,033	100.0	56,590	100.0	127,459	100.0	55,709	100.0	58,262	100.0	9,701	100.0	9,074	100.0	61,380	100.0	10,799	100.
American Indian/Alaska Native 69 0.3 172 0.2 69 0.1 271 0.2 282 0.5 386 0.7 51 0.5 159 1.8 561 0.9 31 Asian Maian Marican 6,753 30.3 38,784 43.0 36,354 66.0 77,843 61.4 29,404 53.2 27,478 47.2 4.345 44.8 1,583 17.8 11,590 3.2 25 Black/African American 6,291 28.3 36,829 40.9 5,319 9.7 14,662 11.6 6,542 11.8 14,189 24.4 62.9 6.5 2,055 23.1 23,045 37.9 1,54 Native Hawaiian/Pacific Islander 18 0.1 778 0.1 44 0.1 55 0.0 37 0.1 44 0.1 12 0.1 17 0.2 22,175 32.4 Multiple races 32.9 1.5 959 1.1 1.483 2.7 2.256 1.8 996 1.8 966 1.0 55,282 10.0 58,184 10.0 9,700 10.0 8,892 10.0 60,889 10.0 10.73 Cendar	Race/ethnicity																				
Asian	-	69	0.3	172	0.2	69	0.1	271	0.2	282	0.5	386	0.7	51	0.5	159	1.8	561	0.9	316	2.
Black/African American 6,753 30.3 38,784 43.0 36,354 66.0 77,843 61.4 29,404 53.2 27,478 47.2 4,345 44.8 1,583 17.8 11,590 19.0 1,63										-							_			251	2.
Hispanic/Latino ⁸ 6,291 28.3 36,829 40.9 5,319 9.7 14,662 11.6 6,542 11.8 14,189 24.4 629 6.5 2,055 23.1 23,045 37.9 1,54 Native Hawaiian/Pacific Islander 18 0.1 78 0.1 44 0.1 55 0.0 37 0.1 44 0.1 12 0.1 17 0.2 446 0.7 8.8 White Hawaiian/Pacific Islander 8,527 38.3 12,260 13.6 11,357 20.6 31,199 24.6 17,453 31.6 15,042 25.9 4,450 45.9 4,775 53.7 22,179 36.4 6.2 Multiple races 329 1.5 959 1.1 1,483 2.7 2,256 1.8 996 1.8 569 1.0 124 1.3 172 1.9 1,129 1.9 47 Subtotal 22,261 10.0 90,152 10.0 55,047 10.0 126,865 10.0 55,282 10.0 58,184 10.0 9,700 10.0 8,892 10.0 60,889 10.0 10.73 1.9 47 Subtotal 14,999 66.8 58,367 64.1 36,858 65.3 86,350 67.8 41,438 74.4 42,367 72.7 7,408 76.4 7,240 79.8 50,333 82.0 8,73 17 18,996 1.8 19,997 1.0 19	Black/African American	6.753		,		36.354		77.843	61.4	29.404	53.2	27.478		4.345				,		1,636	
Native Hawaiian/Pacific Islander	Hispanic/Latino ^a	6 291	28.3	36 829	40.9	5 319	9.7	14 662	11.6	6.542	11.8	-	24 4	629	6.5	2 055	23.1	23 045	37.9	1,546	14.
White Asserting Series of Series Seri	•			,		,		,		,								,		89	0.
Multiple races 329 1.5 959 1.1 1,483 2.7 2,256 1.8 996 1.8 569 1.0 124 1.3 172 1.9 1,129 1.9 47 Subtotal 22,261 100.0 90,152 100.0 55,047 100.0 126,865 100.0 55,282 100.0 58,184 100.0 9,700 100.0 8,892 100.0 60,889 100.0 10,73 Gender Male 14,999 66.8 58,367 64.1 36,858 65.3 86,350 67.8 41,438 74.4 42,367 72.7 7,408 76.4 7,240 79.8 50,333 82.0 8,73 Female 7,275 32.4 31,656 34.8 18,639 33.0 40,323 31.6 13,593 24.4 15,373 26.4 2,177 22.4 1,777 19.6 9,973 16.3 1,94 Transgender 178 0.8 1,006 1.1 917 1.6 767 0.6 670 1.2 519 0.9 116 1.2 52 0.6 1,061 1.7 10 Subtotal 22,452 100.0 91,029 100.0 56,414 100.0 127,440 100.0 55,701 100.0 58,259 100.0 9,701 100.0 9,699 100.0 61,367 100.0 10,78 Transmission risk category Male-to-male sexual contact 7,341 34.3 25,135 31.5 17,376 36.6 49,889 41.7 25,946 53.1 25,551 49.4 5,512 58.2 4,596 55.6 35,607 63.7 5,09 Male-to-male sexual contact 401 1.9 733 0.9 902 1.9 1,511 1.3 699 1.4 1,576 3.1 88 0.9 684 8.3 3,212 5.8 1,04 Heterosexual contact 401 1.9 733 0.9 902 1.9 1,511 1.3 699 1.4 1,576 3.1 88 0.9 684 8.3 3,212 5.8 1,04 Heterosexual contact 8,409 39.2 41,514 52.0 21,274 44.8 58,635 49.0 17,613 36.0 20,083 38.8 3,277 34.6 2,019 24.4 11,619 20.8 2,18 Perinatal infection 573 2.7 2,482 3.1 1,434 3.0 3,624 3.0 1,245 2.6 987 1.9 102 1.1 224 2.7 1,061 1.9 7 Other 312 1.5 836 1.1 498 1.1 1,012 0.9 525 1.1 443 0.9 100 1.1 106 1.3 588 1.1 21				_																6,424	
Subtotal 22,261 10.0 90,152 10.0 55,047 10.0 126,865 10.0 55,282 10.0 58,184 10.0 9,700 10.0 8,892 10.0 60,889 10.0 10,73 Gender Male 14,999 66.8 58,367 64.1 36,858 65.3 86,350 67.8 41,438 74.4 42,367 72.7 7,408 76.4 7,240 79.8 50,333 82.0 8,73 Female 7,275 32.4 31,656 34.8 18,639 33.0 40,323 31.6 13,593 24.4 15,373 26.4 2,177 22.4 1,777 19.6 9,973 16.3 1,94 Transgender 178 0.8 1,006 1.1 917 1.6 767 0.6 670 1.2 519 0.9 116 1.2 52 0.6 1,061 1.7 10 Subtotal 7,341 34.3 25,135 31.5		,						,		,								,		472	4.
Male 14,999 66.8 58,367 64.1 36,858 65.3 86,350 67.8 41,438 74.4 42,367 72.7 7,408 76.4 7,240 79.8 50,333 82.0 8,73 Female 7,275 32.4 31,656 34.8 18,639 33.0 40,323 31.6 13,593 24.4 15,373 26.4 2,177 22.4 1,777 19.6 9,973 16.3 1,94 Transgender 178 0.8 1,006 1.1 917 1.6 767 0.6 670 1.2 519 0.9 116 1.2 52 0.6 1,061 1.7 10 Subtotal 22,452 100.0 91,029 100.0 127,440 100.0 55,701 100.0 58,259 100.0 9,069 100.0 61,367 100.0 10,78 Transmission risk category Male-to-male sexual contact 7,341 34.3 25,135 31.5 17,3	•					,		,	_		-							, -		10,734	100.
Male 14,999 66.8 58,367 64.1 36,858 65.3 86,350 67.8 41,438 74.4 42,367 72.7 7,408 76.4 7,240 79.8 50,333 82.0 8,73 Female 7,275 32.4 31,656 34.8 18,639 33.0 40,323 31.6 13,593 24.4 15,373 26.4 2,177 22.4 1,777 19.6 9,973 16.3 1,94 Transgender 178 0.8 1,006 1.1 917 1.6 767 0.6 670 1.2 519 0.9 116 1.2 52 0.6 1,061 1.7 10 Subtotal 22,452 100.0 91,029 100.0 127,440 100.0 55,701 100.0 58,259 100.0 9,069 100.0 61,367 100.0 10,78 Transmission risk category Male-to-male sexual contact 7,341 34.3 25,135 31.5 17,3	Gender																				
Female 7,275 32.4 31,656 34.8 18,639 33.0 40,323 31.6 13,593 24.4 15,373 26.4 2,177 22.4 1,777 19.6 9,973 16.3 1,94 Transgender 178 0.8 1,006 1.1 917 1.6 767 0.6 670 1.2 519 0.9 116 1.2 52 0.6 1,061 1.7 10 Subtotal 22,452 100.0 91,029 100.0 56,414 100.0 127,440 100.0 55,701 100.0 58,259 100.0 9,701 100.0 9,069 100.0 61,367 100.0 10,78 Transmission risk category Male-to-male sexual contact 7,341 34.3 25,135 31.5 17,376 36.6 49,889 41.7 25,946 53.1 25,551 49.4 5,512 58.2 4,596 55.6 35,607 63.7 5,09 Male-to-male sexual contact 401 1.9 733 0.9 902 1.9 1,511 1.3 699 1.4 1,576 3.1 88 0.9 684 8.3 3,212 5.8 1,04 and injection drug use Heterosexual contact 401 1.9 733 0.9 21,274 44.8 58,635 49.0 17,613 36.0 20,083 38.8 3,277 34.6 2,019 24.4 11,619 20.8 2,18 Perinatal infection 573 2.7 2,482 3.1 1,434 3.0 3,624 3.0 1,245 2.6 987 1.9 102 1.1 224 2.7 1,061 1.9 7 Other 312 1.5 836 1.1 498 1.1 1,012 0.9 525 1.1 443 0.9 100 1.1 106 1.3 588 1.1 21		14 999	66.8	58 367	64 1	36 858	65.3	86 350	67.8	41 438	74 4	42 367	72 7	7 408	76 4	7 240	79.8	50 333	82.0	8,737	81.
Transgender 178 0.8 1,006 1.1 917 1.6 767 0.6 670 1.2 519 0.9 116 1.2 52 0.6 1,061 1.7 10 Subtotal 22,452 100.0 91,029 100.0 56,414 100.0 127,440 100.0 55,701 100.0 58,259 100.0 9,701 100.0 9,069 100.0 61,367 100.0 10,78 Transmission risk category Male-to-male sexual contact 7,341 34.3 25,135 31.5 17,376 36.6 49,889 41.7 25,946 53.1 25,551 49.4 5,512 58.2 4,596 55.6 35,607 63.7 5,09 Injection drug use 4,393 20.5 9,110 11.4 5,987 12.6 5,012 4.2 2,852 5.8 3,065 5.9 393 4.2 634 7.7 3,792 6.8 89 Male-to-male sexual contact 401 1.9 733 0.9 902 1.9 1,511 1.3 699 1.4 1,576 3.1 88 0.9 684 8.3 3,212 5.8 1,04 and injection drug use Heterosexual contact 5 8,409 39.2 41,514 52.0 21,274 44.8 58,635 49.0 17,613 36.0 20,083 38.8 3,277 34.6 2,019 24.4 11,619 20.8 2,18 Perinatal infection 573 2.7 2,482 3.1 1,434 3.0 3,624 3.0 1,245 2.6 987 1.9 102 1.1 224 2.7 1,061 1.9 7 Other 312 1.5 836 1.1 498 1.1 1,012 0.9 525 1.1 443 0.9 100 1.1 106 1.3 588 1.1 21		,		,		,		,		,		,						,			18.
Subtotal 22,452 100.0 91,029 100.0 56,414 100.0 127,440 100.0 55,701 100.0 58,259 100.0 9,701 100.0 9,069 100.0 61,367 100.0 10,78 Transmission risk category Male-to-male sexual contact 7,341 34.3 25,135 31.5 17,376 36.6 49,889 41.7 25,946 53.1 25,551 49.4 5,512 58.2 4,596 55.6 35,607 63.7 5,09 Injection drug use 4,393 20.5 9,110 11.4 5,987 12.6 5,012 4.2 2,852 5.8 3,065 5.9 393 4.2 634 7.7 3,792 6.8 89 Male-to-male sexual contact and injection drug use 401 1.9 733 0.9 902 1.9 1,511 1.3 699 1.4 1,576 3.1 88 0.9 684 8.3 3,212 5.8 1,04 <td< td=""><td></td><td></td><td></td><td>,</td><td></td><td>,</td><td></td><td>,</td><td></td><td>,</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>106</td><td>1.</td></td<>				,		,		,		,										106	1.
Male-to-male sexual contact 7,341 34.3 25,135 31.5 17,376 36.6 49,889 41.7 25,946 53.1 25,551 49.4 5,512 58.2 4,596 55.6 35,607 63.7 5,09 Injection drug use 4,393 20.5 9,110 11.4 5,987 12.6 5,012 4.2 2,852 5.8 3,065 5.9 393 4.2 634 7.7 3,792 6.8 89 Male-to-male sexual contact 401 1.9 733 0.9 902 1.9 1,511 1.3 699 1.4 1,576 3.1 88 0.9 684 8.3 3,212 5.8 1,04 and injection drug use Heterosexual contact 8,409 39.2 41,514 52.0 21,274 44.8 58,635 49.0 17,613 36.0 20,083 38.8 3,277 34.6 2,019 24.4 11,619 20.8 2,18 Perinatal infection 573 2.7 2,482 3.1 1,434 3.0 3,624 3.0 1,245 2.6 987 1.9 102 1.1 224 2.7 1,061 1.9 7 Other 312 1.5 836 1.1 498 1.1 1,012 0.9 525 1.1 443 0.9 100 1.1 106 1.3 588 1.1 21	9	_		,														,		10,784	
Male-to-male sexual contact 7,341 34.3 25,135 31.5 17,376 36.6 49,889 41.7 25,946 53.1 25,551 49.4 5,512 58.2 4,596 55.6 35,607 63.7 5,09 Injection drug use 4,393 20.5 9,110 11.4 5,987 12.6 5,012 4.2 2,852 5.8 3,065 5.9 393 4.2 634 7.7 3,792 6.8 89 Male-to-male sexual contact 401 1.9 733 0.9 902 1.9 1,511 1.3 699 1.4 1,576 3.1 88 0.9 684 8.3 3,212 5.8 1,04 and injection drug use Heterosexual contact 8,409 39.2 41,514 52.0 21,274 44.8 58,635 49.0 17,613 36.0 20,083 38.8 3,277 34.6 2,019 24.4 11,619 20.8 2,18 Perinatal infection 573 2.7 2,482 3.1 1,434 3.0 3,624 3.0 1,245 2.6 987 1.9 102 1.1 224 2.7 1,061 1.9 7 Other 312 1.5 836 1.1 498 1.1 1,012 0.9 525 1.1 443 0.9 100 1.1 106 1.3 588 1.1 21	Transmission risk category																				
Injection drug use 4,393 20.5 9,110 11.4 5,987 12.6 5,012 4.2 2,852 5.8 3,065 5.9 393 4.2 634 7.7 3,792 6.8 89 Male-to-male sexual contact 401 1.9 733 0.9 902 1.9 1,511 1.3 699 1.4 1,576 3.1 88 0.9 684 8.3 3,212 5.8 1,04 and injection drug use Heterosexual contact ^b 8,409 39.2 41,514 52.0 21,274 44.8 58,635 49.0 17,613 36.0 20,083 38.8 3,277 34.6 2,019 24.4 11,619 20.8 2,18 Perinatal infection 573 2.7 2,482 3.1 1,434 3.0 3,624 3.0 1,245 2.6 987 1.9 102 1.1 224 2.7 1,061 1.9 7 Other ^c 312 1.5 836 1.1 498 1.1 1,012 0.9 525 1.1 443 0.9 100 1.1 106 1.3 588 1.1 21	0 ,	7 341	34 3	25 135	31.5	17 376	36.6	49 889	41 7	25 946	53 1	25 551	49 4	5 512	58.2	4 596	55.6	35 607	63.7	5 095	53.
Male-to-male sexual contact and injection drug use Heterosexual contact Perinatal infection 312 1.5 836 1.1 902 1.9 1,511 1.3 699 1.4 1,576 3.1 88 0.9 684 8.3 3,212 5.8 1,04 1,04 2,18 2,18 2,18 2,18 2,18 2,18 2,18 2,18		,		,		,		,		,		,						,		897	9.
Perinatal infection 573 2.7 2,482 3.1 1,434 3.0 3,624 3.0 1,245 2.6 987 1.9 102 1.1 224 2.7 1,061 1.9 7 Other 312 1.5 836 1.1 498 1.1 1,012 0.9 525 1.1 443 0.9 100 1.1 106 1.3 588 1.1 21	Male-to-male sexual contact			-, -		,		- , -				,						,		1,045	11.
Perinatal infection 573 2.7 2,482 3.1 1,434 3.0 3,624 3.0 1,245 2.6 987 1.9 102 1.1 224 2.7 1,061 1.9 7 Other ^c 312 1.5 836 1.1 498 1.1 1,012 0.9 525 1.1 443 0.9 100 1.1 106 1.3 588 1.1 21	, ,	8 409	39.2	41 514	52.0	21 274	44 8	58 635	49 N	17 613	36 O	20 083	38.8	3 277	34.6	2 019	24.4	11 619	20.8	2,189	23.
Other ^c 312 1.5 836 1.1 498 1.1 1,012 0.9 525 1.1 443 0.9 100 1.1 106 1.3 588 1.1 21						,		,				,						,		70	0.
, , , , , , , , , , , , , , , , , , ,						, -		- , -										,			2.
Subtatal 24 /20 100 0 70 010 100 0 47 /71 100 0 110 602 100 0 40 00 100 0 51 705 100 0 0 72 100 0 0 26 100 0 55 070 100 0 054	Subtotal		100.0	79.810	100.0	47.471	100.0	119,683	100.0	48.880	100.0	51.705	100.0	9.472	100.0	8,263	100.0	55.879	100.0	9.513	

Table 8. Ryan White HIV/AIDS Program clients (non-ADAP), by HHS region and selected characteristics, 2014—United States and 3 territories (cont)

	Regio	n 1	Regio	n 2	Regio	n 3	Regior	1 4	Regio	า 5	Regio	n 6	Regio	n 7	Regio	n 8	Regio	n 9	Regio	n 10
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Poverty level																				
0-100%	13,372	62.5	53,177	60.6	34,596	66.5	75,735	63.4	32,594	65.7	35,292	74.2	5,060	54.2	4,724	60.6	37,140	63.4	6,019	57.8
101-138%	2,267	10.6	9,615	11.0	5,587	10.7	15,515	13.0	5,989	12.1	4,690	9.9	1,313	14.1	1,046	13.4	8,688	14.8	1,628	15.6
139-250%	3,756	17.5	9,116	10.4	8,113	15.6	20,517	17.2	6,873	13.9	5,593	11.8	2,202	23.6	1,332	17.1	9,223	15.8	1,960	18.8
251-400%	1,174	5.5	6,995	8.0	2,546	4.9	6,778	5.7	2,330	4.7	1,700	3.6	704	7.5	544	7.0	2,645	4.5	611	5.9
>400%	841	3.9	8,894	10.1	1,208	2.3	1,007	0.8	1,816	3.7	304	0.6	61	0.7	155	2.0	846	1.5	190	1.8
Subtotal	21,410	100.0	87,797	100.0	52,050	100.0	119,552	100.0	49,602	100.0	47,579	100.0	9,340	100.0	7,801	100.0	58,542	100.0	10,408	100.0
Health care coverage																				
Private employer	1,493	6.7	4,245	4.9	4,186	8.0	10,419	8.7	2,973	5.8	1,779	3.1	979	10.5	1,460	16.7	2,002	3.5	495	4.9
Private individual	1,970	8.9	3,925	4.5	3,121	6.0	4,897	4.1	3,606	7.0	2,934	5.1	1,659	17.9	422	4.8	1,500	2.6	1,089	10.7
Medicare	2,430	11.0	5,758	6.6	6,976	13.3	14,090	11.8	5,521	10.7	6,408	11.2	504	5.4	1,098	12.6	3,737	6.5	1,477	14.5
Medicaid	10,260	46.3	44,070	50.5	20,492	39.1	27,854	23.2	18,617	36.1	8,163	14.3	1,821	19.6	1,833	21.0	22,188	38.3	4,183	41.2
Medicare and Medicaid	2,416	10.9	5,540	6.4	3,572	6.8	8,200	6.8	4,340	8.4	2,802	4.9	1,639	17.6	1,092	12.5	6,251	10.8	760	7.5
Veterans Administration	25	0.1	45	0.1	132	0.3	395	0.3	186	0.4	142	0.3	41	0.4	68	0.8	208	0.4	45	0.4
Indian Health Service	0	0.0	4	0.0	2	0.0	2	0.0	0	0.0	3	0.0	0	0.0	5	0.1	9	0.0	90	0.9
Other plan	567	2.6	1,491	1.7	1,482	2.8	2,538	2.1	1,577	3.1	7,408	13.0	117	1.3	121	1.4	3,644	6.3	223	2.2
No coverage	1,282	5.8	15,003	17.2	9,923	19.0	46,626	38.9	10,205	19.8	22,486	39.3	1,170	12.6	2,118	24.3	11,775	20.3	755	7.4
Multiple coverages	1,707	7.7	7,214	8.3	2,486	4.8	4,836	4.0	4,598	8.9	5,037	8.8	1,359	14.6	507	5.8	6,580	11.4	1,039	10.2
Subtotal	22,150	100.0	87,295	100.0	52,372	100.0	119,857	100.0	51,623	100.0	57,162	100.0	9,289	100.0	8,724	100.0	57,894	100.0	10,156	100.0
Housing status																				
Stable	19,006	86.4	72,312	83.4	45,139	85.6	109,970	92.2	41,762	85.0	37,837	68.3	8,234	88.3	7,484	88.2	46,260	78.4	7,909	77.8
Temporary	2,250	10.2	9,268	10.7	5,199	9.9	5,841	4.9	5,538	11.3	15,612	28.2	826	8.9	709	8.4	8,831	15.0	761	7.5
Unstable	743	3.4	5,080	5.9	2,415	4.6	3,474	2.9	1,806	3.7	1,964	3.5	262	2.8	297	3.5	3,936	6.7	1,502	14.8
Subtotal	21,999	100.0	86,660	100.0	52,753	100.0	119,285	100.0	49,106	100.0	55,413	100.0	9,322	100.0	8,490	100.0	59,027	100.0	10,172	100.0
Total ^d	22,455	_	91,034	_	56,771	_	127,460	_	55,713	_	58,264	_	9,701	_	9,075	_	61,383	_	10,799	_

Note. See Technical Notes for the states/territories included in each region.

^a Hispanics/Latinos can be of any race.

b Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^c Includes hemophilia, blood transfusion, and unknown risk factor.

d Subtotals for each subpopulation are displayed to reflect the denominator used for the percentage calculation of each subpopulation; due to missing data, the values in each column may not sum to the column to the

Table 9. Ryan White HIV/AIDS Program clients (non-ADAP), by state, 2014—United States and 3 territories

	Adults and Adoleso		Childre		Total
State	No.	%	No.	%	No.
Alabama	9,134	98.2	168	1.8	9,302
Alaska	501	99.6	2	0.4	503
Arizona	2,074	100.0	1	0.1	2,075
Arkansas	6,700	98.6	93	1.4	6,795
California	50,000	98.9	538	1.1	50,539
Colorado	6,482	96.9	207	3.1	6,690
Connecticut	5,254	99.6	23	0.4	5,277
Delaware	1,657	100.0	0	0.0	1,657
District of Columbia	7,090	98.9	76	1.1	7,166
Florida	52,173	97.1	1,588	3.0	53,761
Georgia	20,524	98.4	341	1.6	20,865
Hawaii	995	99.9	1	0.1	996
Idaho	552	100.0	0	0.0	552
Illinios	22,968	98.8	287	1.2	23,255
Indiana	4,222	99.8	8	0.2	4,230
Iowa	1,289	99.8	3	0.2	1,292
Kansas	834	99.4	5	0.6	839
Kentucky	3,612	99.5	20	0.6	3,632
Louisiana	12,832	98.9	139	1.1	12,971
Maine	825	99.2	7	0.8	832
Maryland	13,418	98.8	162	1.2	13,761
Massachusetts	13,034	99.3	92	0.7	13,127
	8,952	99.3 97.8	205	2.2	9,157
Michigan Minneagta	4,966		39		
Minnesota Minainainai		99.2 97.7		0.8	5,008
Mississippi Missouri	4,018	98.7	93 91	2.3	4,111
Missouri Montana	6,877 369			1.3	6,968 369
	602	100.0	0	0.0	
Nebraska		100.0	0	0.0	602
Nevada	2,965	98.0	61	2.0	3,026
New Hampshire	780	97.7	18	2.3	798
New Jersey	18,228	98.4	297	1.6	18,525
New Mexico	2,083	99.8	5	0.2	2,089
New York	58,943	99.5	321	0.5	59,265
North Carolina	14,420	98.8	170	1.2	14,590
North Dakota	166	99.4	1	0.6	167
Ohio	9,674	98.9	106	1.1	9,781
Oklahoma	2,680	100.0	1	0.0	2,681
Oregon	3,238	98.5	50	1.5	3,288
Pennsylvania	24,541	98.7	331	1.3	24,872
Rhode Island	1,829	97.9	39	2.1	1,868
South Carolina	10,108	99.0	102	1.0	10,211
South Dakota	392	99.2	3	0.8	395
Tennessee	10,905	99.2	83	0.8	10,988
Texas	37,950	98.7	497	1.3	38,448
Utah	1,311	99.9	2	0.2	1,313
Vermont	553	100.0	0	0.0	553
Virginia	8,487	99.5	42	0.5	8,529
Washington	6,435	99.7	21	0.3	6,456
West Virginia	786	100.0	0	0.0	786
Wisconsin	4,142	96.7	140	3.3	4,282
Wyoming	137	97.2	4	2.8	141
Subtotal	482,707	98.6	6,483	1.3	489,384
Territories Guam	25	02.6	2	7.4	27
Puerto Rico		92.6	2 51	7.4	27 13.006
	12,955	99.6	51	0.4	13,006
U.S. Virgin Islands Subtotal	237 13,217	99.6 99.6	1 54	0.4 0.4	238 13,271
Total	495,924	98.7	6,537	1.3	502,655

Note. Percentages shown are based on the row total.

Data are based on provider location. Clients receiving services in multiple states were not included in state-specific totals.

Table 10. Ryan White HIV/AIDS Program clients (non-ADAP), by race/ethnicity and state, 2014—United States and 3 territories

	American Alaska N		Asia	n	Black/Af Americ		Hispanic/l	_atino ^a	Native Have Pacific Is		Whit	e	Multiple	races	Total
State	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.
Alabama	9	0.1	32	0.4	6,362	69.2	319	3.5	2	0.0	2,418	26.3	54	0.6	9,302
Alaska	181	36.0	16	3.2	63	12.5	42	8.4	2	0.4	186	37.0	13	2.6	503
Arizona	2	0.1	4	0.2	972	46.9	124	6.0	4	0.2	878	42.4	87	4.2	2,075
Arkansas	193	2.9	101	1.5	970	14.3	2,153	31.8	17	0.3	3,104	45.8	235	3.5	6,795
California	337	0.7	1,677	3.4	9,856	19.7	19,959	39.9	271	0.5	17,452	34.9	527	1.1	50,539
Colorado	85	1.3	92	1.4	1,280	19.7	1,554	23.9	11	0.2	3,346	51.4	139	2.1	6,690
Connecticut	7	0.1	22	0.4	2,181	41.4	1,890	35.9	3	0.1	1,117	21.2	48	0.9	5,277
Delaware	4	0.2	2	0.1	1,033	62.3	78	4.7	1	0.1	481	29.0	58	3.5	1,657
District of Columbia	12	0.2	40	0.6	5,484	82.7	581	8.8	1	0.0	454	6.9	57	0.9	7,166
Florida	63	0.1	247	0.5	27,559	51.6	11,314	21.2	25	0.1	12,760	23.9	1,480	2.8	53,761
Georgia	14	0.1	115	0.6	16,203	77.8	984	4.7	12	0.1	3,315	15.9	188	0.9	20,865
Hawaii	13	1.3	118	11.9	54	5.4	130	13.1	114	11.5	469	47.1	98	9.8	996
Idaho	9	1.6	2	0.4	45	8.2	67	12.1	1	0.2	419	75.9	9	1.6	552
Illinios	63	0.3	224	1.0	13,484	58.6	4,223	18.3	14	0.1	4,764	20.7	252	1.1	23,255
Indiana	6	0.1	90	2.1	1,677	39.7	276	6.5	2	0.1	2,085	49.3	94	2.2	4,230
Iowa	8	0.6	47	3.6	320	24.8	115	8.9	1	0.1	782	60.6	18	1.4	1,292
Kansas	8	1.0	6	0.7	240	28.6	74	8.8	3	0.4	496	59.1	12	1.4	839
Kentucky	10	0.3	22	0.6	1,119	31.2	226	6.3	2	0.1	2,125	59.2	85	2.4	3,632
Louisiana	15	0.1	34	0.3	9,522	73.5	406	3.1	6	0.1	2,761	21.3	207	1.6	12,971
Maine	6	0.7	3	0.4	127	15.3	40	4.8	0	0.0	615	74.0	40	4.8	832
Maryland	19	0.1	89	0.7	11,168	81.8	574	4.2	7	0.1	1,624	11.9	179	1.3	13,761
Massachusetts	35	0.3	193	1.5	3,750	29.0	3,762	29.1	12	0.1	5,006	38.7	190	1.5	13,127
Michigan	33	0.4	68	0.7	5,469	59.9	485	5.3	6	0.1	2,751	30.1	319	3.5	9,157
Minnesota	127	2.6	84	1.7	2,213	44.4	466	9.4	9	0.2	1,974	39.6	108	2.2	5,008
Mississippi	4	0.1	9	0.2	3,261	79.6	79	1.9	3	0.1	711	17.4	32	0.8	4,111
Missouri	25	0.4	27	0.4	3,633	52.1	323	4.6	7	0.1	2,865	41.1	88	1.3	6,968
Montana	34	9.2	1	0.3	15	4.1	9	2.4	1	0.3	301	81.6	8	2.2	369
Nebraska	10	1.7	9	1.5	152	25.3	117	19.4	1	0.2	307	51.0	6	1.0	602
Nevada	18	0.6	41	1.4	710	23.6	802	26.6	23	0.8	1,152	38.2	268	8.9	3,026
New Hampshire	3	0.4	15	1.9	124	15.5	99	12.4	0	0.0	536	67.2	21	2.6	798
New Jersey	17	0.1	173	0.9	10,210	55.2	5,030	27.2	17	0.1	2,819	15.2	238	1.3	18,525
New Mexico	102	5.0	10	0.5	101	4.9	947	46.1	3	0.2	869	42.3	22	1.1	2,089
New York	154	0.3	895	1.5	28,427	48.7	18,867	32.3	61	0.1	9,327	16.0	676	1.2	59,265
North Carolina	142	1.0	82	0.6	9,476	65.3	1,007	6.9	7	0.1	3,674	25.3	135	0.9	14,590
North Dakota	8	4.8	1	0.6	56	33.5	8	4.8	0	0.0	90	53.9	4	2.4	167
Ohio	14	0.1	52	0.5	4,784	49.2	534	5.5	2	0.0	4,157	42.8	178	1.8	9,781
Oklahoma	151	5.6	36	1.3	620	23.1	219	8.2	2	0.1	1,496	55.8	156	5.8	2,681
Oregon	23	0.7	51	1.6	269	8.2	511	15.6	13	0.4	2,169	66.4	233	7.1	3,288
Pennsylvania	25	0.1	178	0.7	13,564	54.8	3,356	13.6	26	0.1	6,613	26.7	977	4.0	24,872
Rhode Island	14	0.8	34	1.8	517	27.7	477	25.6	1	0.1	798	42.8	23	1.2	1,868
South Carolina	17	0.2	18	0.2	7.455	73.0	320	3.1	3	0.0	2,328	22.8	68	0.7	10,211
South Dakota	16	4.1	4	1.0	7, 4 35	19.2	168	42.5	0	0.0	127	32.2	4	1.0	395
Tennessee	12	0.1	54	0.5	6,408	58.4	413	3.8	1	0.0	3,868	35.3	214	2.0	10,988
Texas	116	0.3	392	1.0	16,263	42.3	12,493	32.5	29	0.0	9,038	23.5	97	0.3	38,448
Utah	11	0.8	31	2.4	139	10.6	294	22.4	5	0.1	817	62.2	16	1.2	1,313

Table 10. Ryan White HIV/AIDS Program clients (non-ADAP), by race/ethnicity and state, 2014—United States and 3 territories (cont)

	American Alaska N		Asia	n	Black/Af Americ		Hispanic/I	_atino ^a	Native Hav		Whit	e	Multiple	races	Total
State	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.
Vermont	4	0.7	7	1.3	54	9.8	23	4.2	2	0.4	455	82.4	7	1.3	553
Virginia	8	0.1	109	1.4	4,938	65.2	714	9.4	8	0.1	1,592	21.0	208	2.8	8,529
Washington	103	1.6	182	2.8	1,259	19.6	926	14.5	73	1.1	3,650	56.9	217	3.4	6,456
West Virginia	1	0.1	3	0.4	167	21.3	16	2.0	1	0.1	593	75.5	4	0.5	786
Wisconsin	39	0.9	50	1.2	1,777	42.4	558	13.3	4	0.1	1,722	41.1	45	1.1	4,282
Wyoming	5	3.6	2	1.4	17	12.1	22	15.6	0	0.0	94	66.7	1	0.7	141
Subtotal	2,335	0.5	5,794	1.2	235,623	48.1	98,174	20.1	819	0.2	133,550	27.3	8,443	1.7	489,384
Territories															
Guam	0	0.0	2	7.4	0	0.0	1	3.7	21	77.8	2	7.4	1	3.7	27
Puerto Rico	1	0.0	1	0.0	18	0.1	12,841	98.8	0	0.0	99	0.8	43	0.3	13,006
U.S. Virgin Islands	0	0.0	1	0.4	129	54.2	91	38.2	0	0.0	15	6.3	2	0.8	238
Subtotal	1	0.0	4	0.0	147	1.1	12,933	97.5	21	0.2	116	0.9	46	0.3	13,271
Total	2,336	0.5	5,798	1.2	235,770	47.3	111,107	22.3	840	0.2	133,666	26.8	8,489	1.7	502,655

Note. Percentages shown are based on the row total.

Data are based on provider location. Clients receiving services in multiple states were not included in state-specific totals.

^a Hispanics/Latinos can be of any race.

Table 11. Ryan White HIV/AIDS Program clients (non-ADAP), by transmission risk category and state, 2014—United States and 3 territories

	Male-to-r sexual co		Injection use	drug	Male-to-ma sexual contact injection drug	ct and	Heterose contac		Perinat infection		Other	b	Total
State	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.
Alabama	2,943	43.2	367	5.4	50	0.7	3,230	47.4	204	3.0	22	0.3	6,816
Alaska	179	38.3	66	14.1	38	8.1	173	37.0	2	0.4	9	1.9	467
Arizona	1,088	53.1	156	7.6	67	3.3	710	34.6	16	8.0	13	0.6	2,050
Arkansas	3,810	57.6	443	6.7	454	6.9	1,671	25.3	141	2.1	95	1.4	6,614
California	29,669	64.6	3,146	6.9	2,644	5.8	9,196	20.0	827	1.8	448	1.0	45,930
Colorado	3,406	57.0	460	7.7	449	7.5	1,373	23.0	204	3.4	81	1.4	5,973
Connecticut	1,174	22.8	1,269	24.6	61	1.2	2,472	47.9	111	2.2	69	1.3	5,156
Delaware	538	32.5	309	18.7	58	3.5	717	43.4	19	1.2	13	8.0	1,654
District of Columbia	2,153	40.9	231	4.4	30	0.6	2,608	49.5	216	4.1	28	0.5	5,266
Florida	19,723	39.1	1,936	3.8	508	1.0	25,926	51.3	1,951	3.9	463	0.9	50,507
Georgia	9,485	46.5	673	3.3	294	1.4	9,269	45.4	566	2.8	111	0.5	20,398
Hawaii	690	74.7	42	4.6	9	1.0	163	17.6	8	0.9	12	1.3	924
Idaho	293	55.6	47	8.9	50	9.5	128	24.3	1	0.2	8	1.5	527
Illinios	9,432	51.0	1,375	7.4	205	1.1	6,754	36.5	537	2.9	203	1.1	18,506
Indiana	2,408	57.6	195	4.7	24	0.6	1,462	35.0	38	0.9	54	1.3	4,181
Iowa	676	54.7	93	7.5	49	4.0	402	32.5	7	0.6	10	8.0	1,237
Kansas	506	60.7	44	5.3	0	0.0	260	31.2	14	1.7	10	1.2	834
Kentucky	2,006	56.4	209	5.9	137	3.9	1,114	31.3	41	1.2	50	1.4	3,557
Louisiana	4,207	37.6	739	6.6	164	1.5	5,838	52.2	170	1.5	75	0.7	11,193
Maine	452	56.9	81	10.2	22	2.8	198	24.9	16	2.0	26	3.3	795
Maryland	2,072	24.8	1,382	16.5	92	1.1	4,339	51.8	407	4.9	79	0.9	8,371
Massachusetts	4,387	35.3	2,615	21.0	229	1.8	4,716	37.9	334	2.7	166	1.3	12,447
Michigan	4,682	54.1	424	4.9	151	1.7	3,088	35.7	215	2.5	98	1.1	8,658
Minnesota	2,056	45.3	273	6.0	186	4.1	1,891	41.7	86	1.9	45	1.0	4,537
Mississippi	1,556	38.4	79	2.0	17	0.4	2,232	55.1	143	3.5	23	0.6	4,050
Missouri	4,036	59.3	225	3.3	23	0.3	2,376	34.9	76	1.1	71	1.0	6,807
Montana	219	59.7	39	10.6	23	6.3	80	21.8	0	0.0	6	1.6	367
Nebraska	294	49.5	31	5.2	16	2.7	239	40.2	5	8.0	9	1.5	594
Nevada	1,423	59.7	161	6.8	104	4.4	580	24.3	83	3.5	33	1.4	2,384
New Hampshire	325	44.9	99	13.7	34	4.7	216	29.8	37	5.1	13	1.8	724
New Jersey	4,008	25.8	2,394	15.4	158	1.0	8,126	52.3	677	4.4	190	1.2	15,553
New Mexico	1,313	69.1	118	6.2	124	6.5	315	16.6	11	0.6	19	1.0	1,900
New York	18,175	35.6	4,582	9.0	512	1.0	25,808	50.5	1,504	2.9	515	1.0	51,096
North Carolina	5,381	38.9	763	5.5	271	2.0	6,974	50.4	340	2.5	100	0.7	13,829
North Dakota	69	43.7	7	4.4	10	6.3	71	44.9	0	0.0	1	0.6	158
Ohio	5,380	58.3	349	3.8	65	0.7	3,161	34.3	195	2.1	75	8.0	9,225

Table 11. Ryan White HIV/AIDS Program clients (non-ADAP), by transmission risk category and state, 2014—United States and 3 territories (cont)

	Male-to-r	nale	Injection	drug	Male-to-m sexual contac		Heterose		Perinat	al			
	sexual co		use		injection dru		contac		infection		Other		Total
State	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.
Oklahoma	1,543	57.9	209	7.9	145	5.4	716	26.9	11	0.4	40	1.5	2,664
Oregon	1,754	58.2	290	9.6	343	11.4	564	18.7	23	8.0	38	1.3	3,012
Pennsylvania	8,617	37.3	3,418	14.8	596	2.6	9,577	41.4	651	2.8	259	1.1	23,118
Rhode Island	688	38.7	277	15.6	36	2.0	679	38.2	71	4.0	29	1.6	1,780
South Carolina	3,943	39.1	381	3.8	88	0.9	5,340	53.0	208	2.1	121	1.2	10,081
South Dakota	170	48.2	15	4.3	10	2.8	152	43.1	3	0.9	3	0.9	353
Tennessee	4,852	46.5	604	5.8	146	1.4	4,550	43.6	171	1.6	122	1.2	10,445
Texas	17,400	51.3	1,843	5.4	1,076	3.2	12,504	36.9	779	2.3	296	0.9	33,898
Utah	662	52.0	97	7.6	177	13.9	310	24.4	13	1.0	14	1.1	1,273
Vermont	315	59.8	52	9.9	19	3.6	128	24.3	4	8.0	9	1.7	527
Virginia	3,557	43.0	565	6.8	108	1.3	3,804	45.9	133	1.6	114	1.4	8,281
Washington	2,869	52.1	494	9.0	614	11.2	1,324	24.0	44	8.0	162	2.9	5,507
West Virginia	439	56.2	82	10.5	18	2.3	229	29.3	8	1.0	5	0.6	781
Wisconsin	1,988	52.7	236	6.3	68	1.8	1,257	33.3	174	4.6	50	1.3	3,773
Wyoming	70	50.4	16	11.5	15	10.8	33	23.7	4	2.9	1	0.7	139
Subtotal	199,081	45.4	34,001	7.7	10,787	2.5	179,043	40.8	11,499	2.6	4,506	0.0	438,917
Territories													
Guam	15	55.6	0	0.0	1	3.7	9	33.3	2	7.4	0	0.0	27
Puerto Rico	2,908	22.5	2,120	16.4	62	0.5	7,404	57.3	299	2.3	130	1.0	12,923
U.S. Virgin Islands	44	18.5	14	5.9	1	0.4	176	74.0	2	8.0	1	0.4	238
Subtotal	2,967	22.5	2,134	16.2	64	0.5	7,589	57.5	303	2.3	131	0.0	13,188
Total	202,048	44.7	36,135	8.0	10,851	2.4	186,632	41.3	11,802	2.6	4,637	1.0	452,105

Note. Percentages shown are based on the row total.

Data are based on provider location. Clients receiving services in multiple states were not included in state-specific totals.

^a Heterosexual contact with a person known to have, or to be at high risk for, HIV infection. ^b Includes hemophilia, blood transfusion, and unknown risk factor.

Table 12a. Retention in care among Ryan White HIV/AIDS Program clients (non-ADAP), by year and selected characteristics, 2010–2014—United States and 3 territories

	<u> </u>	2010			2011	, ,		2012			2013			2014	
		Retain	ned		Retain	ed		Retair	ed		Retain	ed		Retain	ned
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
Age group (yr)															
<13	1,485	1,316	88.6	1,298	1,144	88.1	1,199	1,067	89.0	1,061	935	88.1	1,002	898	89.6
13–14	582	516	88.7	560	498	88.9	433	390	90.1	339	298	87.9	328	290	88.4
15–19	3,174	2,690	84.8	3,025	2,539	83.9	2,637	2,164	82.1	2,226	1,863	83.7	2,123	1,745	82.2
20–24	11,276	8,513	75.5	12,046	9,176	76.2	12,698	9,524	75.0	13,055	9,825	75.3	12,280	9,016	73.4
25–29	18,043	13,811	76.5	19,216	14,714	76.6	20,526	15,693	76.5	21,676	16,377	75.6	22,153	16,464	74.3
30–34	24,025	18,966	78.9	24,828	19,493	78.5	25,091	19,669	78.4	25,429	19,669	77.4	24,803	18,898	76.2
35–39	29,992	24,258	80.9	28,812	23,253	80.7	28,122	22,546	80.2	27,421	21,697	79.1	26,802	20,899	78.0
40–44	43,960	36,093	82.1	41,606	33,880	81.4	39,137	31,993	81.8	35,917	29,167	81.2	32,960	26,293	79.8
45–49	53,118	44,147	83.1	52,345	43,640	83.4	51,049	42,300	82.9	47,306	38,759	81.9	43,037	34,892	81.1
50–54	41,255	34,758	84.3	43,108	36,412	84.5	44,991	37,927	84.3	45,827	38,007	82.9	45,790	37,851	82.7
55–59	25,097	21,404	85.3	27,421	23,427	85.4	29,753	25,478	85.6	30,525	25,698	84.2	31,719	26,577	83.8
60–64	12,164	10,504	86.4	13,675	11,818	86.4	15,226	13,136	86.3	16,308	13,866	85.0	17,814	15,182	85.2
≥65	7,455	6,338	85.0	8,126	7,001	86.2	9,232	8,013	86.8	9,931	8,338	84.0	11,275	9,657	85.7
Race/ethnicity															
American Indian/Alaska Native	1,294	1,037	80.1	1,219	952	78.1	1,175	941	80.1	1,234	959	77.7	1,136	871	76.7
Asian	2,696	2,282	84.6	2,901	2,473	85.3	3,261	2,741	84.1	3,239	2,662	82.2	3,265	2,605	79.8
Black/African American	126,496	102,740	81.2	129,427	104,448	80.7	130,189	105,467	81.0	128,931	103,283	80.1	126,317	100,807	79.8
Hispanic/Latino ^a	60,641	50,686	83.6	60,834	51,901	85.3	64,142	54,625	85.2	66,143	55,783	84.3	66,470	55,401	83.4
Native Hawaiian/Pacific Islander	509	402	79.0	615	504	82.0	477	376	78.8	426	317	74.4	375	279	74.4
White	73,560	61,132	83.1	73,029	60,229	82.5	73,424	59,701	81.3	70,139	55,942	79.8	67,749	53,465	78.9
Multiple races	2,868	2,476	86.3	3,365	2,841	84.4	3,819	3,230	84.6	4,452	3,705	83.2	5,141	4,167	81.1
Gender															
Male	188,457	154,434	82.0	192,187	157,534	82.0	197,210	161,044	81.7	194,526	156,233	80.3	191,109	152,075	79.6
Female	81,178	67,323	82.9	81,551	67,605	82.9	80,362	66,834	83.2	80,011	66,329	82.9	78,281	64,512	82.4
Transgender	2,022	1,582	78.2	2,291	1,830	79.9	2,502	2,009	80.3	2,459	1,920	78.1	2,646	2,074	78.4
Transmission risk category															
Male-to-male sexual contact	103,547	85,851	82.9	107,194	89,131	83.2	113,731	93,435	82.2	114,566	92,322	80.6	115,391	91,632	79.4
Injection drug use	24,115	19,550	81.1	23,040	18,702	81.2	21,548	17,597	81.7	21,815	17,743	81.3	19,490	15,975	82.0
Male-to-male sexual contact and injection drug use	6,532	5,443	83.3	6,273	5,174	82.5	6,434	5,157	80.2	5,714	4,421	77.4	5,947	4,624	77.8
Heterosexual contact ^b	102,874	84,961	82.6	106,728	88,125	82.6	107,774	89,170	82.7	108,446	89,353	82.4	108,802	89,259	82.0
Perinatal infection	5,538	4,867	87.9	5,606	4,871	86.9	5,299	4,524	85.4	5,248	,	84.0	5,218	,	84.4
Other ^c	10,969	4,867 8,599	78.4	11,403	4,87 i 8,916	78.2	5,299 9,625	4,524 7,569	78.6	10,308	4,406 7,041	77.0	2,221	4,406 1,807	81.4
Other	10,969	0,099	10.4	11,403	0,910	10.2	9,025	7,509	10.0	10,308	7,941	11.0	۷,۷۷۱	1,007	01.4

Table 12a. Retention in care among Ryan White HIV/AIDS Program clients (non-ADAP), by year and selected characteristics, 2010–2014—United States and 3 territories (cont)

		2010			2011			2012			2013			2014	
		Retain	ed		Retain	ed		Retair	ed		Retain	ed		Retair	ned
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
Poverty level ^d															
0–100%	149,541	123,892	82.9	169,186	139,015	82.2	173,195	141,076	81.5	178,686	144,088	80.6	_	_	_
101–200%	48,735	42,034	86.3	53,505	45,707	85.4	56,265	47,660	84.7	58,725	48,873	83.2	_	_	_
201–300%	13,725	11,830	86.2	15,200	12,875	84.7	16,453	13,856	84.2	17,871	14,930	83.5	_	_	_
>300%	11,991	10,146	84.6	12,385	10,073	81.3	12,274	10,212	83.2	11,479	9,598	83.6	_	_	_
0–100%	_	_	_	_	_		_	_	_	_	_	_	169,482	136,345	80.5
101–138%	_	_	_	_	_	_	_	_	_			_	31,748	26,237	82.6
139–250%	_	_	_	_	_	_	_	_	_			_	37,932	31,042	81.8
251–400%	_	_	_	_	_	_	_	_	_	_	_	_	13,813	10,986	79.5
>400%	_	_	_	_	_	_	_	_	_	_	_	_	7,075	5,771	81.6
Health care coverage ^d															
Private only	30,629	25,860	84.4	31,844	26,560	83.4	33,602	27,572	82.1	32,315	26,257	81.3			
Medicare only	20,906	17,791	85.1	22,002	18,537	84.3	21,077	17,672	83.8	20,906	17,190	82.2			
Medicaid only	64,350	51,944	80.7	66,549	54,173	81.4	63,976	52,464	82.0	62,512	50,469	80.7	_	_	
Other public	20,622	17,240	83.6	19,309	16,370	84.8	25,813	22,052	85.4	24,692	20,931	84.8			_
Other private	10,355	8,909	86.0	9,080	7,772	85.6	5,634	4,733	84.0	3,306	2,613	79.0		_	_
No coverage	68,019	55,427	81.5	81,221	65,660	80.8	82,715	66,181	80.0	85,908	68,157	79.0		_	_
Multiple coverages	31,638	27,569	87.1	33,292	28,840	86.6	39,791	33,959	85.3	40,886	34,758	85.0	_	_	
Private employer													17,083	13,766	80.6
Private individual	_	_	_	_	_	_	_	_	_	_		_	14,052	10,879	77.4
Medicare	_	_	_	_	_	_	_	_		_		_	24,077	20,079	83.4
Medicaid	_	_	_	_	_	_	_	_	_			_	85,873	69,850	81.3
Medicare and Medicaid	_	_	_	_	_	_	_	_	_	_		_	18,048		86.0
Veterans Administration	_	_	_	_	_	_	_	_		_		_	399	15,515 324	81.2
Indian Health Service	_	_	_	_	_	_	_	_	_	_		_	60	324 47	78.3
Other plan		_	_	_	_	_	_	_				_	10,859	8,683	80.0
No coverage	_	_	_	_	_	_	_	_	_	_		_	77,353	60,966	78.8
Multiple coverages	_	_	_	_	_	_	_	_	_	_	_	_	18,991	15,418	81.2
wulliple coverages	_	_	_	_	_	_	_	_	_	_	_	_	10,991	10,410	01.2
Housing status															
Stable	203,632	170,483	83.7	213,613	178,186	83.4	220,306	183,340	83.2	224,318	184,530	82.3	223,834	182,808	81.7
Temporary	31,813	25,247	79.4	33,327	26,641	79.9	33,133	26,059	78.7	32,289	25,677	79.5	32,203	24,861	77.2
Unstable	6,233	4,653	74.7	7,770	5,970	76.8	7,217	5,283	73.2	8,925	6,445	72.2	10,057	7,327	72.9
Total ^e	271,703	223,373	82.2	276,067	226,996	82.2	280,109	229,909	82.1	277,023	224,501	81.0	272,193	218,758	80.4

Retention in care was based on data for PLWH who had at least 1 outpatient ambulatory medical care visit by September 1 of the measurement year, with a second visit at least 90 days after.

^a Hispanics/Latinos can be of any race.

^b Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^c Includes hemophilia, blood transfusion, and unknown risk factor.

^d Data collected in 2014 used different categories than previous years. See Technical Notes for additional details.

^e Because column totals were calculated independently of the values for the subpopulations, the values in each column may not sum to the column total.

Table 12b. Retention in care among Ryan White HIV/AIDS Program clients (non-ADAP), by year and state, 2010–2014—United States and 3 territories

	2	2010		2	2011		2	012		2	2013		:	2014	
		Retaine	d		Retaine	ed		Retaine	ed		Retaine	d		Retaine	∌d
State	Total No.	No.	%												
Alabama	3,574	3,012	84.3	3,853	3,215	83.4	3,723	3,163	85.0	3,958	3,527	89.1	3,636	3,107	85.5
Alaska	342	250	73.1	319	236	74.0	312	228	73.1	297	213	71.7	305	221	72.5
Arizona	895	652	72.9	979	683	69.8	1,026	756	73.7	982	700	71.3	784	500	63.8
Arkansas	1,249	1,045	83.7	2,144	1,829	85.3	2,346	2,000	85.3	2,393	2,024	84.6	1,963	1,467	74.7
California	34,098	28,482	83.5	37,655	31,379	83.3	38,468	31,277	81.3	30,615	23,266	76.0	26,668	19,399	72.7
Colorado	3,623	2,994	82.6	2,893	2,301	79.5	2,620	2,140	81.7	3,328	2,697	81.0	3,442	2,827	82.1
Connecticut	3,573	3,014	84.4	4,067	3,411	83.9	4,462	3,801	85.2	3,624	3,099	85.5	3,413	2,907	85.2
Delaware	1,435	1,267	88.3	1,496	1,339	89.5	1,509	1,323	87.7	1,492	1,307	87.6	1,459	1,276	87.5
District of Columbia	5,719	4,729	82.7	5,680	4,855	85.5	5,194	4,373	84.2	5,485	4,576	83.4	5,017	4,151	82.7
Florida	27,324	22,507	82.4	27,186	22,101	81.3	28,190	23,131	82.1	26,666	20,137	75.5	27,136	22,132	81.6
Georgia	15,609	13,195	84.5	16,069	13,517	84.1	16,552	14,081	85.1	17,166	14,562	84.8	17,184	14,872	86.6
Hawaii	415	309	74.5	498	375	75.3	511	364	71.2	433	292	67.4	365	265	72.6
Idaho	178	144	80.9	183	155	84.7	221	171	77.4	227	189	83.3	180	141	78.3
Illinios	7,891	6,158	78.0	12,392	9,986	80.6	13,457	10,703	79.5	12,984	10,118	77.9	12,442	9,781	78.6
Indiana	679	406	59.8	159	59	37.1	628	340	54.1	713	458	64.2	2,474	1,836	74.2
Iowa	841	686	81.6	901	737	81.8	600	453	75.5	607	461	76.0	475	383	80.6
Kansas	428	372	86.9	755	655	86.8	877	781	89.1	517	449	86.9	384	336	87.5
Kentucky	3,084	2,472	80.2	2,888	2,320	80.3	2,993	2,427	81.1	2,552	2,040	79.9	2,359	2,022	85.7
Louisiana	6,524	5,438	83.4	6,471	5,041	77.9	6,318	5,142	81.4	5,304	3,880	73.2	4,845	3,430	70.8
Maine	314	278	88.5	317	273	86.1	477	399	83.7	507	433	85.4	499	424	85.0
Maryland	7,311	6,268	85.7	7,311	5,936	81.2	7,804	6,539	83.8	8,850	7,209	81.5	7,383	6,009	81.4
Massachusetts	4,660	4,139	88.8	4,208	3,759	89.3	5,008	4,396	87.8	6,232	5,508	88.4	6,636	5,710	86.1
Michigan	4,826	3,840	79.6	5,186	4,064	78.4	5,550	4,292	77.3	4,651	3,601	77.4	4,308	3,238	75.2
Minnesota	2,199	1,870	85.0	2,045	1,611	78.8	1,910	1,449	75.9	2,361	1,960	83.0	1,924	1,488	77.3
Mississippi	1,411	1,000	70.9	1,346	1,109	82.4	1,657	1,194	72.1	1,516	1,204	79.4	1,359	1,156	85.1
Missouri	2,146	1,798	83.8	1,824	1,326	72.7	1,672	1,181	70.6	1,929	1,478	76.6	1,529	854	55.9
Montana	239	202	84.5	221	190	86.0	217	189	87.1	167	139	83.2	188	145	77.1
Nebraska	421	350	83.1	485	414	85.4	472	408	86.4	439	379	86.3	400	347	86.8
Nevada	958	674	70.4	956	693	72.5	983	779	79.3	1,150	791	68.8	1,147	710	61.9
New Hampshire	409	343	83.9	426	359	84.3	269	145	53.9	352	158	44.9	143	100	69.9
New Jersey	10,519	8,664	82.4	10,207	8,187	80.2	9,489	7,938	83.7	9,809	8,357	85.2	8,636	6,969	80.7
New Mexico	1,379	1,142	82.8	923	789	85.5	940	811	86.3	1,450	1,254	86.5	1,598	1,357	84.9
New York	33,713	25,533	75.7	30,940	25,325	81.9	28,863	24,068	83.4	26,632	22,414	84.2	26,623	22,564	84.8
North Carolina	9,714	8,026	82.6	10,170	8,353	82.1	10,855	9,018	83.1	9,773	8,223	84.1	9,421	7,937	84.3
North Dakota	37	21	56.8	43	26	60.5	53	30	56.6	0	0	0.0	0	0	0.0
Ohio	3,573	2,861	80.1	4,283	3,470	81.0	5,486	4,075	74.3	6,653	5,051	75.9	6,433	4,373	68.0
Oklahoma	1,263	1,100	87.1	1,271	1,067	84.0	1,433	1,140	79.6	1,819	1,370	75.3	1,790	1,330	74.3
Oregon	1,231	1,102	89.5	1,321	1,247	94.4	1,366	1,306	95.6	1,406	1,173	83.4	1,083	908	83.8
Pennsylvania	14,763	12,672	85.8	14,336	12,080	84.3	15,462	13,067	84.5	16,525	13,932	84.3	15,576	13,217	84.9
Rhode Island	1,237	1,039	84.0	1,259	1,083	86.0	1,345	1,168	86.8	1,486	1,259	84.7	1,446	1,229	85.0
South Carolina	6,849	6,014	87.8	7,110	6,282	88.4	7,826	6,687	85.5	8,343	7,304	87.6	8,266	7,200	87.1

Table 12b. Retention in care among Ryan White HIV/AIDS Program clients (non-ADAP), by year and state, 2010–2014—United States and 3 territories (cont)

		2010			2011			2012			2013			2014	
		Retaine	d		Retaine	ed		Retain	ed		Retaine	ed		Retaine	<u>∙d</u>
State	Total No.	No.	%												
South Dakota	185	152	82.2	211	160	75.8	256	160	62.5	230	97	42.2	266	172	64.7
Tennessee	7,054	6,012	85.2	5,757	4,831	83.9	3,825	3,291	86.0	3,633	3,078	84.7	4,475	3,662	81.8
Texas	18,447	14,858	80.5	18,361	14,417	78.5	17,564	13,462	76.7	20,438	16,401	80.3	20,289	15,328	75.6
Utah	715	624	87.3	509	415	81.5	603	469	77.8	589	504	85.6	523	422	80.7
Vermont	375	336	89.6	387	326	84.2	400	321	80.3	404	351	86.9	405	340	84.0
Virginia	5,064	4,186	82.7	4,927	3,895	79.1	5,051	4,017	79.5	5,703	4,553	79.8	4,859	3,311	68.1
Washington	3,028	2,552	84.3	2,203	1,866	84.7	2,187	1,507	68.9	1,983	1,111	56.0	1,977	1,589	80.4
West Virginia	582	468	80.4	640	505	78.9	634	514	81.1	690	528	76.5	678	518	76.4
Wisconsin	1,032	650	63.0	1,456	1,009	69.3	1,444	1,188	82.3	1,542	1,227	79.6	1,996	1,654	82.9
Wyoming	88	61	69.3	99	62	62.6	129	76	58.9	122	79	64.8	98	70	71.4
Subtotal	263,223	215,967	82.0	267,326	219,323	82.0	271,237	221,938	81.8	266,727	215,121	80.7	256,485	205,384	80.1
Territories															
Guam	16	12	75.0	19	12	63.2	20	18	90.0	23	19	82.6	23	16	69.6
Puerto Rico	5,673	5,050	89.0	6,440	5,785	89.8	7,141	6,583	92.2	8,517	7,855	92.2	8,713	8,005	91.9
U.S. Virgin Islands	215	176	81.9	217	147	67.7	201	137	68.2	157	113	72.0	201	150	74.6
Subtotal	5,904	5,238	88.7	6,676	5,944	89.0	7,362	6,738	91.5	8,697	7,987	91.8	8,937	8,171	91.4
Total	271,703	223,373	82.2	276,067	226,996	82.2	280,109	229,909	82.1	277,023	224,501	81.0	272,193	218,758	80.4

Note. Data are based on provider location. Clients receiving services in multiple states were not included in state-specific totals.

Table 13a. Viral suppression among Ryan White HIV/AIDS Program clients (non-ADAP), by year and selected characteristics, 2010–2014—United States and 3 territories

	2	2010			2011			2012			2013			2014	
-		Viral													
		Suppres	sion												
	Total No.	No.	%												
Age group (yr)															
<13	1,260	904	71.8	1,186	827	69.7	1,099	854	77.7	1,040	834	80.2	1,021	856	83.8
13–14	520	346	66.5	537	365	68.0	427	310	72.6	344	257	74.7	319	265	83.1
15–19	3,079	1,572	51.1	3,114	1,622	52.1	2,771	1,519	54.8	2,470	1,488	60.2	2,329	1,497	64.3
20–24	11,595	5,156	44.5	12,503	6,186	49.5	13,647	7,126	52.2	14,207	8,474	59.7	13,591	8,726	64.2
25–29	18,009	9,832	54.6	19,355	11,421	59.0	21,316	13,282	62.3	23,191	15,682	67.6	24,238	17,167	70.8
30–34	23,374	14,410	61.7	24,377	16,068	65.9	25,675	17,669	68.8	26,644	19,397	72.8	26,329	20,034	76.1
35–39	28,684	19,350	67.5	27,814	19,538	70.3	28,266	20,528	72.6	28,507	21,679	76.1	28,366	22,286	78.6
40–44	41,455	29,202	70.4	39,955	29,296	73.3	39,190	29,517	75.3	36,814	29,003	78.8	34,226	27,803	81.2
45–49	49,405	36,212	73.3	49,863	37,844	75.9	50,543	39,315	77.8	48,146	38,876	80.8	44,591	37,160	83.3
50–54	37,764	28,377	75.1	40,781	31,711	77.8	44,484	35,603	80.0	46,029	38,296	83.2	47,013	40,236	85.6
55–59	22,629	17,643	78.0	25,695	20,637	80.3	28,995	24,005	82.8	30,441	26,050	85.6	32,309	28,364	87.8
60–64	10,795	8,794	81.5	12,678	10,628	83.8	14,787	12,637	85.5	16,089	14,179	88.1	18,002	16,199	90.0
≥65	6,532	5,459	83.6	7,336	6,347	86.5	8,839	7,782	88.0	9,745	8,830	90.6	11,369	10,458	92.0
Race/ethnicity															
American Indian/Alaska Native	1,246	877	70.4	1,174	875	74.5	1,210	923	76.3	1,263	986	78.1	1,192	989	83.0
Asian	2,641	2,081	78.8	2,825	2,344	83.0	3,300	2,721	82.5	3,320	2,908	87.6	3,424	3,050	89.1
Black/African American	118,257	74,827	63.3	124,332	83,370	67.1	130,129	90,972	69.9	132,115	97,658	73.9	132,079	101,827	77.1
Hispanic/Latino ^a	56,038	41,237	73.6	58,857	44,738	76.0	65,068	50,689	77.9	67,673	55,084	81.4	69,183	58,086	84.0
Native Hawaiian/Pacific Islander	488	344	70.5	593	462	77.9	450	356	79.1	427	328	76.8	392	317	80.9
White	70,583	53,829	76.3	69,810	55,167	79.0	72,663	59,144	81.4	71,841	60,556	84.3	70,112	60,734	86.6
Multiple races	2,774	1,952	70.4	3,111	2,264	72.8	3,794	2,826	74.5	4,548	3,567	78.4	5,343	4,425	82.8
Gender															
Male	178,220	126,369	70.9	184,918	136,471	73.8	197,929	150,129	75.9	200,207	158,779	79.3	200,093	164,193	82.1
Female	75,024	49,746	66.3	78,055	54,575	69.9	79,567	58,259	73.2	80,897	62,420	77.2	80,865	64,837	80.2
Transgender	1,886	1,160	61.5	2,182	1,422	65.2	2,519	1,741	69.1	2,538	1,831	72.1	2,719	2,013	74.0
Transmission risk category															
Male-to-male sexual contact	99,602	71,630	71.9	103,972	77,961	75.0	114,611	87,874	76.7	118,606	95,004	80.1	121,192	100,312	82.8
Injection drug use	22,401	15,342	68.5	22,348	15,870	71.0	21,351	15,946	74.7	22,106	17,345	78.5	19,875	16,106	81.0
Male-to-male sexual contact	6,347	4,515	71.1	6,133	4,499	73.4	6,414	4,730	73.7	5,824	4,491	77.1	6,104	4,853	79.5
and injection drug use	06 200	GE 200	67.0	101 710	70 400	74.0	107 240	70 440	74.0	110 120	06.040	77.0	112 116	04.046	01.0
Heterosexual contact ^b	96,328	65,299	67.8	101,712	72,422	71.2	107,349	79,419	74.0	110,438	86,010	77.9	113,416	91,816	81.0
Perinatal infection	5,024	3,070	61.1	5,411	3,183	58.8	5,258	3,233	61.5	5,317	3,430	64.5	5,281	3,643	69.0
Other ^c	9,661	6,579	68.1	11,253	8,062	71.6	10,023	7,513	75.0	10,731	8,446	78.7	2,292	1,956	85.3

Table 13a. Viral suppression among Ryan White HIV/AIDS Program clients (non-ADAP), by year and selected characteristics, 2010–2014—United States and 3 territories (cont)

	2	010			2011		:	2012			2013		;	2014	
		Viral			Viral			Viral			Viral			Viral	ī
		Suppres			Suppres			Suppres			Suppres			Suppres	sion
	Total No.	No.	%												
Poverty level ^d															
0–100%	143,210	96,335	67.3	164,839	115,744	70.2	174,430	126,156	72.3	184,640	139,850	75.7	_	_	_
101–200%	46,327	35,187	76.0	51,487	40,432	78.5	56,119	44,928	80.1	59,759	50,161	83.9	_	_	_
201–300%	13,130	10,398	79.2	14,588	11,874	81.4	16,426	13,499	82.2	18,198	15,632	85.9	_	_	_
>300%	11,008	7,941	72.1	11,491	8,709	75.8	12,683	10,348	81.6	11,793	10,360	87.9	_	_	_
0–100%	_	_	_	_	_	_	_	_	_	_	_	_	176,449	139,172	78.9
101–138%	_	_	_	_	_	_	_	_	_	_	_	_	32,830	27,881	84.9
139–250%	_	_	_	_	_	_	_	_	_	_	_	_	39,535	34,563	87.4
251-400%	_	_	_	_	_	_	_	_	_	_	_	_	14,462	12,617	87.2
>400%	_	_	_	_	_	_	_	_	_	_	_	_	8,535	7,279	85.3
Health care coverage ^d															
Private only	28,609	22,001	76.9	29,070	23,267	80.0	32,915	27,220	82.7	32,774	28,112	85.8	_	_	_
Medicare only	19,446	14,943	76.8	20,554	16,488	80.2	20,988	17,169	81.8	21,149	17,811	84.2	_	_	_
Medicaid only	57,968	37,423	64.6	64,212	43,324	67.5	63,598	45,080	70.9	63,294	47,178	74.5	_	_	_
Other public	19,264	14,138	73.4	18,891	14,086	74.6	26,700	20,246	75.8	25,763	20,445	79.4	_	_	_
Other private	10,503	7,568	72.1	9,155	6,917	75.6	5,241	4,011	76.5	3,346	2,670	79.8	_	_	_
No coverage	67,972	44,478	65.4	80,748	56,270	69.7	85,261	60,661	71.2	91,184	68,718	75.4	_	_	_
Multiple coverages	29,815	22,230	74.6	31,583	24,214	76.7	38,395	30,681	79.9	40,769	34,007	83.4	_	_	_
Private employer	_	_	_	_	_	_	_	_	_	_	_	_	17,865	15,768	88.3
Private individual	_	_	_	_	_	_	_	_	_	_	_	_	14,696	12,909	87.8
Medicare	_	_	_	_	_	_	_	_	_	_	_	_	24,566	21,474	87.4
Medicaid	_	_	_	_	_	_	_	_	_	_	_	_	88,553	69,748	78.8
Medicare and Medicaid	_	_	_	_	_	_	_	_	_	_	_	_	18,300	15,722	85.9
Veterans Administration	_	_	_	_	_	_	_	_	_	_	_	_	419	375	89.5
Indian Health Service	_	_	_	_	_	_	_	_	_	_	_	_	69	56	81.2
Other plan	_	_	_	_	_	_	_	_	_	_	_	_	11,259	9,408	83.6
No coverage	_	_	_	_	_	_	_	_	_	_	_	_	83,454	64,573	77.4
Multiple coverages	_		_	_	_	_	_	_	_	_	_	_	19,956	17,218	86.3
Housing status															
Stable	191,214	136,184	71.2	205,573	152,509	74.2	221,603	169,222	76.4	229,596	183,930	80.1	233,438	193,210	82.8
Temporary	30,287	19,305	63.7	33,380	22,559	67.6	33,510	23,431	69.9	34,219	25,155	73.5	34,012	26,189	77.0
Unstable	5,994	3,285	54.8	7,828	4,812	61.5	7,379	4,421	59.9	9,341	6,007	64.3	10,621	7,124	67.1
Total ^e	255,172	177,300	69.5	265,195	192,491	72.6	280,045	210,152	75.0	283,669	223,046	78.6	283,811	231,140	81.4

^a Hispanics/Latinos can be of any race.
^b Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^c Includes hemophilia, blood transfusion, and unknown risk factor.

d Data collected in 2014 used different categories than previous years. See Technical Notes for additional details.
e Because column totals were calculated independently of the values for the subpopulations, the values in each column may not sum to the column total.

Table 13b. Viral Suppression among Ryan White HIV/AIDS Program clients (non-ADAP), by race/ethnicity and state, 2010–2014—United States and 3 territories

		2010			2011			2012			2013			2014	
		Viral Suppress		_	Viral Suppress		_	Viral Suppress		_	Viral Suppress	sion	_	Viral Suppres	sion
State	Total No.	No.	%	Total No.	No.	%									
Alabama	3,727	2,492	66.9	3,974	2,805	70.6	3,864	2,820	73.0	4,179	3,104	74.3	3,885	2,846	73.3
Alaska	305	210	68.9	300	212	70.7	284	208	73.2	299	235	78.6	316	263	83.2
Arizona	724	440	60.8	623	393	63.1	1,049	664	63.3	1,009	791	78.4	695	570	82.0
Arkansas	1,206	1,001	83.0	1,533	1,288	84.0	1,826	1,438	78.8	2,163	1,884	87.1	2,065	1,785	86.4
California	32,459	24,431	75.3	35,408	27,507	77.7	38,248	29,818	78.0	30,443	24,955	82.0	26,109	21,914	83.9
Colorado	3,511	2,659	75.7	2,999	2,390	79.7	2,501	1,911	76.4	3,498	2,886	82.5	3,619	3,101	85.7
Connecticut	3,575	2,539	71.0	3,929	2,828	72.0	4,398	3,444	78.3	3,713	3,028	81.6	3,521	3,013	85.6
Delaware	1,517	1,047	69.0	1,553	1,162	74.8	1,564	1,210	77.4	1,552	1,239	79.8	1,527	1,276	83.6
District of Columbia	5,589	3,731	66.8	5,889	4,543	77.1	5,496	4,149	75.5	5,659	4,354	76.9	4,926	4,096	83.2
Florida	24,438	16,227	66.4	22,789	15,424	67.7	25,024	18,016	72.0	24,842	19,313	77.7	27,644	22,439	81.2
Georgia	15,221	10,267	67.5	15,887	11,651	73.3	15,613	11,409	73.1	17,543	13,222	75.4	17,725	13,846	78.1
Hawaii	349	268	76.8	383	273	71.3	355	253	71.3	293	221	75.4	497	424	85.3
Idaho	193	156	80.8	207	169	81.6	245	213	86.9	241	210	87.1	190	173	91.1
Illinios	7,636	5,318	69.6	11,368	8,401	73.9	12,854	10,085	78.5	13,433	10,718	79.8	12,964	10,676	82.4
Indiana	600	349	58.2	202	114	56.4	613	393	64.1	721	501	69.5	2,204	1,890	85.8
Iowa	906	675	74.5	920	724	78.7	635	521	82.1	666	556	83.5	501	458	91.4
Kansas	459	334	72.8	768	590	76.8	909	715	78.7	533	423	79.4	436	352	80.7
Kentucky	2,940	1,964	66.8	2,929	2,169	74.1	2,919	2,210	75.7	2,694	2,142	79.5	2,409	2,030	84.3
Louisiana	5,804	3,071	52.9	5,787	3,108	53.7	6,026	3,688	61.2	5,615	3,566	63.5	5,235	3,701	70.7
Maine	323	258	79.9	316	260	82.3	478	410	85.8	516	463	89.7	504	456	90.5
Maryland	6,202	3,952	63.7	7,414	5,179	69.9	7,386	5,465	74.0	8,583	6,757	78.7	7,389	5,923	80.2
Massachusetts	5,293	4,228	79.9	4,231	3,492	82.5	4,867	4,096	84.2	6,641	5,662	85.3	6,750	5,979	88.6
Michigan	4,887	3,362	68.8	5,322	3,816	71.7	5,745	4,289	74.7	4,871	3,924	80.6	4,627	3,865	83.5
Minnesota	2,271	1,774	78.1	2,138	1,704	79.7	2,096	1,706	81.4	2,419	2,084	86.2	1,979	1,741	88.0
Mississippi	1,302	722	55.5	1,261	784	62.2	1,582	935	59.1	1,552	1,080	69.6	1,461	1,081	74.0
Missouri	2,387	1,577	66.1	1,499	905	60.4	1,694	1,206	71.2	2,199	1,687	76.7	1,746	1,384	79.3
Montana	251	205	81.7	226	197	87.2	222	205	92.3	190	169	89.0	202	188	93.1
Nebraska	449	317	70.6	500	385	77.0	492	380	77.2	469	379	80.8	416	354	85.1
Nevada	1,050	697	66.4	974	712	73.1	1,047	773	73.8	1,187	811	68.3	1,282	859	67.0
New Hampshire	377	309	82.0	448	375	83.7	287	250	87.1	408	365	89.5	147	124	84.4
New Jersey	9,836	6,063	61.6	9,720	6,254	64.3	10,360	7,439	71.8	10,438	7,941	76.1	9,032	7,247	80.2
New Mexico	1,382	1,116	80.8	926	726	78.4	990	805	81.3	1,603	1,393	86.9	1,651	1,481	89.7
New York	24,483	16,255	66.4	29,496	20,436	69.3	29,404	21,886	74.4	26,905	21,141	78.6	29,341	23,456	79.9
North Carolina	9,894	7,168	72.5	9,797	7,321	74.7	11,182	8,543	76.4	10,311	8,070	78.3	10,072	8,176	81.2
North Dakota	43	38	88.4	39	38	97.4	57	48	84.2	70	62	88.6	70	67	95.7
Ohio	3,824	2,337	61.1	3,728	2,671	71.7	4,769	3,443	72.2	7,050	5,461	77.5	6,870	5,554	80.8
Oklahoma	1,344	983	73.1	1,323	971	73.4	1,540	1,113	72.3	1,918	1,502	78.3	1,931	1,579	81.8
Oregon	1,277	942	73.8	1,355	1,044	77.1	1,330	1,067	80.2	1,491	1,232	82.6	1,140	965	84.7
Pennsylvania	15,053	11,194	74.4	14,619	11,031	75.5	15,910	12,411	78.0	17,120	13,900	81.2	16,014	13,475	84.2
Rhode Island	1,281	963	75.2	1,311	1,058	80.7	1,392	1,152	82.8	1,520	1,317	86.6	1,462	1,291	88.3
South Carolina	6,805	4,982	73.2	7,464	5,560	74.5	8,270	6,363	76.9	8,730	6,943	79.5	8,762	7,162	81.7

Table 13b. Viral Suppression among Ryan White HIV/AIDS Program clients (non-ADAP), by race/ethnicity and state, 2010–2014—United States and 3 territories (cont)

		2010			2011			2012			2013			2014	
		Viral Suppress			Viral Suppress	sion	_	Viral Suppress			Viral Suppress			Viral Suppress	
State	Total No.	No.	%												
South Dakota	176	135	76.7	197	154	78.2	210	166	79.1	178	152	85.4	222	189	85.1
Tennessee	6,787	4,634	68.3	6,043	4,228	70.0	4,006	2,841	70.9	3,814	2,817	73.9	4,684	3,678	78.5
Texas	18,689	12,521	67.0	19,147	13,371	69.8	20,554	14,505	70.6	22,076	16,335	74.0	21,871	17,068	78.0
Utah	654	466	71.3	428	293	68.5	551	399	72.4	618	482	78.0	534	423	79.2
Vermont	378	319	84.4	373	317	85.0	391	340	87.0	421	385	91.5	428	402	93.9
Virginia	5,236	3,841	73.4	4,958	3,887	78.4	5,236	4,206	80.3	6,022	4,994	82.9	5,431	4,673	86.0
Washington	3,096	2,417	78.1	2,270	2,005	88.3	2,452	1,994	81.3	2,073	1,738	83.8	2,019	1,782	88.3
West Virginia	601	497	82.7	675	543	80.4	675	570	84.4	719	612	85.1	692	600	86.7
Wisconsin	423	287	67.9	1,243	905	72.8	1,437	1,104	76.8	1,809	1,473	81.4	2,184	1,869	85.6
Wyoming	51	32	62.8	95	65	68.4	128	103	80.5	135	111	82.2	120	101	84.2
Subtotal	247,264	171,770	69.5	256,984	186,438	72.5	271,163	203,378	75.0	273,152	214,790	78.6	267,501	218,045	81.5
Territories															
Guam	16	9	56.3	17	8	47.1	19	12	63.2	22	13	59.1	19	10	52.6
Puerto Rico	5,102	3,657	71.7	5,919	4,358	73.6	7,147	5,433	76.0	8,681	6,790	78.2	8,833	7,267	82.3
U.S. Virgin Islands	181	108	59.7	186	113	60.8	189	127	67.2	179	131	73.2	215	161	74.9
Subtotal	5,299	3,774	71.2	6,122	4,479	73.2	7,355	5,572	75.8	8,882	6,934	78.1	9,067	7,438	82.0
Total	255,172	177,300	69.5	265,195	192,491	72.6	280,045	210,152	75.0	283,669	223,046	78.6	283,811	231,140	81.4

Note. Data are based on provider location. Clients receiving services in multiple states were not included in state-specific totals.

Table 14a. Retention in care among women (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2014—United States and 3 territories

Total No.	Retained		
Age group (yr) Ro. No.	retairied	Ret	tained
Age group (yr) 13-14 0 0 0.0 4 4 100.0 117 102 87.2 40 38 95.0 0 0.0 0.0 15 14 93.3 7 15-19 2 2 100.0 7 5 71.4 676 582 86.1 170 140 82.4 1 1 100.0 69 52 75.4 24 20-24 8 6 75.0 17 13 76.5 1,800 1,386 77.0 486 378 77.8 5 4 80.0 348 263 75.6 74 25-29 16 13 81.3 49 42 85.7 2,680 2,023 75.5 77.3 640 82.8 5 3 60.0 647 486 75.1 113 30-34 37 27 73.0 118 90 76.3 3,792 79.1 78.2 1,312 1,07		Total	0/
13-14 0 0 0 0 0 0 4 4 100.0 117 102 87.2 40 38 95.0 0 0 0 0 0 15 14 93.3 7 15-19 2 2 100.0 7 5 71.4 676 582 86.1 170 140 82.4 1 1 100.0 69 52 75.4 24 20-24 8 6 75.0 17 13 76.5 1,800 1,386 77.0 486 378 77.8 5 4 80.0 348 263 75.6 74 25-29 16 13 81.3 49 42 85.7 2,680 2,023 75.5 773 640 82.8 5 3 60.0 647 486 75.1 113 30-34 37 27 73.0 118 90 76.3 3,727 2,915 78.2 1,312 1,073 81.8 10 7 70.0 977 737 75.4 148 35-39 38 30 79.0 125 101 80.8 4,882 3,796 77.8 1,799 1,522 84.6 13 9 69.2 1,246 937 75.2 170 40-44 45 35 77.8 129 109 84.5 6,178 5,030 81.4 2,323 1,978 85.2 10 8 80.0 1,611 1,255 77.9 235 45-49 51 45 88.2 84 65 77.4 7,478 6,132 82.0 2,680 2,033 85.9 10 7 70.0 1,959 1,574 80.4 277 50-54 44 33 75.0 81 67 82.7 7,644 6,459 84.0 2,851 2,519 88.4 11 10 90.9 2,001 1,643 82.1 294 55-59 46 39 84.8 46 36 78.3 5,815 4,924 84.7 2,014 1,787 88.7 9 8 88.9 1,386 1,153 83.2 213 60-64 19 18 94.7 36 31 86.1 3,217 2,763 85.9 1,125 1,009 89.7 8 8 100.0 729 606 83.1 120 ≥65 16 11 68.8 31 29 93.6 2,046 1,761 86.1 984 896 91.1 2 0 0.0 445 379 85.2 53 **Transmission risk category** Injection drug use 69 54 78.3 19 15 79.0 3,061 2,593 84.7 1,311 1,114 85.0 9 7 77.8 2,141 1,707 79.7 219 Heterosexual contact 224 181 80.8 592 488 82.4 38,311 31,413 82.0 13,825 12,015 86.9 63 48 76.2 8,361 6,678 79.9 1,386 1, Perinatal infection 5 4 80.0 13 10 76.9 1,590 1,341 84.3 504 427 84.7 1 1 100.0 224 185 82.6 69 Other 6 6 4 66.7 32 27 84.4 517 404 78.1 255 229 89.8 3 2 66.7 172 136 79.1 26	No. %	No. No.	<u>%</u>
15-19	6 85.7	183 16	64 89.6
20-24 8 6 75.0 17 13 76.5 1,800 1,386 77.0 486 378 77.8 5 4 80.0 348 263 75.6 74 25-29 16 13 81.3 49 42 85.7 2,680 2,023 75.5 773 640 82.8 5 3 60.0 647 486 75.1 113 30-34 37 27 73.0 118 90 76.3 3,727 2,915 78.2 1,312 1,073 81.8 10 7 70.0 977 737 75.4 148 35-39 38 30 79.0 125 101 80.8 4,882 3,796 77.8 1,799 1,522 84.6 13 9 69.2 1,246 937 75.2 170 40-44 45 35 77.8 129 109 84.5 6,178 5,030 81.4 2,323 1,978 85.2 10 8 80.0 1,611 1,255 77.9 235 45-49 51 45 88.2 84 65 77.4 7,478 6,132 82.0 2,680 2,303 85.9 10 7 70.0 1,959 1,574 80.4 277 50-54 44 33 75.0 81 67 82.7 7,694 6,459 84.0 2,851 2,519 88.4 11 10 90.9 2,001 1,643 82.1 294 55-59 46 39 84.8 46 36 78.3 5,815 4,924 84.7 2,014 1,787 88.7 9 8 88.9 1,386 1,153 83.2 213 60-64 19 18 94.7 36 31 86.1 3,217 2,763 85.9 1,125 1,009 89.7 8 8 100.0 729 606 83.1 120 ≥65 16 11 68.8 31 29 93.6 2,046 1,761 86.1 984 896 91.1 2 0 0.0 445 379 85.2 53 **Transmission risk category** Injection drug use 69 54 78.3 19 15 79.0 3,061 2,593 84.7 1,311 1,114 85.0 9 7 77.8 2,141 1,707 79.7 219 Heterosexual contact 224 181 80.8 592 488 82.4 38,311 31,413 82.0 13,825 12,015 86.9 63 48 76.2 8,361 6,678 79.9 1,386 1,991 1,590 1,590 1,590 1,341 84.3 504 427 84.7 1 1 100.0 224 185 82.6 69 Other 6 6 4 66.7 32 27 84.4 517 404 78.1 255 229 89.8 3 2 66.7 172 136 79.1 26	20 83.3		02 84.5
25-29	56 75.7	2,738 2,10	
30–34 37 27 73.0 118 90 76.3 3,727 2,915 78.2 1,312 1,073 81.8 10 7 70.0 977 737 75.4 148 35–39 38 30 79.0 125 101 80.8 4,882 3,796 77.8 1,799 1,522 84.6 13 9 69.2 1,246 937 75.2 170 40–44 45 35 77.8 129 109 84.5 6,178 5,030 81.4 2,323 1,978 85.2 10 8 80.0 1,611 1,255 77.9 235 45–49 51 45 88.2 84 65 77.4 7,478 6,132 82.0 2,680 2,303 85.9 10 7 70.0 1,959 1,574 80.4 277 50–54 44 33 75.0 81 67 82.7 7,694 6,459 84.0 2,851 2,519 88.4 11 10 90.9 2,001 1,643 82.1 294 55–59 46 39 84.8 46 36 78.3 5,815 4,924 84.7 2,014 1,787 88.7 9 8 88.9 1,386 1,153 83.2 213 60–64 19 18 94.7 36 31 86.1 3,217 2,763 85.9 1,125 1,009 89.7 8 8 100.0 729 606 83.1 120 ≥65 16 11 68.8 31 29 93.6 2,046 1,761 86.1 984 896 91.1 2 0 0.0 445 379 85.2 53 **Transmission risk category Injection drug use 69 54 78.3 19 15 79.0 3,061 2,593 84.7 1,311 1,114 85.0 9 7 77.8 2,141 1,707 79.7 219 Heterosexual contact 224 181 80.8 592 488 82.4 38,311 31,413 82.0 13,825 12,015 86.9 63 48 76.2 8,361 6,678 79.9 1,386 1, Perinatal infection 5 4 80.0 13 10 76.9 1,590 1,341 84.3 504 427 84.7 1 1 100.0 224 185 82.6 69 Other 6 4 66.7 32 27 84.4 517 404 78.1 255 229 89.8 3 2 66.7 172 136 79.1 26	85 75.2	4,283 3,29	
35–39	112 75.7	6,329 4,96	
40-44	133 78.2	8,273 6,52	
45-49 51 45 88.2 84 65 77.4 7,478 6,132 82.0 2,680 2,303 85.9 10 7 70.0 1,959 1,574 80.4 277 50-54 44 33 75.0 81 67 82.7 7,694 6,459 84.0 2,851 2,519 88.4 11 10 90.9 2,001 1,643 82.1 294 55-59 46 39 84.8 46 36 78.3 5,815 4,924 84.7 2,014 1,787 88.7 9 8 88.9 1,386 1,153 83.2 213 60-64 19 18 94.7 36 31 86.1 3,217 2,763 85.9 1,125 1,009 89.7 8 8 100.0 729 606 83.1 120 ≥65 16 11 68.8 31 29 93.6 2,046 1,761 86.1 984 896 91.1 2 0 0.0 445 379 85.2 53 Transmission risk category Injection drug use 69 54 78.3 19 15 79.0 3,061 2,593 84.7 1,311 1,114 85.0 9 7 77.8 2,141 1,707 79.7 219 Heterosexual contact 224 181 80.8 592 488 82.4 38,311 31,413 82.0 13,825 12,015 86.9 63 48 76.2 8,361 6,678 79.9 1,386 1, Perinatal infection 5 4 80.0 13 10 76.9 1,590 1,341 84.3 504 427 84.7 1 1 100.0 224 185 82.6 69 Other 6 6 4 66.7 32 27 84.4 517 404 78.1 255 229 89.8 3 2 66.7 172 136 79.1 26	200 85.1	10,531 8,6	
50-54	236 85.2	12,539 10,36	
55-59	262 89.1	12,976 10,99	
60-64 19 18 94.7 36 31 86.1 3,217 2,763 85.9 1,125 1,009 89.7 8 8 100.0 729 606 83.1 120 ≥65 16 11 68.8 31 29 93.6 2,046 1,761 86.1 984 896 91.1 2 0 0.0 445 379 85.2 53 **Transmission risk category Injection drug use 69 54 78.3 19 15 79.0 3,061 2,593 84.7 1,311 1,114 85.0 9 7 77.8 2,141 1,707 79.7 219 Heterosexual contact 224 181 80.8 592 488 82.4 38,311 31,413 82.0 13,825 12,015 86.9 63 48 76.2 8,361 6,678 79.9 1,386 1, Perinatal infection 5 4 80.0 13 10 76.9 1,590 1,341 84.3 504 427 84.7 1 1 100.0 224 185 82.6 69 Other 6 6 4 66.7 32 27 84.4 517 404 78.1 255 229 89.8 3 2 66.7 172 136 79.1 26	189 88.7	9,529 8,13	
≥65	97 80.8	5,254 4,53	
category Injection drug use 69 54 78.3 19 15 79.0 3,061 2,593 84.7 1,311 1,114 85.0 9 7 77.8 2,141 1,707 79.7 219 Heterosexual contact ^b 224 181 80.8 592 488 82.4 38,311 31,413 82.0 13,825 12,015 86.9 63 48 76.2 8,361 6,678 79.9 1,386 1, Perinatal infection 5 4 80.0 13 10 76.9 1,590 1,341 84.3 504 427 84.7 1 1 100.0 224 185 82.6 69 Other ^c 6 4 66.7 32 27 84.4 517 404 78.1 255 229 89.8 3 2 66.7 172 136 79.1 26	44 83.0	3,577 3,12	
Injection drug use 69 54 78.3 19 15 79.0 3,061 2,593 84.7 1,311 1,114 85.0 9 7 77.8 2,141 1,707 79.7 219 Heterosexual contact ^b 224 181 80.8 592 488 82.4 38,311 31,413 82.0 13,825 12,015 86.9 63 48 76.2 8,361 6,678 79.9 1,386 1, Perinatal infection 5 4 80.0 13 10 76.9 1,590 1,341 84.3 504 427 84.7 1 1 100.0 224 185 82.6 69 Other ^c 6 4 66.7 32 27 84.4 517 404 78.1 255 229 89.8 3 2 66.7 172 136 79.1 26			
Heterosexual contact ^b 224 181 80.8 592 488 82.4 38,311 31,413 82.0 13,825 12,015 86.9 63 48 76.2 8,361 6,678 79.9 1,386 1, Perinatal infection 5 4 80.0 13 10 76.9 1,590 1,341 84.3 504 427 84.7 1 1 100.0 224 185 82.6 69 Other ^c 6 4 66.7 32 27 84.4 517 404 78.1 255 229 89.8 3 2 66.7 172 136 79.1 26			
Perinatal infection 5 4 80.0 13 10 76.9 1,590 1,341 84.3 504 427 84.7 1 1 100.0 224 185 82.6 69 Other ^c 6 4 66.7 32 27 84.4 517 404 78.1 255 229 89.8 3 2 66.7 172 136 79.1 26	190 86.8	6,829 5,68	
Other ^c 6 4 66.7 32 27 84.4 517 404 78.1 255 229 89.8 3 2 66.7 172 136 79.1 26	1,153 83.2	62,762 51,97	76 82.8
	58 84.1	2,406 2,02	26 84.2
HHS region ^d	23 88.5	1,011 82	25 81.6
Region 1 12 10 83.3 48 42 87.5 1,574 1,333 84.7 1,428 1,274 89.2 1 1 100.0 873 747 85.6 56	45 80.4	3,992 3,45	
	169 86.7	16,278 13,95	
	307 86.2	11,095 9,23	
	561 87.0	22,774 19,39	
· · · · · · · · · · · · · · · · · · ·	111 78.7	6,948 5,39	
Region 6 43 32 74.4 74 57 77.0 4,473 3,263 73.0 1,688 1,392 82.5 6 5 83.3 1,108 816 73.7 65	44 67.7	7,457 5,60	
Region 7 5 3 60.0 11 8 72.7 355 241 67.9 54 49 90.7 0 0 0.0 221 158 71.5 11	9 81.8		68 71.2
Region 8 24 16 66.7 22 18 81.8 302 251 83.1 200 159 79.5 2 2 100.0 280 217 77.5 15	11 73.3		74 79.8
Region 9 47 34 72.3 164 114 69.5 1,400 959 68.5 1,985 1,594 80.3 40 29 72.5 1,111 796 71.7 100	72 72.0	4,847 3,59	
Region 10 52 47 90.4 30 23 76.7 234 201 85.9 90 73 81.1 11 7 63.6 219 182 83.1 38	36 94.7	674 56	69 84.4
Poverty level			
	1,067 83.4	54,156 44,93	
	146 84.4	8,245 6,9	
	146 83.0	8,118 6,76	
251-400% 5 4 80.0 39 27 69.2 1,540 1,224 79.5 359 280 78.0 3 3 100.0 531 432 81.4 47 >400% 5 5 100.0 31 27 87.1 697 553 79.3 219 186 84.9 2 2 100.0 254 199 78.4 18	43 91.5 15 83.3	2,524 2,0° 1,226 98	13 79.8 87 80.5
Health care coverage			
Private employer 13 11 84.6 46 36 78.3 2,567 2,097 81.7 487 396 81.3 5 3 60.0 842 681 80.9 56	47 83.9	4,016 3,27	71 81.4
Private individual 13 9 69.2 46 38 82.6 1.814 1.438 79.3 374 308 82.4 5 4 80.0 507 428 84.4 95	78 82.1	2,854 2,30	
Medicare 15 11 73.3 25 21 84.0 3.885 3.250 83.7 761 681 89.5 4 2 50.0 1,093 896 82.0 114	98 86.0	5,897 4,95	
	570 81.3	32,184 26,68	
	161 87.5	5,599 4,87	
Veterans Administration 1 1 100.0 1 1 100.0 41 38 92.7 5 4 80.0 0 0 0.0 14 13 92.9 5	2 40.0		59 88.1
Indian Health Service 17 14 82.4 1 1 100.0 0 0 0.0 0 0 0.0 0 0 0.0 1 1 100.0 0	0 0.0		16 84.2
Other plan 6 4 66.7 53 40 75.5 1,284 1,041 81.1 793 679 85.6 8 7 87.5 382 294 77.0 32	29 90.6	2,558 2,09	
	274 85.1	17.320 14.1	
Multiple coverages 45 39 86.7 63 54 85.7 2,922 2,456 84.1 1,024 888 86.7 6 5 83.3 999 789 79.0 199			

Table 14a. Retention in care among women (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2014—United States and 3 territories (cont)

	Americ	an Ind	lian/				Blac	k/African	1				Native	Hawa	iian/									
	Alasi	ca Nati	ve		Asian		An	nerican		Hispa	nic/Latine	o ^a	Pacific	Islar	nder	V	Vhite		Mul	tiple races	5		Total	
		Reta	ined		Reta	ined		Retair	ned		Retain	ed		Reta	ained		Retair	ned		Retair	ed		Retain	ied
	Total			Total			Total			Total			Total			Total			Total			Total		
	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%
Housing status																								
Stable	240	196	81.7	611	509	83.3	39,454	32,564	82.5	14,141	12,331	87.2	69	53	76.8	9,661	7,815	80.9	1,374	1,158	84.3	65,550	54,626	83.3
Temporary	41	31	75.6	81	60	74.1	4,341	3,509	80.8	1,722	1,428	82.9	10	9	90.0	1,149	845	73.5	243	194	79.8	7,587	6,076	80.1
Unstable	32	27	84.4	23	16	69.6	1,499	1,153	76.9	382	306	80.1	3	2	66.7	427	317	74.2	87	70	80.5	2,453	1,891	77.1
Total ^e	322	259	80.4	727	592	81.4	46,310	37,873	81.8	16,557	14,283	86.3	84	65	77.4	11,433	9,099	79.6	1,728	1,440	83.3	77,161	63,611	82.4

^a Hispanics/Latinos can be of any race.

^b Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^c Includes hemophilia, blood transfusion, and unknown risk factor.

 $^{^{\}rm d}\,\mbox{See}$ Technical Notes for the states/territories in each region.

e Because totals were calculated independently of the values for the subpopulations, the values in each column may not sum to the column total.

Table 14b. Viral suppression among women (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2014—United States and 3 territories

		ican Ind			Asian		Black/Af	rican Am	erican	Hisna	nic/Latin	o ^a		Hawaii		,	White		Mul	tiple rac	es		Total	
		Vir Suppre	al		Vir. Suppre			Vira Suppres	ıl		Vira Suppres	ı		Vir Suppre	al		Vira Suppres			Vira Suppre	al		Vira Suppres	
	Total			Total			Total			Total			Total			Total			Total			Total		
Ago group (vr)	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	<u>%</u>
Age group (yr) 13-14	0	0	0.0	4	4	100.0	116	93	80.2	41	35	85.4	0	0	0.0	14	13	92.9	6	4	66.7	181	149	82.3
15–19	3	2	66.7	7	6	85.7	693	445	64.2	174	123	70.7	1	1	100.0	81	62	76.5	24	18	75.0	983	657	66.8
20–24	9	8	88.9	20	14	70.0	1,892	1,092	57.7	515	333	64.7	7	2	28.6	377	248	65.8	78	47	60.3	2,898	1,744	60.2
25–29	15	11	73.3	50	44	88.0	2,892	1,847	63.9	819	562	68.6	4	2	50.0	699	498	71.2	117	76	65.0	4,596	3,040	66.1
30–34 35–39	40 38	32 32	80.0 84.2	117 127	107	91.5 93.7	3,911 5,182	2,763 3,861	70.7 74.5	1,365 1,913	1,055 1,505	77.3 78.7	8	7	87.5 68.8	1,007 1,293	761 1,005	75.6 77.7	159 179	119	74.8 82.7	6,607 8,748	4,844 6,681	73.3 76.4
40–44	36 44	32	72.7	131	119 113	93.7 86.3	6.359	4.921	77.4	2.394	1,955	81.7	16 11	11 8	72.7	1,293	1,347	81.2	236	148 193	81.8	10,833	8,569	76. 4 79.1
45–49	54	49	90.7	93	85	91.4	7,705	6,124	79.5	2,753	2,264	82.2	9	8	88.9	1,999	1,721	86.1	285	245	86.0	12,898	10,496	81.4
50–54	50	41	82.0	82	72	87.8	7,881	6,476	82.2	2,934	2,518	85.8	13	12		2,033	1,793	88.2	296	268	90.5	13,289	11,180	84.1
55–59	48	42	87.5	46	45	97.8	5,906	5,029	85.2	2,030	1,807	89.0	7	6	85.7	1,415	1,286	90.9	217	197	90.8	9,669	8,412	87.0
60–64	19	15	79.0	36	32	88.9	3,277	2,886	88.1	1,129	1,032	91.4	8	8		746	686	92.0	118	102	86.4	5,333	4,761	89.3
≥65	17	16	94.1	30	30	100.0	2,072	1,852	89.4	992	903	91.0	1	1	100.0	465	440	94.6	57	52	91.2	3,634	3,294	90.6
Transmission risk category																								
Injection drug use	69	58	84.1	18	14	77.8	3,103	2,468	79.5	1,342	1,037	77.3	9	8	88.9	2,177	1,758	80.8	219	186	84.9	6,937	5,529	79.7
Heterosexual contact [□]	239	197	82.4	610	548	89.8	39,774	31,315	78.7	14,263	11,937	83.7	64	49		8,668	7,305	84.3	1,429	1,194	83.6	65,047	52,545	80.8
Perinatal infection	6	5	83.3	14	13	92.9	1,590	978	61.5	509	339	66.6	3	2	66.7	234	183	78.2	72	45	62.5	2,428	1,565	64.5
Other ^c	4	4	100.0	32	28	87.5	532	437	82.1	263	214	81.4	2	1	50.0	176	157	89.2	26	24	92.3	1,035	865	83.6
HHS region ^d	44	7	62.6	40	40	100.0	4.000	4.055	04.2	4 450	4 220	04.0	4	4	100.0	004	700	00.0	50	5 4	00.4	4.070	0.477	05.4
Region 1	11 22	7 18	63.6 81.8	48 132	48 121	100.0 91.7	1,608 8,152	1,355 6,312	84.3 77.4	1,452 7.120	1,229 5.716	84.6 80.3	1 10	1 9	100.0 90.0	891 1.454	786 1,258	88.2 86.5	59 202	51 160	86.4 79.2	4,070 17,092	3,477 13,594	85.4 79.5
Region 2 Region 3	14	11	78.6	73	72	98.6	8,348	6,767	81.1	1.054	911	86.4	4	4		1,454	1,160	84.9	357	302	79.2 84.6	11,217	9,227	79.3 82.3
Region 4	56	48	85.7	98	86	87.8	17,121	13,248	77.4	2,055	1,755	85.4	5	4	80.0	3,362	2,776	82.6	665	562	84.5	23,362	18,479	79.1
Region 5	45	35	77.8	73	65	89.0	4,694	3,723	79.3	859	742	86.4	6	4	66.7	1,357	1,161	85.6	147	114	77.6	7,181	5,844	81.4
Region 6	48	40	83.3	78	66	84.6	4,799	3,497	72.9	1,796	1,449	80.7	6	5	83.3	1,194	925	77.5	71	56	78.9	7,992	6,038	75.6
Region 7	7	6	85.7	12	11	91.7	383	292	76.2	62	53	85.5	0	0	0.0	242	201	83.1	11	11	100.0	717	574	80.1
Region 8	24	19	79.2	23	20	87.0	321	270	84.1	206	178	86.4	2	2	100.0	292	247	84.6	16	12	75.0	884	748	84.6
Region 9	47	42	89.4	162	142	87.7	1,334	1,054	79.0	2,012	1,697	84.3	38	26		1,063	890	83.7	96	81	84.4	4,752	3,932	82.7
Region 10	56	48	85.7	32	30	93.8	249	206	82.7	94	86	91.5	11	9	81.8	219	186	84.9	38	33	86.8	699	598	85.6
Poverty level																								
0–100%	260	210	80.8	439	391	89.1	33,123	25,275	76.3	12,911	10,507	81.4	57	39		7,749	6,279	81.0	1,316	1,074	81.6	55,855	43,775	78.4
101–138%	27	25	92.6	92	86	93.5	5,321	4,319	81.2	1,478	1,259	85.2	10	9	90.0	1,367	1,199	87.7	174	153	87.9	8,469	7,050	83.2
139–250%	30	27	90.0	108	99	91.7	5,212	4,406	84.5	1,389	1,240	89.3	10	10		1,426	1,281	89.8	181	156	86.2	8,356	7,219	86.4
251–400% >400%	6 5	6 5	100.0 100.0	41 33	38 30	92.7 90.9	1,607 872	1,369 693	85.2 79.5	378 311	341 241	90.2 77.5	3 2	3	100.0 100.0	549 278	494 265	90.0 95.3	49 19	44 16	89.8 84.2	2,633 1,520	2,295 1,252	87.2 82.4
7 10070	Ü	Ü	100.0	00	00	00.0	012	000	70.0	011	2	77.0	-	_	100.0	210	200	00.0	10	10	01.2	1,020	1,202	OZ. I
Health care coverage																								
Private employer	13	12	92.3	46	43	93.5	2,648	2,228	84.1	498	447	89.8	6	6		867	799	92.2	57	52	91.2	4,135	3,587	86.7
Private individual	17	15	88.2	48	43	89.6	1,857	1,602	86.3	394	347	88.1	5	4	80.0	534	481	90.1	97	85	87.6	2,952	2,577	87.3
Medicare Medicaid	15 145	13 116	86.7 80.0	25 274	21 250	84.0 91.2	3,972 19,464	3,324 14,585	83.7 74.9	780 7,986	684 6,403	87.7 80.2	4 37	4 26	100.0 70.3	1,116 4,278	1,002 3,485	89.8 81.5	116 719	100 567	86.2 78.9	6,028 32,903	5,148 25,432	85.4 77.3
Medicaid Medicare and Medicaid	145 27	26	96.3	274	250 18	90.0	3,363	2,785	74.9 82.8	937	814	86.9	3 <i>1</i>	26 3	70.3 75.0	1,166	1,017	87.2	187	162	78.9 86.6	5,704	4,825	77.3 84.6
Veterans Administration	1	1	100.0	1	10	100.0	44	31	70.5	6	5	83.3	0	0	0.0	1,100	1,017	76.9	5	4	80.0	70	52	74.3
Indian Health Service	20	14	70.0	1	1	100.0	0	0	0.0	1	0	0.0	0	0	0.0	1	0	0.0	0	0	0.0	23	15	65.2
Other plan	7	6	85.7	51	48	94.1	1,319	1,085	82.3	818	698	85.3	7	4	57.1	395	332	84.1	34	27	79.4	2,631	2,200	83.6
No coverage	43	34	79.1	199	174	87.4	11,455	8,666	75.7	4,331	3,593	83.0	11	11		2,184	1,659	76.0	337	280	83.1	18,560	14,417	77.7
Multiple coverages	48	42	87.5	63	58	92.1	3,036	2,494	82.2	1,078	906	84.0	6	5	83.3	1,042	913	87.6	202	178	88.1	5,475	4,596	83.9

Table 14b. Viral suppression among women (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2014—United States and 3 territories (cont)

		ican Ind ska Nati			Asian		Black/A	rican Am	erican	Hispa	ınic/Latin	o ^a		e Hawa fic Islar			White		Mul	tiple rac	es		Total	
		Vir Suppre			Vir Suppre			Vira Suppres			Vira Suppres			Vi Suppr	ral ession		Vira Suppres			Vir Suppre		_	Vira Suppres	
	Total			Total			Total			Total			Total			Total			Total			Total		
	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	<u>%</u>
Housing status																								
Stable	253	214	84.6	629	569	90.5	40,799	32,241	79.0	14,579	12,128	83.2	72	60	83.3	9,954	8,497	85.4	1,410	1,193	84.6	67,696	54,902	81.1
Temporary	43	32	74.4	82	73	89.0	4,584	3,405	74.3	1,799	1,436	79.8	9		44.4	1,222	929	76.0	250	196	78.4	7,989	6,075	76.0
Unstable	31	25	80.7	24	23	95.8	1,551	1,003	64.7	411	292	71.1	3	1	33.3	427	284	66.5	91	63	69.2	2,538	1,691	66.6
Total ^e	337	280	83.1	743	671	90.3	47,886	37,389	78.1	17,059	14,092	82.6	85	66	77.7	11,787	9,860	83.7	1,772	1,469	82.9	79,669	63,827	80.1

^a Hispanics/Latinos can be of any race.

^b Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^c Includes hemophilia, blood transfusion, and unknown risk factor.

^d See Technical Notes for the states/territories in each region.

e Because totals were calculated independently of the values for the subpopulations, the values in each column may not sum or column total.

Table 15a. Retention in care among men (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2014—United States and 3 territories

		ican In			Asian		Black/Afr	rican Am	erican	Hispa	nic/Latin	no ^a		Hawa			White		Mult	iple race	s	-	Γotal	
		Retai	ined		Retai	ned		Retair	ned		Retair	ned		Reta	ined		Retair	ed		Retair	ned		Retain	ed
	Total			Total			Total			Total			Total			Total			Total			Total		
	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%
Age group (yr)	2	1	E0.0	0	0	0.0	107	92	86.0	23	22	05.7	1	1	100.0	10	9	90.0	0	0	0.0	143	125	07.4
13–14 15–19	2 6	4	50.0 66.7	10		100.0	812	92 661	81.4	216	22 167	95.7 77.3	0	0	100.0	86	65	90.0 75.6	26	0 20	76.9	1,156	927	87.4 80.2
20–24	25	14	56.0	112	87	77.7	5,774	4,162	72.1	1,931	1,433	74.2	13	9	69.2	1,204	876	72.8	210	144	68.6	9,269	6,725	72.6
25–29	65	43	66.2	233	160	68.7	9,394	6,883	73.3	3,924	2,974	75.8	25	16	64.0	3,297	2,420	73.4	353	263	74.5	17,291	12,759	73.8
30–34	68	51	75.0	233 275	214	77.8	7.659	5,694	74.3	5,269	4,124	78.3	40	23	57.5	4,292	3.180	73.4 74.1	328	249	74.5 75.9	17,291	13,535	75.5
35–39	82	56	68.3	337	271	80.4	6.543	5,094	76.6	6,002	4,862	81.0	32	24	75.0	4,690	3,526	75.2	297	249	75.4	17,983	13,977	77.7
40–44	106	75	70.8	475	385	81.1	7,454	5,808	77.9	7,023	5,774	82.2	29	20	69.0	6,349	4.840	76.2	371	296	79.8	21,807	17,198	78.9
45–49	146	118	80.8	402	328	81.6	10,657	8,493	79.7	8,285	6,964	84.1	44	34	77.3	9,819	7.690	78.3	511	433	84.7	29,864	24,060	80.6
50–54	149	116	77.9	275	220	80.0	12.026	9,816	81.6	7,477	6,359	85.1	46	33	71.7	11,666	9,413	80.7	579	479	82.7	32,218	26,436	82.1
55–59	82	65	79.3	174	137	78.7	9,132	7,590	83.1	4,541	3,900	85.9	27	23	85.2	7,518	6,166	82.0	360	297	82.5	21,834	18,178	83.3
60–64	44	37	84.1	112	94	83.9	5,217	4,439	85.1	2,509	2,186	87.1	6	6	100.0	4,298	3,582	83.3	188	164	87.2	12,374	10,170	84.9
≥65	18	15	83.3	62	50	80.7	2,998	2,523	84.2	1,702	1,497	88.0	10	9	90.0	2,697	2,277	84.4	97	82		7,584	6,453	85.1
203	10	13	00.0	02	30	00.7	2,330	2,323	04.2	1,702	1,437	00.0	10	3	30.0	2,037	2,211	04.4	31	02	04.5	7,504	0,433	05.1
Transmission risk category																								
Male-to-male sexual contact	499	389	78.0	1,481	1,151	77.7	38,789	30,173	77.8	28,527	23,368	81.9	205	148	72.2	41,181	32,779	79.6	2,055	1,633	79.5	112,737	89,641	79.5
Injection drug use	57	37	64.9	75	57	76.0	5,077	4,173	82.2	4,008	3,387	84.5	11	8	72.7	3,088	2,378	77.0	218	164	75.2	12,534	10,204	81.4
Male-to-male sexual contact	73	47	64.4	33	21	63.6	1,280	1,009	78.8	1,044	806	77.2	7	6	85.7	3,153	2,442	77.5	209	174	83.3	5,799	4,505	77.7
and injection drug use																								
Heterosexual contact ^b	116	89	76.7	623	544	87.3	26,113	20,905	80.1	12,455	10,527	84.5	34	24	70.6	5,348	4,175	78.1	686	562	81.9	45,375	36,826	81.2
Perinatal infection	8	3	37.5	11	10	90.9	1,177	963	81.8	415	345	83.1	3	3	100.0	177	141	79.7	47	39	83.0	1,838	1,504	81.8
Other ^c	10	8	80.0	43	35	81.4	434	358	82.5	255	212	83.1	1	1	100.0	424	333	78.5	25	21	84.0	1,192	968	81.2
HHS region ^d																								
Region 1	20	18	90.0	127	112	88.2	1,730	1,445	83.5	2,266	1,958	86.4	9	0	100.0	4,087	3,455	84.5	126	106	84.1	8,365	7,103	84.9
Region 2	39	32	82.1	426	390	91.6	9,565	7,760	81.1	12,848	11,371	88.5	9	7	77.8	3,949	3,301	83.6	328	280	85.4	27,164	23,141	85.2
Region 3	21	17	81.0	216	187	86.6	13,249	10,623	80.2	2,390	1,974	82.6	16	13	81.3	5,695	4,712	82.7	560	467	83.4	22,147	17,993	81.2
Region 4	128	105	82.0	272	240	88.2	28,509	23,652	83.0	7,030	5,952	84.7	27	23	85.2	13,371	11,245	84.1	832	720	86.5	50,169	41,937	83.6
Region 5	66	53	80.3	223	178	79.8	10,347	7,666	74.1	3,237	2,586	79.9	11	10	90.9	7,835	5,802	74.1	376	287	76.3	22,095	16,582	75.0
Region 6	167	124	74.3	227	185	81.5	7,645	5,433	71.1	7,353	5,808	79.0	18	13	72.2	5,846	4,338	74.1	201	132	65.7	21,457	16,033	74.7
Region 7	14	12	85.7	22	19	86.4	753	436	57.9	248	187	75.4	3	2	66.7	1,032	761	73.7	26	15	57.7	2,098	1,432	68.3
Region 8	52	35	67.3	46	38	82.6	429	359	83.7	870	674		7	4	57.1	2,089	1,710	81.9	55	43	78.2	3,548	2,863	80.7
Region 9	191	129	67.5	802	528	65.8	3,322	2,083	62.7	11,241	8,633	76.8	144	95	66.0	8,426	5,969	70.8	365	244	66.9	24,491	17,681	72.2
Region 10	82	63	76.8	65	49	75.4	382	304	79.6	435	360	82.8	23	19	82.6	1,710	1,354	79.2	118	94	79.7	2,815	2.243	79.7
region to	02	00	70.0	00	10	70.1	002	001	70.0	100	000	02.0	20	10	02.0	1,7 10	1,001	70.2	110	01	70.7	2,010	2,210	70.7
Poverty level			- c -				50 555	00		00	05 :				- c ·	00.515	00				- c ·		00 = 10	- c :
0–100%	494	365	73.9	1,281	1,008	78.7	50,290	39,358	78.3	30,397	25,192	82.9	154	108	70.1	26,945	20,928	77.7	2,027	1,589	78.4	111,588	88,548	79.4
101–138%	93	75	80.7	331	263	79.5	8,686	7,149	82.3	5,882	4,959	84.3	28	19	67.9	7,524	6,075	80.7	446	380	85.2	22,990	18,920	82.3
139–250%	116	86	74.1	421	346	82.2	10,390	8,503	81.8	6,754	5,577	82.6	43	34	79.1	10,986	8,850	80.6	536	439	81.9	29,246	23,835	81.5
251–400%	47	38	80.9	173	133	76.9	3,750	2,925	78.0	2,192	1,737	79.2	23	18	78.3	4,733	3,815	80.6	155	128	82.6	11,073	8,794	79.4
>400%	18	15	83.3	131	112	85.5	1,354	1,077	79.5	1,150	964	83.8	15	13	86.7	2,995	2,446	81.7	76	66	86.8	5,739	4,693	81.8
Health care coverage																								
Private employer	57	47	82.5	174	137	78.7	4,515	3,649	80.8	1,895	1,499	79.1	27	21	77.8	6,003	4,831	80.5	153	120	78.4	12,824	10,304	80.3
Private individual	49	37	75.5	204	169	82.8	3,893	2,980	76.6	1,676	1,264	75.4	16	12	75.0	4,895	3,783	77.3	201	141	70.2	10,934	8,386	76.7
Medicare	58	42	72.4	85	77	90.6	7,822	6,551	83.8	2,426	2,066	85.2	17	10	58.8	7,158	5,885	82.2	282	234	83.0	17,848	14,865	83.3
Medicaid	212	159	75.0	712	563	79.1	22,766	18,074	79.4	14,933	12,515	83.8	81	64	79.0	11,591	9,066	78.2	989	800	80.9	51,284	41,241	80.4
Medicare and Medicaid	76	64	84.2	75	67	89.3	4,863	4,136	85.1	2,300	2,010	87.4	19	16	84.2	4,571	3,897	85.3	329	283	86.0	12,233	10,473	85.6
Veterans Administration	3	2	66.7	1	1	100.0	92	71	77.2	71	53	74.7	0	0	0.0	159	133	83.7	4	3	75.0	330	263	79.7
Indian Health Service	37	28	75.7	1	1	100.0	0	0	0.0	1	1	100.0	0	0	0.0	0	0	0.0	1	0	0.0	40	30	75.0
Other plan	41	28	68.3	137	98	71.5	2,391	1,898	79.4	3,182	2,631	82.7	21	15	71.4	2,245	1,706	76.0	82	60	73.2	8,099	6,436	79.5
No coverage	150	106	70.7	820	661	80.6	25,523	19,416	76.1	18,847	15,469	82.1	64	46	71.9	12,623	9,636	76.3	786	616	78.4	58,813	45,950	78.1
Multiple coverages	100	76	76.0	201	155	77.1	4,288	3,447	80.4	2,804	2,295	81.9	17	10	58.8	5,488	4,381	79.8	440	361	82.1	13,338	10,725	80.4
. •																								

Table 15a. Retention in care among men (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2014—United States and 3 territories (cont)

		ican In ska Na			Asian		Black/Afr	ican Ame	erican	Hispa	ınic/Latin	o ^a		e Hawa fic Islaı			White		Mult	iple race	s		Total	
		Reta	ined		Retail	ned		Retair	ned		Retair	ed		Reta	ined		Retair	ed	_	Retair	ed	_	Retain	ied
	Total			Total			Total			Total			Total			Total			Total			Total		
	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%
Housing status																								
Stable	640	493	77.0	2,019	1,643	81.4	62,570	50,134	80.1	38,839	32,511	83.7	235	175	74.5	47,451	38,045	80.2	2,517	2,051	81.5	154,271	125,052	81.1
Temporary	93	64	68.8	344	249	72.4	9,361	7,034	75.1	7,799	6,198	79.5	24	13	54.2	5,517	4,076	73.9	506	391	77.3	23,644	18,025	76.2
Unstable	45	29	64.4	57	34	59.7	3,714	2,681	72.2	1,385	1,024	73.9	9	8	88.9	1,879	1,299	69.1	240	175	72.9	7,329	5,250	71.6
Total ^e	793	595	78.0	2,467	1,956	79.3	77,773	61,175	78.7	48,902	40,262	82.3	273	198	72.5	55,926	44,044	78.8	3,320	2,651	79.9	189,454	150,881	79.6

^a Hispanics/Latinos can be of any race.

^b Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^c Includes hemophilia, blood transfusion, and unknown risk factor.

^d See Technical Notes for the states/territories in each region.

e Because totals were calculated independently of the values for the subpopulations, the values in each column may not sum to the column total.

Table 15b. Viral suppression among men (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2014—United States and 3 territories

		ican Ind ska Nati	ve		Asian		Black/Af	rican Ame		Hispa	anic/Latin			e Hawai fic Islan	der		White		Mul	tiple rac			Total	
		Vir. Suppre			Vira Suppre			Vira Suppres			Vira Suppres			Vir. Suppre			Vira Suppres			Vira Suppre			Viral Suppres	
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
Age group (yr)																								
13–14	2	2	100.0	0	0	0.0	101	81	80.2	21	20	95.2	1	1	100.0	13	12	92.3	0	0	0.0	138	116	
15–19	6	5	83.3	10	9	90.0	906	564	62.3	253	163	64.4	0	0	0.0	111	73	65.8	31	13	41.9	1,317	827	62.8
20–24	32	22	68.8	132	99	75.0	6,439	4,001	62.1	2,168	1,519	70.1	15	10	66.7	1,352	981	72.6	238	166	69.8	10,376	6,798	65.5
25–29	72	52	72.2	266	220	82.7	10,309	6,955	67.5	4,327	3,344	77.3	23	16	69.6	3,626	2,809	77.5	377	298	79.1	19,000	13,694	72.1
30–34	72	57	79.2	297	255	85.9	8,196	5,958	72.7	5,624	4,549	80.9	43	32	74.4	4,559	3,650	80.1	344	272	79.1	19,135	14,773	77.2
35–39	88	74	84.1	352	313	88.9	6,954	5,172	74.4	6,336	5,285	83.4	35	27	77.1	4,955	4,051	81.8	310	245	79.0	19,030	15,167	79.7
40–44	113	91	80.5	490	445	90.8	7,807	6,017	77.1	7,286	6,203	85.1	29	22	75.9	6,619	5,590	84.5	377	315	83.6	22,721	18,683	82.2
45–49	154	130	84.4	420	385	91.7	11,123	8,784	79.0	8,599	7,386	85.9	48	40	83.3	10,136	8,917	88.0	541	463	85.6	31,021	26,105	84.2
50–54	150	132	88.0	278	249	89.6	12,470	10,101	81.0	7,625	6,727	88.2	47	44	93.6	11,916	10,739	90.1	598	523	87.5	33,084	28,515	86.2
55–59	86	71	82.6	189	174	92.1	9,341	7,877	84.3	4,634	4,111	88.7	30	27 8	90.0	7,615	7,042	92.5	359	322	89.7	22,254	19,624	88.2
60–64	41	38	92.7	113	108	95.6	5,268	4,573	86.8	2,510	2,262	90.1	8	•	100.0	4,324	4,091	94.6	198	176	88.9	12,462	11,256	90.3
≥65	20	19	95.0	64	60	93.8	3,014	2,684	89.1	1,702	1,586	93.2	10	10	100.0	2,706	2,600	96.1	95	90	94.7	7,611	7,049	92.6
Transmission risk category	500	450	05.0	4 504	4.000	00.0	44.054	04.055	75.0	00.070	05.540	05.4	040	470	00.0	40.070	07.050	00.0	0.450	4.040	04.0	440.000	00.000	00.0
Male-to-male sexual contact	532	453	85.2	1,561	1,393	89.2	41,254	31,055	75.3	29,878	25,519	85.4	216	179	82.9	42,676	37,656	88.2	2,152	1,813	84.3	118,269	98,068	82.9
Injection drug use	58	46	79.3	80	70	87.5	5,162	4,151	80.4	4,084	3,348	82.0	13	11	84.6	3,183	2,660	83.6	220	183	83.2	12,800	10,469	81.8
Male-to-male sexual contact and injection drug use	71	56	78.9	41	30	73.2	1,299	987	76.0	1,081	865	80.0	8	5	62.5	3,230	2,634	81.6	215	160	74.4	5,945	4,737	79.7
Heterosexual contact ^o	123	102	82.9	659	594	90.1	27,453	21,532	78.4	13,014	10,965	84.3	36	30	83.3	5,561	4,789	86.1	723	606	83.8	47,569	38,618	
Perinatal infection	8	6	75.0	12	9	75.0	1,173	768	65.5	421	283	67.2	3	3	100.0	191	149	78.0	49	25	51.0	1,857	1,243	66.9
Other ^c	10	7	70.0	47	44	93.6	446	364	81.6	265	224	84.5	1	1	100.0	444	411	92.6	24	23	95.8	1,237	1,074	86.8
HHS region ^d																								
Region 1	21	19	90.5	137	124	90.5	1,783	1,498	84.0	2,325	2,024	87.1	10	10	100.0	4,155	3,848	92.6	130	111	85.4	8,561	7,634	89.2
Region 2	49	37	75.5	486	427	87.9	10,424	7,971	76.5	13,768	11,337	82.3	17	13	76.5	4,399	3,823	86.9	358	299	83.5	29,501	23,907	81.0
Region 3	22	16	72.7	218	197	90.4	13,655	11,052	80.9	2,415	2,095	86.8	16	13	81.3	5,910	5,330	90.2	574	488	85.0	22,810	19,191	84.1
Region 4	134	109	81.3	291	252	86.6	30,002	22,666	75.6	7,225	6,258	86.6	28	24	85.7	13,831	12,040	87.1	879	748	85.1	52,390	42,097	80.4
Region 5	74	62	83.8	237	215	90.7	10,907	8,516	78.1	3,403	3,014	88.6	11	10	90.9	8,033	7,185	89.4	383	313	81.7	23,048	19,315	83.8
Region 6	175	141	80.6	245	213	86.9	8,271	5,908	71.4	7,824	6,484	82.9	16	13	81.3	6,220	5,115	82.2	207	164	79.2	22,958	18,038	78.6
Region 7	14	12	85.7	24	22	91.7	861	657	76.3	259	224	86.5	4	4	100.0	1,152	1,004	87.2	33	25	75.8	2,347	1,948	83.0
Region 8	51	40	78.4	48	46	95.8	478	386	80.8	904	768	85.0	6	3	50.0	2,199	1,916	87.1	57	47	82.5	3,743	3,206	85.7
Region 9	195	165	84.6	811	719	88.7	3,175	2,375	74.8	11,439	9,687	84.7	149	120	80.5	8,292	7,088	85.5	368	294	79.9	24,429	20,448	83.7
Region 10	90	84	93.3	67	61	91.0	395	323	81.8	464	403	86.9	25	25	100.0	1,746	1,549	88.7	120	96	80.0	2,907	2,541	87.4
Poverty level																								
0–100%	514	413	80.4	1,358	1,202	88.5	52,947	39,431	74.5	31,548	26,045	82.6	159	125	78.6	27,942	23,409	83.8	2,121	1,697	80.0	116,589	92,322	79.2
101–138%	96	86	89.6	338	309	91.4	9,059	7,283	80.4	6,088	5,360	88.0	27	24	88.9	7,750	6,936	89.5	464	398	85.8	23,822	20,396	85.6
139–250%	122	108	88.5	451	407	90.2	10,973	9,082	82.8	7,073	6,318	89.3	46	41	89.1	11,354	10,374	91.4	559	494	88.4	30,578	26,824	87.7
251–400% >400%	51 25	47 20	92.2 80.0	180 160	161 136	89.4 85.0	3,941 1,750	3,193 1,373	81.0 78.5	2,292 1,571	2,016 1,276	88.0 81.2	30 17	23 15	76.7 88.2	4,941 3,219	4,526 2,980	91.6 92.6	160 89	149 82	93.1 92.1	11,595 6,831	10,115 5,882	87.2 86.1
	20	20	00.0	100	100	00.0	1,700	1,070	70.0	1,071	1,270	01.2	.,	10	00.2	0,210	2,000	02.0	00	02	02.1	0,001	0,002	00.1
Health care coverage Private employer	60	52	86.7	185	173	93.5	4.706	3.933	83.6	1.997	1.777	89.0	31	27	87.1	6.287	5,806	92.4	160	143	89.4	13,426	11.911	88.7
Private individual	56	50	89.3	217	198	91.2	4,073	3,387	83.2	1,778	1,582	89.0	17	16	94.1	5,068	4,654	91.8	218	182	83.5	11,427	10,069	88.1
Medicare	55	47	85.5	83	79	95.2	7,986	6,708	84.0	2,487	2,234	89.8	18	17	94.1	7,259	6,676	92.0	285	259	90.9	18,173	16,020	88.2
Medicaid	227	187	82.4	743	655	88.2	23,610	17,827	75.5	15,429	12,642	81.9	84	69	82.1	12,050	10,194	84.6	1,022	819	80.1	53,165	42,393	79.7
Medicare and Medicaid	75	66	88.0	743	71	91.0	4,957	4,090	82.5	2,294	2,022	88.1	18	17	94.4	4,609	4,153	90.1	343	303	88.3	12,374	10,722	86.6
Veterans Administration	3	3	100.0	1	1	100.0	4,937	4,090	87.8	68	67	98.5	0	0	0.0	169	159	94.1	343 7	6	85.7	346	322	93.1
Indian Health Service	41	37	90.2	1	1	100.0	0	00	0.0	2	1	50.0	0	0	0.0	0	0	0.0	1	1	100.0	45	40	88.9
Other plan	47	37	78.7	146	132	90.4	2.486	1.982	79.7	3.302	2.826	85.6	21	16	76.2	2.333	1.977	84.7	89	71	79.8	8.424	7.041	83.6
No coverage	158	115	72.8	901	779	86.5	28,009	1,982	79.7	20.107	16,820	83.7	74	55	76.2	13,413	10,830	80.7	842	668	79.6 79.3	63,504	49.147	63.6 77.4
Multiple coverages	104	93	89.4	211	192	91.0	4,555	3,733	82.0	3,000	2,633	87.8	18	16	88.9	5,670	5,162	91.0	460	394	85.7	14,018	12,223	87.2
wunipie coverages	104	93	05.4	211	192	91.0	4,000	3,133	02.0	3,000	2,033	01.0	10	10	00.9	5,070	5,102	91.0	400	354	00.7	14,010	12,223	01.2

49

Table 15b. Viral suppression among men (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2014—United States and 3 territories (cont)

		rican Ind ska Nati			Asian		Black/Af	rican Ame	erican	Hispa	anic/Latin	o ^a		ve Hawai ific Islan			White		Mul	tiple race	es		Total	
		Vira Suppre			Vira Suppres			Vira Suppres			Vira Suppres			Vir Suppre			Vira Suppres			Vira Suppre			Viral Suppress	
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
Housing status																								
Stable	675	577	85.5	2,136	1,907	89.3	65,865	51,363	78.0	40,556	34,774	85.7	252	213	84.5	49,212	43,701	88.8	2,638	2,239	84.9	161,334	134,774	83.5
Temporary	95	72	75.8	366	322	88.0	9,995	7,217	72.2	8,272	6,688	80.9	24	17	70.8	5,760	4,612	80.1	533	436	81.8	25,045	19,364	77.3
Unstable	47	30	63.8	58	47	81.0	3,992	2,605	65.3	1,471	1,013	68.9	10	6	60.0	1,941	1,373	70.7	251	169	67.3	7,770	5,243	67.5
Total ^e	836	693	82.9	2,611	2,317	88.7	81,928	62,767	76.6	51,085	43,155	84.5	289	237	82.0	57,932	50,555	87.3	3,468	2,883	83.1	198,149	162,607	82.1

^a Hispanics/Latinos can be of any race.

^b Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^c Includes hemophilia, blood transfusion, and unknown risk factor.

^d See Technical Notes for the states/territories in each region.

e Because totals were calculated independently of the values for the subpopulations, the values in each column may not sum to the column total.

Total No. N	0 0.0 0 0.0 3 75.0 8 72.7 4 50.0 6 85.7 5 100.0 3 75.0	18 42 38	No.	1 100.0 8 80.0
Age group (yr) No.	0 0.0 0 0.0 3 75.0 8 72.7 4 50.0 6 85.7 5 100.0 3 75.0	No.	No. 1 10 37 1	1 100.0
Age group (yr) 13-14 0	0 0.0 0 0.0 3 75.0 8 72.7 4 50.0 6 85.7 5 100.0 3 75.0	1 18 42 38	1 0 37 1	1 100.0
13–14 0 0 0 0.0 0 0 0.0 1 1 1 100.0 0 0 0 0.0 0 0 0 0.0 0 0 0 0.0 0 0 0 0.0 0 0 0 0.0 0 0 0 0.0 0 0 0 0.0 0 0 0 0.0 0 0 0 0.0 0 0 0 0.0 0 0 0 0.0 0 0 0 0.0 0 0 0 0.0 0 0 0 0.0 0 0 0 0.0 0 0 0 0.0 0 0 0 0.0 0 0 0 0.0 0 0 0.0 0 0 0 0.0 0 0 0 0.0 0 0 0 0.0 0 0 0 0.0 0 0 0 0.0 0 0 0 0.0 0 0 0 0.0 0 0 0 0.0 0 0 0 0.0 0 0 0 0.0 0 0 0 0.0 0 0 0 0.0 0 0 0 0 0.0 0 0 0 0.0 0 0 0 0 0.0 0 0 0 0 0.0 0 0 0 0 0.0 0 0 0 0 0.0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 0.0 3 75.0 8 72.7 4 50.0 6 85.7 5 100.0 3 75.0	18 42 38	10 37 1:	
15-19	0 0.0 3 75.0 8 72.7 4 50.0 6 85.7 5 100.0 3 75.0	18 42 38	10 37 1:	
20-24 1 1 1 100.0 1 0 0.0 130 86 66.2 35 25 71.4 0 0 0 0.0 16 14 87.5 4 25-29 1 1 1 100.0 10 8 80.0 275 183 66.6 96 77 80.2 3 2 66.7 31 27 87.1 11 30-34 4 3 75.0 6 5 83.3 218 176 80.7 123 97 78.9 2 2 100.0 28 19 67.9 8 35-39 1 1 1 100.0 5 3 60.0 179 135 75.4 136 108 79.4 1 0 0.0 29 23 79.3 7 40-44 0 0 0 0.0 11 9 81.8 143 107 74.8 181 159 87.9 2 2 100.0 39 27 69.2 5 45-49 5 5 100.0 11 7 63.6 140 110 78.6 134 122 91.0 1 1 100.0 52 41 78.9 4 50-54 4 2 50.0 3 3 100.0 133 96 72.2 82 75 91.5 1 1 100.0 39 34 87.2 6 55-59 0 0 0 0.0 3 2 66.7 66 51 77.3 44 37 84.1 2 2 100.0 23 19 82.6 8 60-64 0 0 0 0.0 0 0 0 0 0 0 0 0 7 17 17 100.0 7 6 85.7 0 0 0 0.0 4 4 100.0 1 HHS region ^b	3 75.0 8 72.7 4 50.0 6 85.7 5 100.0 3 75.0	18 42 38	37 1	
25-29	8 72.7 4 50.0 6 85.7 5 100.0 3 75.0	42 38		129 69.0
30–34	4 50.0 6 85.7 5 100.0 3 75.0	38	77 3	306 71.7
35–39	6 85.7 5 100.0 3 75.0			306 71.7 306 78.7
40-44 0 0 0 0.0 11 9 81.8 143 107 74.8 181 159 87.9 2 2 100.0 39 27 69.2 5 45-49 5 5 100.0 11 7 63.6 140 110 78.6 134 122 91.0 1 1 100.0 52 41 78.9 4 50-54 4 2 50.0 3 3 100.0 133 96 72.2 82 75 91.5 1 1 100.0 39 34 87.2 6 55-59 0 0 0 0.0 3 2 66.7 66 51 77.3 44 37 84.1 2 2 100.0 23 19 82.6 8 60-64 0 0 0 0.0 0 0 0 0.0 37 32 86.5 16 16 100.0 0 0 0.0 16 13 81.3 0 ≥65 0 0 0 0.0 0 0 0.0 17 17 100.0 7 6 85.7 0 0 0 0.0 4 4 100.0 1	5 100.0 3 75.0	35		276 77.1
45–49 5 5 100.0 11 7 63.6 140 110 78.6 134 122 91.0 1 1 100.0 52 41 78.9 4 50–54 4 2 50.0 3 3 100.0 133 96 72.2 82 75 91.5 1 1 100.0 39 34 87.2 6 55–59 0 0 0 0.0 3 2 66.7 66 51 77.3 44 37 84.1 2 2 100.0 23 19 82.6 8 60–64 0 0 0 0.0 0 0 0.0 37 32 86.5 16 16 100.0 0 0 0.0 16 13 81.3 0 ≥65 0 0 0 0.0 0 0 0 0.0 17 17 100.0 7 6 85.7 0 0 0 0.0 4 4 100.0 1 HHS region ^b	3 75.0	38		309 81.1
50-54		34		289 83.3
55-59 0 0 0 0.0 3 2 66.7 66 51 77.3 44 37 84.1 2 2 100.0 23 19 82.6 8 60-64 0 0 0.0 0 0 0.0 37 32 86.5 16 16 100.0 0 0 0.0 16 13 81.3 0 ≥65 0 0 0 0.0 0 0 0.0 17 17 100.0 7 6 85.7 0 0 0 0.0 4 4 100.0 1 HHS region ^b	6 100.0	26		217 81.0
60-64 0 0 0.0 0 0 0.0 37 32 86.5 16 16 100.0 0 0 0.0 16 13 81.3 0 ≥65 0 0 0.0 0 0 0.0 17 17 100.0 7 6 85.7 0 0 0 0.0 4 4 100.0 1 HHS region ^b	6 75.0	14		117 80.1
≥65 0 0 0.0 0 0 0.0 17 17 100.0 7 6 85.7 0 0 0.0 4 4 100.0 1 HHS region ^b	0 0.0			61 88.4
•	1 100.0			28 96.6
u				
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1 100.0	10	10	83 83.0
· ·	6 85.7	34		281 81.9
Region 3 0 0 0.0 6 6 100.0 374 284 75.9 72 57 79.2 1 1 100.0 27 23 85.2 15 1		49		385 77.8
	5 71.4	45		386 84.3
v	1 25.0	27		208 75.6
3	2 100.0	25		188 73.7
	0 0.0			13 52.0
	0 0.0		2	9 75.0
Region 9 3 2 66.7 19 12 63.2 129 74 57.4 327 278 85.0 8 7 87.5 55 39 70.9 14 1		55		9 75.0 122 76.0
• • • • • • • • • • • • • • • • • • • •	0 71.4			36 81.8
Region 10 3 3 100.0 2 1 50.0 9 8 88.9 14 12 85.7 1 0 0.0 15 12 80.0 0	J 0.0		14	30 01.0
Poverty level				
0-100% 8 6 75.0 36 29 80.6 1097 813 74.1 599 508 84.8 7 6 85.7 193 156 80.8 37 3		1,97	,	
	5 62.5	23	38 1	199 83.6
	2 50.0	19	91 1	155 81.2
	1 50.0	6	66	53 80.3
>400% 1 1 100.0 2 2 100.0 12 9 75.0 8 5 62.5 0 0 0.0 5 4 80.0 0	0.0	2	28	21 75.0
Health care coverage				
1 mail omple) of the tenth of t	0.0			39 86.7
- That management of the first	1 50.0			73 69.5
1 1000 2 1 000 01 11 010 0 0 0 0 0 0 0 0	4 80.0	13		118 88.7
	9 79.2	,		344 78.9
Medicare and Medicaid 3 1 33.3 4 3 75.0 66 51 77.3 27 26 96.3 1 1 100.0 20 18 90.0 8	7 87.5	12	29 1	107 82.9
Veterans Administration 0	0.0		0	0 0.0
Indian Health Service 1 1 100.0 0 0 0.0 0 0 0.0 0 0 0 0 0 0 0	0.0		1	1 100.0
Other plan 0 0 0.0 2 1 50.0 43 33 76.7 61 53 86.9 0 0 0.0 9 8 88.9 0	0.0	11	5	95 82.6
No coverage 4 3 75.0 10 10 100.0 342 236 69.0 378 313 82.8 3 2 66.7 67 54 80.6 0	0.0			240 76 (
Multiple coverages 5 5 100.0 5 3 60.0 84 68 81.0 30 25 83.3 0 0 0.0 19 13 68.4 3	0 0.0	80	14 6	618 76.9

Table 16a. Retention in care among transgender adults and adolescents (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2014—United States and 3 territories (cont)

		ican In ska Na			Asian			ck/Afric		Hispa	anic/La	tino ^a		e Haw fic Isla			White		Mul	tiple ra	ces	-	Γotal	
	<u></u>	Reta	ined		Reta	ined		Retai	ned		Retai	ined		Reta	ined		Retai	ned		Reta	ined		Retain	ned
	Total			Total			Total			Total		-	Total			Total			Total			Total		
	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%
Housing status																								
Stable	15	13	86.7	41	33	80.5	978	757	77.4	673	578	86.7	10	8	80.0	217	177	81.6	38	28	73.7	1,972	1,594	80.8
Temporary	1	0	0.0	5	2	40.0	215	151	70.2	136	114	86.7	0	0	0.0	28	19	67.9	7	6	85.7	392	292	74.5
Unstable	0	0	0.0	2	2	100.0	123	75	61.0	32	22	86.7	1	1	100.0	24	20	83.3	6	5	83.3	188	125	66.5
Total ^c	16	13	81.3	50	37	74.0	1346	999	74.2	857	725	84.6	12	10	83.3	277	221	79.8	54	42	77.8	2,612	2,047	78.4

^a Hispanics/Latinos can be of any race.

^b See Technical Notes for the states/territories in each region.

^c Because totals were calculated independently of the values for the subpopulations, the values in each row and column may not sum to the column total.

Table 16b. Viral suppression among transgender adults and adolescents (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2014—United States and 3 territories

		rican Ind Iska Nati			Asian			ck/Africa merican	in	Hispa	anic/Lati	no ^a		e Hawai fic Islan			White		<u>M</u> u	Itiple rac	es		Total	
		Vir			Vir			Vira			Vira			Vir			Vir			Vir			Vir	
	Total	Suppre	ssion	Total	Suppre	ession	Total	Suppre	ssion	Total	Suppre	ssion	Total	Suppre	ssion	Total	Suppre	ession	Total	Suppre	ssion	Total	Suppre	ssion
	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%
Age group (yr)																								
13–14	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
15–19	0	0	0.0	0	0	0.0	12	4	33.3	3	1	33.3	0	0	0.0	0	0	0.0	0	0	0.0	15	5	33.3
20-24	1	1	100.0	2	1	50.0	141	72	51.1	42	27	64.3	1	0	0.0	16	7	43.8	4	2	50.0	207	110	53.1
25–29	1	1	100.0	9	7	77.8	293	188	64.2	109	73	67.0	2	2	100.0	32	24	75.0	12	7	58.3	458	302	
30–34	3	2		5	5	100.0	229	151	65.9	124	92	74.2	2	1	50.0	28	16	57.1	10	7	70.0	401	274	
35–39	1	1	100.0	4	3	75.0	182	129	70.9	140	117	83.6	1	1	100.0	34	24	70.6	9	6	66.7	371	281	75.7
40–44	0	0	0.0	10	10		146	115	78.8	191	158	82.7	2	2		37	27	73.0	7	6	85.7	393	318	
45–49	5	4	80.0	11	9	81.8	139	101	72.7	137	123	89.8	1	1	100.0	48	43	89.6	5	3	60.0	346		
50–54	3	3	100.0	3	3	100.0	131	104	79.4	77	67	87.0	1	1	100.0	39	34	87.2	6	5	83.3	260	217	
55–59	0	0	0.0	2	2	100.0	62	46	74.2	44	37	84.1	2	2	100.0	23	22	95.7	7	5	71.4	140	114	
60–64	0	0	0.0	0		0.0	35	28	80.0	15	15	100.0	0	0	0.0	16	14	87.5	0	0	0.0	66	57	
≥65	0	0	0.0	0		0.0	16	15	93.8	7	5	71.4	0	0	0.0	4	4	100.0	1	1	100.0	28	25	
HHS region ^b																								
Region 1	0	0	0.0	7	6	85.7	31	24	77.4	37	35	94.6	0	0	0.0	18	17	94.4	1	1	100.0	94	83	88.3
Region 2	1	1	100.0	8	6	75.0	169	112	66.3	167	124	74.3	1	0	0.0	29	23	79.3	9	7	77.8	384	273	
Region 3	0	0	0.0	6	6	100.0	373	289	77.5	70	54	77.1	1	1	100.0	27	20	74.1	16	12	75.0	493	382	
Region 4	2	1	50.0	2	-	50.0	325	226	69.5	62	53	85.5	0	0	0.0	64	51	79.7	7	3	42.9	462	335	
Region 5	3	3		3	3	100.0	188	111	59.0	67	58	86.6	0	0	0.0	31	23	74.2	4	3	75.0	296	201	67.9
Region 6	2	2		1	1	100.0	128	90	70.3	109	89	81.7	0	0	0.0	30	24	80.0	3	2	66.7	273	208	
Region 7	0	0	0.0	0	0	0.0	22	16	72.7	3	2	66.7	0	0	0.0	3	3	100.0	0	0	0.0	28	21	
Region 8	1	1		0	0	0.0	1	10	100.0	10	10	100.0	1	0	0.0	0	0	0.0	0	0	0.0	13		
Region 9	2	2	100.0	17	16	94.1	111	62	55.9	337	268	79.5	8	8	100.0	50	37	74.0	12	9	75.0	537	402	
Region 10	3			1	0	0.0	9	5	55.6	14	11	78.6	1	1	100.0	17	13	76.5	0	0	0.0	45	32	
Poverty level																								
0–100%	7	5	71.4	33	30	90.9	1131	768	67.9	621	491	79.1	7	6	85.7	194	149	76.8	41	25	61.0	2,034	1.474	72.5
101–138%	3	3		2	1	50.0	97	65	67.0	108	90	83.3	0	0	0.0	27	19	70.4	7	6	85.7	244	184	
139–250%	2	2	100.0	5	4	80.0	71	58	81.7	82	72	87.8	2	1	50.0	26	24	92.3	5	5	100.0	193	166	86.0
251–400%	1	1		2			25	23	92.0	20	18	90.0	2	2	100.0	12	9	75.0	3	2	66.7	65	57	
>400%	0		0.0	2			15	9	60.0	13	7	53.9	0	0	0.0	5	5	100.0	2	1	50.0	37	24	
Health care coverage																								
Private employer	0	0	0.0	3	3	100.0	19	14	73.7	8	7	87.5	1	1	100.0	13	12	92.3	1	1	100.0	45	38	84.4
Private individual	0	0	0.0	1	1	100.0	61	46	75.4	26	22	84.6	0	0	0.0	15	13	86.7	2	1	50.0	105	83	
Medicare	1	1		1	1		81	63	77.8	18	17	94.4	0	0	0.0	25	21	84.0	5	4	80.0	131	107	
Medicaid	2	2		21	17	81.0	636	445	70.0	308	247	80.2	5	4	80.0	108	83	76.9	24	16	66.7	1,104	814	
Medicare and Medicaio	_	1	50.0	4	2	50.0	68	53	77.9	28	21	75.0	1	1	100.0	21	18	85.7	8	6	75.0	132	102	
Veterans	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0		
Indian Health Service	1	1		0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	1	1	
Other plan	0	0	0.0	0	0	0.0	45	31	68.9	62	52	83.9	0	0	0.0	9	6	66.7	0	0	0.0	116	89	
No coverage	4	3	75.0	11	11	100.0	372	226	60.8	397	315	79.4	4	3	75.0	63	47	74.6	13	8	61.5	864	613	
Multiple coverages	4	4		4	4		87	66	75.9	28	22	78.6	0	0	0.0	18	12	66.7	6	4	66.7	147	112	

Table 16b. Viral suppression among transgender adults and adolescents (aged 13 years and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2014—United States and 3 territories (cont)

'-	Amer	ican Inc	lian/				Bla	ck/Africa	ın				Nativ	ve Hawa	iian/									
	Ala	ska Nati	ive		Asian		Α	merican		Hisp	anic/Lati	no ^a	Pac	ific Islan	der		White		Mul	tiple rac	es		Total	
		Vii	al		Vir	al		Vira	al		Vira	al		Vii	al		Vira	al		Vira	al		Vira	al
		Suppre	ession		Suppre	ession		Suppre	ssion		Suppre	ssion		Suppre	ession		Suppre	ssion		Suppre	ssion		Suppre	ssion
	Total			Total			Total			Total			Total			Total			Total			Total		
	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%
Housing status																								
Stable	13	11	84.6	37	31	83.8	1003	716	71.4	685	567	82.8	10	8	80.0	211	171	81.0	44	31	70.5	2,003	1,535	76.6
Temporary	1	1	100.0	5	5	100.0	222	152	68.5	147	109	74.2	0	0	0.0	32	24	75.0	7	6	85.7	414	297	71.7
Unstable	0	0	0.0	3	3	100.0	138	70	50.7	41	24	58.5	1	1	100.0	28	15	53.6	8	3	37.5	219	116	53.0
<u>Total^c</u>	14	12	85.7	46	40	87.0	1386	953	68.8	889	715	80.4	12	10	83.3	277	215	77.6	61	42	68.9	2,685	1,987	74.0

^a Hispanics/Latinos can be of any race.

^b See Technical Notes for the states/territories in each region.

^c Because totals were calculated independently of the values for the subpopulations, the values in each column may not sum to the column total.

Table 17a. Retention in care among youth and young adults aged 13-24 years, served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2014—United States and 3 territories

		an Ind a Nati		A	sian			k/Africaı nerican	n 	Hispar	nic/Latin	o ^a	Native Pacific			١	White		Multi	ple rac	es		Total	
		Reta	ined	_	Reta	ined		Retai	ned	_	Retai	ned		Reta	ained	_	Retai	ned		Reta	ined	_	Retai	ned
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
Gender	NO.	NO.	/0	NO.	NO.	/0	NO.	NO.	/0	NO.	NO.	/0	NO.	NO.	/0	NO.	NO.	/0	NO.	NO.	/0	NO.	NO.	
Male	33	19	57.6	122	97	79.5	6,693	4,915	73.4	2,170	1,622	74.8	14	10	71.4	1,300	950	73.1	236	164	69.5	10,568	7,777	73.6
Female	10	8		28	22	79.5 78.6	2,593	2,070	79.8	696	556	74.6 79.9	6	5	83.3	432	329	76.2	105	82	78.1	3,870	3,072	
Transgender	10		100.0	1	0	0.0	138	92	66.7	38	28	73.7	0	0		16	14	87.5	4	3	75.0	198	138	
Transmission risk category																								
Male-to-male sexual contact	23	16	69.6	89	69	77.5	4,998	3,597	72.0	1,600	1.171	73.2	10	6	60.0	984	722	73.4	185	129	69.7	7,889	5,710	72.4
Injection drug use	1	1		4	3	75.0	21	12	57.1	16	11	68.8	0	0		42	26	61.9	3	2	66.7	87	55	
Male-to-male sexual contact	1	0		3	2	66.7	24	20	83.3	15	8	53.3	0	0	0.0	64	49	76.6	9	6	66.7	116	85	
and injection drug use	'	U	0.0	3		00.7	27	20	00.0	10	U	55.5	U	U	0.0	0-1	73	70.0	3	U	00.7	110	00	70.0
Heterosexual contact ^b	4	3	75.0	23	18	78.3	1,699	1,246	73.3	445	346	77.8	4	3	75.0	287	206	71.8	48	32	66.7	2,510	1,854	73.9
Perinatal infection	12	6		21	19	90.5	2,295	1,933	84.2	656	551	84.0	4	4		294	243	82.7	88	74	84.1	3,370	2,830	
Other ^c	0	0		2		100.0	2,293	22	78.6	21	16	76.2	0	0		5	3	60.0	1		100.0	57	2,030	
Other	U	U	0.0	2	2	100.0	20	22	70.0	21	10	70.2	U	U	0.0	3	3	00.0	1		100.0	37	44	11.2
HHS region ^d																								
Region 1	3	2		11	9	81.8	189	151	79.9	130	108	83.1	0	0	0.0	97	78	80.4	14		100.0	444	362	
Region 2	1		100.0	29	26	89.7	1,191	954	80.1	861	717	83.3	0	0	0.0	149	120	80.5	29	22		2,260	1,840	
Region 3	1	1	100.0	6	3	50.0	1,320	1,000	75.8	170	138	81.2	0	0	0.0	178	128	71.9	53	43	81.1	1,728	1,313	76.0
Region 4	5	3	60.0	23	17	73.9	3,425	2,723	79.5	367	311	84.7	4	3	75.0	460	365	79.4	81	68	84.0	4,365	3,490	80.0
Region 5	5	5	100.0	9	6	66.7	1,364	946	69.4	156	115	73.7	3	3	100.0	271	198	73.1	41	28	68.3	1,849	1,301	70.4
Region 6	11	6	54.6	17	16	94.1	1,140	737	64.7	578	420	72.7	1	1	100.0	212	157	74.1	24	13	54.2	1,983	1,350	68.1
Region 7	0	0	0.0	3	3	100.0	159	114	71.7	12	8	66.7	1	0	0.0	31	14	45.2	13	6	46.2	219	145	66.2
Region 8	4	1	25.0	5	5	100.0	37	31	83.8	36	26	72.2	1	1	100.0	54	45	83.3	8	5	62.5	145	114	78.6
Region 9	11	7	63.6	38	27	71.1	264	147	55.7	490	286	58.4	9	7	77.8	157	85	54.1	27	14	51.9	996	573	57.5
Region 10	2	2	100.0	5	3	60.0	20	13	65.0	15	10	66.7	1	0	0.0	45	33	73.3	5	4	80.0	93	65	69.9
Poverty level																								
0–100%	34	21	61.8	79	63	79.8	6,774	5,069	74.8	2,049	1,557	76.0	14	10	71.4	1,134	818	72.1	243	171	70.4	10,327	7,709	74.6
101–138%	1	1	100.0	23	19	82.6	947	752	79.4	281	220	78.3	1	1	100.0	165	133	80.6	31	25	80.7	1,449	1,151	79.4
139–250%	4	2	50.0	19	14	73.7	914	704	77.0	294	219	74.5	2	1	50.0	250	187	74.8	34	25	73.5	1,517	1,152	75.9
251-400%	3	2	66.7	8	7	87.5	237	177	74.7	68	56	82.4	1	1	100.0	73	61	83.6	17	14	82.4	407	318	78.1
>400%	0	0	0.0	9	5	55.6	117	92	78.6	43	31	72.1	0	0	0.0	40	35	87.5	7	6	85.7	216	169	78.2
Health care coverage																								
Private employer	5	2	40.0	9	8	88.9	518	416	80.3	100	74	74.0	2	2	100.0	184	142	77.2	11	7	63.6	829	651	78.5
Private individual	2	1	50.0	12	11	91.7	401	286	71.3	92	60	65.2	2	1	50.0	139	97	69.8	28	19	67.9	676	475	70.3
Medicare	2	0	0.0	0	0	0.0	65	39	60.0	16	13	81.3	0	0	0.0	14	9	64.3	3	2	66.7	100	63	63.0
Medicaid	15	11	73.3	42	33	78.6	3,986	3,105	77.9	1,235	962	77.9	5	5	100.0	570	436	76.5	151	113	74.8	6,004	4,665	77.7
Medicare and Medicaid	3	2	66.7	0	0	0.0	114	95	83.3	43	36	83.7	0	0	0.0	31	26	83.9	10	7	70.0	201	166	82.6
Veterans Administration	0	0	0.0	0	0	0.0	11	10	90.9	0	0	0.0	0	0	0.0	8	8	100.0	0	0	0.0	19	18	94.7
Indian Health Service	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Other plan	2	2	100.0	9	5	55.6	274	217	79.2	189	150	79.4	2	1	50.0	79	61	77.2	9	7	77.8	564	443	
No coverage	12	7		60	47	78.3	3,284	2,330	71.0	993	722	72.7	5	4	80.0	526	374	71.1	86	57	66.3	4,966	3,541	
Multiple coverages	3		100.0	12	10	83.3	594	475	80.0	203	170	83.7	2	1	50.0	152	117	77.0	41	32	78.1	1,007	808	
Housing status																								
Stable	35	22	62.9	112	91	81.3	7,287	5,569	76.4	2,038	1,602	78.6	15	12	80.0	1,345	1,024	76.1	257	191	74.3	11,089	8,511	76.8
Temporary	5	4	80.0	34	26	76.5	1,503	1,092	72.7	701	510	72.8	3	2		272	191	70.2	57	40	70.2	2,575	1,865	
Unstable	4	2		2	1	50.0	429	298	69.5	105	64	61.0	1		100.0	93	56	60.2	24	14	58.3	658	436	
Total ^e	44	20	63.6	151	110	75.1	0.427	7,078	75 1	2 004	2,206	76.0	20	15	75.0	1,748	1,293	74.0	345	240	72.2	14,639	10,988	75.1

^a Hispanics/Latinos can be of any race.

^b Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

 $^{^{\}mbox{\scriptsize c}}$ Includes hemophilia, blood transfusion, and unknown risk factor.

 $^{^{\}rm d}$ See Technical Notes for the states/territories in each region.

e Because totals were calculated independently of the values for the subpopulations, the values in each column may not sum to the column total.

Table 17b. Viral suppression among youth and young adults aged 13-24 years, served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2014—United States and 3 territories

		ican Ind ska Nati			Asian			k/Africa nerican	n	Hispa	ınic/Latiı	10 ^a		e Hawaii ic Island			White		Mult	iple race	es		Total	
		Vir Suppre			Vira Suppres			Vira Suppre			Vira Suppre			Vira Suppre			Vira Suppres			Vira Suppres			Vira Suppres	
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
Gender																								
Male	40	29		142	108	76.1	7,446	4,646		2,442	1,702	69.7	16	11	68.8	1,476	1,066	72.2	269	179	66.5	11,831	7,741	65.4
Female	12 1	10		31 2	24 1	77.4 50.0	2,701 153	1,630 76	60.4 49.7	730 45	491 28	67.3 62.2	8 1	3	37.5 0.0	472 16	323 7	68.4 43.8	108 4	69 2	63.9 50.0	4,062 222	2,550 115	
Transgender	'	'	100.0	2	ı	50.0	155	70	49.7	45	20	02.2	'	U	0.0	10	,	43.0	4	2	50.0	222	115	51.0
Transmission risk category																								
Male-to-male sexual contact	30	22		108	87	80.6	5,659	3,515	62.1	1,834	1,293	70.5	13	8		1,135	827	72.9	212	146	68.9	8,991	5,898	
Injection drug use	1	1		4	4	100.0	24	14	58.3	18	14	77.8	0	0		46	28	60.9	2	1	50.0	95	62	
Male-to-male sexual contact	1	1	100.0	4	1	25.0	28	17	60.7	17	10	58.8	0	0	0.0	69	38	55.1	10	6	60.0	129	73	56.6
and injection drug use		_		00	40	00.0	4 000	4 400	50.7	407	000	040			05.0	000	005	00.5		07	040	0.004	4 007	00.0
Heterosexual contact ^o Perinatal infection	6 12	5		26 22	18 19	69.2 86.4	1,888 2,268	1,109	58.7	497 659	322 455	64.8 69.0	4 6	1 5	25.0 83.3	323 314	205 246	63.5 78.3	57 90	37 56	64.9 62.2	2,801 3,371	1,697 2,227	60.6 66.1
Other ^c	0	0		22	19	50.0	2,268	1,437 18	63.4 54.6	22	455 16	72.7	0	0		314	246	78.3 75.0	90		100.0	3,371	39	
Other	U	U	0.0	2	'	50.0	33	10	54.0	22	10	12.1	U	U	0.0	4	3	75.0	,		100.0	02	39	62.9
HHS region ^d																								
Region 1	3		100.0	14	12	85.7	198	133		145	111	76.6	0	0		109	83	76.2	16	10	62.5	485	352	
Region 2	1	1		36	27	75.0	1,327	849	64.0	969	632	65.2	0	0		182	125	68.7	32	20	62.5	2,547	1,654	
Region 3	1	1		5	4	80.0	1,375	866	63.0	174	136	78.2	0	0		201	145	72.1	57	40	70.2	1,813	1,192	
Region 4	6	5		25	20	80.0	3,703	2,293	61.9	372	282	75.8	5	3	60.0	510	369	72.4	90	61	67.8	4,711	3,033	
Region 5	7	5		11	8	72.7	1,535	945	61.6	176	123	69.9	3 1	1	33.3	288	226	78.5	50	27	54.0	2,070	1,335	
Region 6 Region 7	14 0	8		23 3	15 3	65.2 100.0	1,284 191	736 113	57.3 59.2	672 17	453 12	67.4 70.6	1		100.0 100.0	247 41	169 27	68.4 65.9	28 13	13 12	46.4 92.3	2,269 266	1,395 168	
Region 8	4	3		5	4	80.0	43	28	65.1	41	28	68.3	2	0	0.0	63	39	61.9	8	6	75.0	166	108	
Region 9	12	10		43	33	76.7	283	164	58.0	531	354	66.7	12	8		171	100	58.5	26	16	61.5	1,078	685	
Region 10	4	4		5	3	60.0	22	14	63.6	22	16	72.7	1	0		47	38	80.9	5	2	40.0	106	77	
Poverty level																								
0–100%	39	30	76.9	97	74	76.3	7,482	4,499	60.1	2,262	1,506	66.6	17	7	41.2	1,266	867	68.5	268	165	61.6	11,431	7,148	62.5
101–138%	2	1		23	19	82.6	967	640	66.2	301	225	74.8	1		100.0	190	140	73.7	37	26	70.3	1,521	1,052	
139–250%	5	4		24	18	75.0	981	677	69.0	326	260	79.8	3	2		278	214	77.0	39	30	76.9	1,656	1,205	
251–400%	3	3		9	8	88.9	262	178	67.9	75	62	82.7	2		100.0	88	70	79.6	14	11	78.6	453	334	
>400%	0	0	0.0	9	5	55.6	153	97	63.4	75	47	62.7	0	0	0.0	46	37	80.4	8	7	87.5	291	193	66.3
Health care coverage																								
Private employer	6	5	83.3	9	9	100.0	585	411	70.3	111	87	78.4	2	2	100.0	211	165	78.2	15	11	73.3	939	690	73.5
Private individual	2	2	100.0	16	12	75.0	447	319	71.4	103	77	74.8	2	1	50.0	152	123	80.9	31	19	61.3	753	553	
Medicare	2	2	100.0	0	0	0.0	71	43	60.6	16	15	93.8	0	0	0.0	13	10	76.9	3	3	100.0	105	73	69.5
Medicaid	17	16	94.1	44	31	70.5	4,189	2,612	62.4	1,317	904	68.6	9	4	44.4	627	450	71.8	158	107	67.7	6,361	4,124	64.8
Medicare and Medicaid	3	2		0	0	0.0	115	76	66.1	42	28	66.7	0	0	0.0	33	16	48.5	10	6	60.0	203	128	
Veterans Administration	0	0		0	0	0.0	14	8	57.1	1	0	0.0	0	0	0.0	8	6	75.0	1	1	100.0	24	15	
Indian Health Service	0	0		0	0	0.0	0	0	0.0	1	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	1	0	0.0
Other plan	3	1	00.0	11	7	63.6	291	189	65.0	211	151	71.6	2	1	50.0	107	82	76.6	10	6	60.0	635	437	
No coverage	16	8		76	59	77.6	3,800	2,141	56.3	1,167	768	65.8	7	5		600	386	64.3	99	57	57.6	5,765	3,424	
Multiple coverages	4	4	100.0	12	9	75.0	630	445	70.6	221	172	77.8	2	0	0.0	168	128	76.2	48	35	72.9	1,085	793	73.1
Housing status																								
Stable	41	33		133	103	77.4	7,984	5,002	62.7	2,253	1,578	70.0	21	11		1,511	1,104	73.1	286	194	67.8	12,229	8,025	
Temporary	7	6		37	26	70.3	1,646	981	59.6	792	538	67.9	3	2		317	212	66.9	61	39	63.9	2,863	1,804	
Unstable	4	1	25.0	2	2	100.0	479	243	50.7	119	68	57.1	1	1	100.0	98	54	55.1	29	14	48.3	732	383	52.3
Total ^e	53	40	75.5	175	133	76.0	10,302	6,353	61.7	3,217	2,221	69.0	25	14	56.0	1,964	1,396	71.1	381	250	65.6	16,117	10,407	64.6
Viral suppression was based o	n data for I	PLWH w	ho had a	at least 1 o	utpatient	ambula	atory medic	cal care v	isit duri	na the me	asureme	nt vear	and whose	e most re	ecent vii	al load tes	st result w	as <20	0 copies/n	al .				

^a Hispanics/Latinos can be of any race.

^b Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^c Includes hemophilia, blood transfusion, and unknown risk factor.

^d See Technical Notes for the states/territories in each region.

e Because totals were calculated independently of the values for the subpopulations, the values in each column may not sum to the column total.

Table 18a. Retention in care among young men who have sex with men aged 13–24 years, served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2014—United States and 3 territories

		ican In ska Na			Asian			ck/Africa merican	ın	Hispa	anic/Lati	no ^a		e Haw		V	Vhite		Mul	tiple ra	ces		Total	
		Reta	ined		Reta	ined		Retail	ned		Retai	ned		Reta	ined		Reta	ined		Reta	ined		Retai	ined
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
Transmission risk category		1101	,,,	1101	110.	70			70		110.	70	1101		,,,			,,,	1101		,,,		1101	
Male-to-male sexual contact	23	16	69.6	89	69	77.5	4,998	3,597	72.0	1,600	1,171	73.2	10	6	60.0	984	722	73.4	185	129	69.7	7,889	5,710	72.4
Male-to-male sexual contact and injection drug use	1	0	0.0	3	2	66.7	24	20	83.3	15	8	53.3	0	0	0.0	64	49	76.6	9	6	66.7	116	85	73.3
HHS region ^b																								
Region 1	1	1	100.0	5	4	80.0	59	45	76.3	47	38	80.9	0	0	0.0	46	36	78.3	2	2	100.0	160	126	78.8
Region 2	1	1	100.0	18	16	88.9	411	298	72.5	324	267	82.4	0	0	0.0	67	51	76.1	11	9	81.8	832	642	
Region 3	0	0	0.0	2	2	100.0	632	451	71.4	81	65	80.3	0	0		99	72	72.7	28	20	71.4	842	610	
Region 4	4	2	50.0	14	9	64.3	1,955	1,530	78.3	201	168	83.6	2	1	50.0	261	218	83.5	38	32	84.2	2,475	1,960	
Region 5	4	4	100.0	3	1	33.3	816	554	67.9	90	69	76.7	1	1		176	121	68.8	30	22	73.3	1,120	772	
Region 6	6	4	66.7	11	11	100.0	645	401	62.2	420	310	73.8	1	1	100.0	128	100	78.1	16	10	62.5	1,227	837	68.2
Region 7	0	0	0.0	2	2	100.0	107	72	67.3	7	4	57.1	1	0	0.0	24	10	41.7	8	3	37.5	149	91	
Region 8	0	0	0.0	3	3	100.0	10	7	70.0	19	13	68.4	0	0	0.0	40	31	77.5	3	1	33.3	75	55	73.3
Region 9	7	3	42.9	29	20	69.0	151	68	45.0	348	183	52.6	5	3	60.0	101	53	52.5	17	9	52.9	658	339	51.5
Region 10	1	1	100.0	1	0	0.0	9	5	55.6	12	9	75.0	0	0	0.0	35	26	74.3	4	4	100.0	62	45	72.6
Poverty level																								
0–100%	16	10	62.5	50	38	76.0	3,611	2,597	71.9	1,046	750	71.7	6	3	50.0	643	463	80.2	138	93	67.4	5,510	3,954	71.8
101–138%	1	1	100.0	13	11	84.6	491	371	75.6	187	145	77.5	1	1	100.0	106	85	73.1	18	15	83.3	817	629	77.0
139–250%	3	1	33.3	11	8	72.7	545	396	72.7	190	140	73.7	1	0	0.0	186	136	85.0	23	16	69.6	959	697	72.7
251-400%	2	2	100.0	6	5	83.3	141	100	70.9	45	37	82.2	0	0	0.0	40	34	72.0	5	5	100.0	239	183	76.6
>400%	0	0	0.0	5	3	60.0	63	48	76.2	31	21	67.7	0	0	0.0	22	18	81.8	3	3	100.0	124	93	75.0
Health care coverage																								
Private employer	4	2	50.0	7	6	85.7	330	260	78.8	59	42	71.2	1	1	100.0	124	94	75.8	6	3	50.0	531	408	76.8
Private individual	2	1	50.0	9	9	100.0	278	190	68.4	62	36	58.1	1	0	0.0	111	80	72.1	21	15	71.4	484	331	68.4
Medicare	1	0	0.0	0	0	0.0	19	9	47.4	6	5	83.3	0	0	0.0	5	3	60.0	3	2	66.7	34	19	
Medicaid	5	4	80.0	19	15	79.0	1,452	1,066	73.4	498	363	72.9	2	2	100.0	234	169	72.2	63	44	69.8	2,273	1,663	
Medicare and Medicaid	1	0	0.0	0	0	0.0	34	23	67.7	17	14	82.4	0	0		6	5	83.3	3	2	66.7	61	44	
Veterans Administration	0	0	0.0	0	0	0.0	5	4	80.0	0	0	0.0	0	0	0.0	3	3	100.0	0	0	0.0	8	7	0
Indian Health Service	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0		0	0	0.0	0	0	0.0	0	0	
Other plan	1	1	100.0	8	4	50.0	168	126	75.0	131	104	79.4	2	1	50.0	55	42	76.4	5	4	80.0	370	282	
No coverage	8	6	75.0	38	29	76.3	2,315	1,649	71.2	736	535	72.7	3	2		380	284	74.7	66	43	65.2	3,546	2,548	
Multiple coverages	2	2	100.0	7	5	71.4	313	228	72.8	88	69	78.4	0	0	0.0	102	77	75.5	24	19	79.2	536	400	74.6
Housing status																								
Stable	18	11	61.1	64	50	78.1	3,830	2,819	73.6	1,054	790	75.0	6	4		801	602	75.2	145	104	71.7	5,918	4,380	
Temporary	3	3	100.0	25	19	76.0	837	573	68.5	471	335	71.1	2	1	50.0	163	116	71.2	34	25	73.5	1,535	1,072	
Unstable	3	2	66.7	1	1	100.0	261	170	65.1	61	40	65.6	1	1	100.0	62	41	66.1	13	6	46.2	402	261	64.9
Total ^c	24	16	66.7	92	71	77.2	5,022	3,617	72.0	1,615	1,179	73.0	10	6	60.0	1,048	771	73.6	194	135	69.6	8,005	5,795	72.4

Note. Unless otherwise indicated, data presented here include clients who reported male-to-male sexual contact as well as those who reported male-to-male sexual contact and injection drug use.

Retention in care was based on data for PLWH who had at least 1 outpatient ambulatory medical care visit by September 1 of the measurement year, with a second visit at least 90 days after.

^a Hispanics/Latinos can be of any race.

^b See Technical Notes for the states/territories in each region.

^c Because totals were calculated independently of the values for the subpopulations, the values in each column may not sum to the column total.

Table 18b. Viral suppression among young men who have sex with men aged 13–24 years, served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2014—United States and 3 territories

		rican Ind aska Nati			Asian			ck/Africa merican	n	Hisp	anic/Latir	no ^a		ve Hawa ific Islar			White		Mu	Itiple race	es_		Total	
		Vira Suppre			Vira Suppres			Vira Suppres			Vira Suppres			Vir Suppre			Vira Suppres			Vira Suppres			Vira Suppres	
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
Transmission risk category																								
Male-to-male sexual contact Male-to-male sexual contact and injection drug use	30 1	22 1		108 4	87 1	80.6 25.0	5,659 28	3,515 17	62.1 60.7	1,834 17	1,293 10	70.5 58.8	13 0	8		1,135 69	827 38	72.9 55.1	212 10	146 6	68.9 60.0	8,991 129	5,898 73	
HHS region ^b																								
Region 1	1	1	100.0	8	6	75.0	65	43	66.2	55	46	83.6	0	0	0.0	55	40	72.7	3	1	33.3	187	137	73.3
Region 2	1	1	100.0	24	18	75.0	489	310	63.4	383	271	70.8	0	0	0.0	90	61	67.8	15	11	73.3	1,002	672	67.
Region 3	0	0	0.0	2	2	100.0	694	444	64.0	86	68	79.1	0	0	0.0	113	80	70.8	32	23	71.9	927	617	66.6
Region 4	5	4	80.0	16	12	75.0	2,231	1,411	63.3	223	176	78.9	3	1	33.3	296	222	75.0	45	33	73.3	2,819	1,859	65.9
Region 5	6	4	66.7	4	2	50.0	927	567	61.2	104	71	68.3	1	1	100.0	183	147	80.3	37	23	62.2	1,262	815	64.6
Region 6	8	4	50.0	15	12	80.0	715	404	56.5	495	334	67.5	1	1	100.0	152	103	67.8	17	9	52.9	1,403	867	61.8
Region 7	0	0	0.0	2	2	100.0	128	85	66.4	12	7	58.3	1	1	100.0	34	21	61.8	8	7	87.5	185	123	66.5
Region 8	0	0	0.0	3	3	100.0	11	7	63.6	21	12	57.1	1	0	0.0	44	29	65.9	3	1	33.3	83	52	62.7
Region 9	8	7	87.5	33	27	81.8	165	94	57.0	385	253	65.7	6	4	66.7	117	69	59.0	17	10	58.8	731	464	63.5
Region 10	2	2	100.0	1	1	100.0	10	5	50.0	17	13	76.5	0	0	0.0	37	31	83.8	4	2	50.0	71	54	76.
Poverty level																								
0–100%	19	15		64	50	78.1	4,103	2,492	60.7	1,201	821	68.4	7	3		740	513	69.3	155	97	62.6	6,289	3,991	
101–138%	2	1	50.0	14	12	85.7	535	346	64.7	202	156	77.2	1	1		122	90	73.8	22	17	77.3	898	623	
139–250%	4	3		16	11	68.8	623	442	71.0	223	172	77.1	2	1		206	163	79.1	28	23	82.1	1,102	815	
251–400%	2	2		7	7	100.0	159	100	62.9	51	40	78.4	1	1		49	38	77.6	4	3	75.0	273	191	
>400%	0	0	0.0	5	2	40.0	85	52	61.2	51	32	62.8	0	0	0.0	30	23	76.7	4	4	100.0	175	113	64.6
Health care coverage	_			_	_																			
Private employer	5	4	00.0	7	7		377	263	69.8	68	54	79.4	1		100.0	143	113	79.0	10	6	60.0	611	448	
Private individual	2		100.0	13	10	76.9	311	226	72.7	73	52	71.2	1	1		121	99	81.8	24	13	54.2	545	403	
Medicare	1		100.0	0	0	0.0	26	15	57.7	6	6	100.0	0	0	0.0	5	4	80.0	3	3	100.0	41	29	
Medicaid	6	6		21	15	71.4	1,625	1,007	62.0	557	411	73.8	4	2		265	195	73.6	67	50	74.6	2,545	1,686	
Medicare and Medicaid	1	0		0	0	0.0	37	29	78.4	16	12	75.0	0	0	0.0	7	5	71.4	4	2	50.0	65	48	
Veterans Administration	0	0		0	0	0.0	7	4	57.1	0	0	0.0	0	0	0.0	3	2	66.7	1	1	100.0	11	7	
Indian Health Service	0	0		0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	
Other plan	2	1	50.0	9	6	66.7	176	114	64.8	145	105	72.4	2	1	50.0	74	55	74.3	8	5	62.5	416	287	
No coverage	12	7		51	41	80.4	2,683	1,563	58.3	876	578	66.0	5	3	60.0	440	285	64.8	74	46	62.2	4,141	2,523	
Multiple coverages	2	2	100.0	7	5	71.4	339	236	69.6	95	74	77.9	0	0	0.0	117	89	76.1	28	23	82.1	588	429	73.0
Housing status	00	40	00.0	00	00	70.0	4.007	0.750	60.0	1 045	070	70.0	40	_	E0.0	000	004	70.0	407	445	60.0	6 704	4 540	
Stable	23	19		80	63		4,367	2,758	63.2	1,215	878	72.3	10	5		929	681	73.3	167	115	68.9	6,791	4,519	
Temporary	4	3		28	21	75.0	924	557	60.3	540	368	68.2	2		100.0	187	131	70.1	37	29	78.4	1,722	1,111	
Unstable	3	1	33.3	2	2	100.0	298	150	50.3	72	41	56.9	1	1	100.0	67	38	56.7	17	7	41.2	460	240	52.2
Total ^c	31	23	74.2	112	88	78.6	5,687	3,532	62.1	1,851	1,303	70.4	13	8	61.5	1,204	865	71.8	222	152	68.5	9,120	5,971	65.5

Note. Unless otherwise indicated, data presented here include clients who reported male-to-male sexual contact as well as those who reported male-to-male sexual contact and injection drug use.

^a Hispanics/Latinos can be of any race.

^b See Technical Notes for the states/territories in each region.

^c Because totals were calculated independently of the values for the subpopulations, the values in each column may not sum to the column total.

Table 19a. Retention in care among young women aged 13–24 years, served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2014—United States and 3 territories

		ican Ir ska Na			Asian			ck/Africa merican		Hispa	nic/La	tino ^a		e Haw fic Isla			White		Mul	tiple ra	ces		Total	
		Reta	ained		Reta	ained	_	Retai	ned		Reta	ined		Reta	ained		Reta	ined		Reta	ined	_	Retai	ned
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
Transmission risk category															,,,						- , ,			
Injection drug use	1	1	100.0	2	2	100.0	8	6	75.0	5	4	80.0	0	0	0.0	27	18	66.7	2	2	100.0	45	33	73.3
Heterosexual contact ^b	4	3	75.0	14	10		1,166	877	75.2	289	223	77.2	4	3	75.0	221	157	71.0	43	31	72.1	1,741	1,304	74.9
Perinatal infection	4	3		11	9		1,304	1,113	85.4	351	290	82.6	1	1		161	137	85.1	55	47	85.5	1,887	1,600	
Other ^c	0	0		1	1		11	7	63.6	13	9	69.2	0	-		0	0	0.0	1		100.0	26	18	
HHS region ^d																								
Region 1	1	1	100.0	4	4	100.0	73	56	76.7	43	36	83.7	0	0	0.0	30	27	90.0	7	7	100.0	158	131	82.9
Region 2	0	0		6	5		443	380	85.8	287	238	82.9	0			47	40	85.1	11	8	72.7	794	671	84.5
Region 3	1	1		2	0		397	321	80.9	48	39	81.3	0			49	36	73.5	18	17	94.4	515	414	80.4
Region 4	0	0		4	3		880	722	82.1	96	83	86.5	0			136	100	73.5	34	30	88.2	1.150	938	
Region 5	1	1		2	1	50.0	307	230	74.9	36	25	69.4	2			57	49	86.0	8	4	50.0	413	312	
Region 6	2		100.0	3	2		308	210	68.2	91	63	69.2	0			54	32	59.3	5	1	20.0	463	310	
Region 7	0	0		1	1	100.0	33	30	90.9	1	1	100.0	0			3	2	66.7	4	3	75.0	42	37	88.1
Region 8	2	1		2	2		17	15	88.2	10	7	70.0	0			9	9	100.0	2	2		42	36	
Region 9	1	1	100.0	3			65	47	72.3	72	58	80.6	3			25	18	72.0	7	4	57.1	176	134	76.1
Region 10	1		100.0	0			9	7	77.8	1	0	0.0	1	0		4	2	50.0	0	0	0.0	16	10	
Poverty level																								
0–100%	10	8	80.0	14	11	78.6	1,911	1,517	79.4	556	449	80.8	5	4	80.0	315	232	73.7	75	57	76.0	2,886	2,278	78.9
101–138%	0	0	0.0	3	3	100.0	252	211	83.7	46	38	82.6	0	0	0.0	33	29	0.0	8	7	87.5	342	288	84.2
139–250%	0	0	0.0	6	5	83.3	189	160	84.7	50	37	74.0	1	1	100.0	36	29	80.6	9	7	77.8	291	239	82.1
251-400%	0	0	0.0	1	1	100.0	57	48	84.2	14	10	71.4	0	0	0.0	15	13	86.7	7	7	100.0	94	79	84.0
>400%	0	0	0.0	3	1	33.3	32	27	84.4	5	3	60.0	0	0	0.0	10	10	100.0	4	3	75.0	54	44	81.5
Health care coverage																								
Private employer	0	0		1	1	100.0	111	101	91.0	21	14	66.7	0	0		32	28	87.5	3		100.0	168	147	
Private individual	0	0		2	1	50.0	54	40	74.1	16	14	87.5	1	1		15	10	66.7	5	4	80.0	93	70	
Medicare	0	0	0.0	0	0	0.0	24	17	70.8	5	4	80.0	0	0	0.0	6	3	50.0	0	0	0.0	35	24	68.6
Medicaid	5	4		11	10		1,590	1,274	80.1	434	351	80.9	3			233	187	80.3	60	46	76.7	2,336	1,875	
Medicare and Medicaid	2	2	100.0	0	0	0.0	54	49	90.7	16	13	81.3	0		0.0	15	11	73.3	4	3	75.0	91	78	
Veterans Administration	0	0	0.0	0	0	0.0	6	6	100.0	0	0	0.0	0	0	0.0	3	3	100.0	0	0	0.0	9	9	
Indian Health Service	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	
Other plan	0	0		0	0		62	52	83.9	27	23	85.2	0		0.0	16	12	75.0	3	3	100.0	108	90	
No coverage	2	1	50.0	9	6	66.7	485	357	73.6	114	84	73.7	0	0	0.0	71	46	64.8	16	12	75.0	697	506	72.6
Multiple coverages	1	1	100.0	4	4	100.0	165	150	90.9	55	48	87.3	1	0	0.0	30	24	80.0	11	9	81.8	267	236	88.4
Housing status																								
Stable	9	7		23	18		2,030	1,640	80.8	535	447	83.6	5		00.0	342	269	78.7	81	64	79.0	3,025	2,449	
Temporary	1		100.0	5	4		398	311	78.1	119	84	70.6	1	1		63	43	68.3	13	9	69.2	600	453	
Unstable	0	0	0.0	0	0	0.0	110	86	78.2	26	15	57.7	0	0	0.0	19	11	57.9	8	7	87.5	163	119	73.0
Total ^e	10	8	80.0	28	22	78.6	2,593	2,070	79.8	696	556	79.9	6	5	83.3	432	329	76.2	105	82	78.1	3,870	3,072	79.4

^a Hispanics/Latinos can be of any race.

^b Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^c Includes hemophilia, blood transfusion, and unknown risk factor.

^d See Technical Notes for the states/territories in each region.

e Because totals were calculated independently of the values for the subpopulations, the values in each column may not sum to the column total.

Table 19b. Viral suppression among young women aged 13–24 years, served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2014—United States and 3 territories

		ican In						k/Africa	ın					∕e Hawa										
	Ala	ska Nat	ive		Asian		Ar	nerican		Hispa	anic/Lat		Paci	ific Islar	der		White		Mul	tiple ra	ces		Total	
		Vir	al		Vira	al		Vira	al		Vir	al		Vir	al		Vira	al		Vir	al		Vir	ʻal
	_	Suppre	ssion	_	Suppre	ssion	_	Suppre	ssion	_	Suppre	ssion		Suppre	ssion	_	Suppre	ssion	_	Suppre	ssion		Suppre	ssion
	Total			Total			Total			Total			Total			Total			Total			Total		
	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%
Transmission risk category																								
Injection drug use	1	1	100.0	2	2	100.0	10	6	60.0	7	5	71.4	0	0	0.0	32	17	53.1	1	0	0.0	53	31	58.5
Heterosexual contact ^b	6	5	83.3	16	11	68.8	1,276	752	58.9	313	207	66.1	4	1	25.0	246	154	62.6	48	31	64.6	1,909	1,161	60.8
Perinatal infection	4	3	75.0	12	11	91.7	1,293	790	61.1	356	239	67.1	3	2	66.7	173	138	79.8	56	37	66.1	1,897	1,220	64.3
Other ^c	0	0	0.0	1	0	0.0	11	8	72.7	13	8	61.5	0	0	0.0	0	0	0.0	1	1	100.0	26	17	65.4
HHS region ^d																								
Region 1	1	1	100.0	4	4	100.0	76	49	64.5	48	33	68.8	0	0	0.0	33	27	81.8	7	4	57.1	169	118	69.8
Region 2	0	0	0.0	6	5	83.3	465	300	64.5	314	190	60.5	0	0	0.0	56	40	71.4	10	5	50.0	851	540	
Region 3	1	-		2	2	100.0	398	239	60.1	50	36	72.0	0	0	0.0	54	40	74.1	17	12	70.6	522	330	
Region 4	0	0	0.0	4	3	75.0	876	506	57.8	80	60	75.0	0	0	0.0	147	94	64.0	36	25	69.4	1.143	688	
Region 5	1	•	100.0	2	1	50.0	345	220	63.8	41	28	68.3	2	0	0.0	60	46	76.7	10	3	30.0	461	299	
Region 6	3	2	66.7	5	3	60.0	338	204	60.4	94	67	71.3	0	0	0.0	59	40	67.8	5	1	20.0	504	317	
Region 7	0	0	0.0	1	1	100.0	40	16	40.0	1	1	100.0	0	0	0.0	4	3	75.0	4	4		50	25	
Region 8	2		100.0	2	1	50.0	19	12	63.2	12	10	83.3	0	0	0.0	12	6	50.0	2	2		49	33	
Region 9	1		100.0	4	3	75.0	72	40	55.6	74	52	70.3	5	3	60.0	26	15	57.7	6	5	83.3	188	119	
· ·	2		100.0	0	0	0.0	10	8	80.0	2	2	100.0	1	0	0.0	4	3	75.0	0	0	0.0	19	15	
Region 10	2	2	100.0	U	U	0.0	10	0	60.0	2	2	100.0	,	U	0.0	4	3	75.0	U	U	0.0	19	15	76.9
Poverty level																								
0–100%	12	10	83.3	16	12	75.0	2,031	1,198	59.0	588	376	64.0	7	2	28.6	340	229	67.4	78	47	60.3	3,072	1,874	
101–138%	0	0	0.0	3	2	66.7	241	159	66.0	48	33	68.8	0	0	0.0	39	24	61.5	9	7	77.8	340	225	
139–250%	0	0	0.0	6	6	100.0	178	108	60.7	47	42	89.4	1	1	100.0	41	29	70.7	9	6	66.7	282	192	
251–400%	0	0	0.0	1	1	100.0	59	45	76.3	13	12	92.3	0	0	0.0	19	16	84.2	6	5	83.3	98	79	
>400%	0	0	0.0	3	2	66.7	37	28	75.7	10	6	60.0	0	0	0.0	8	6	75.0	4	3	75.0	62	45	72.6
Health care coverage																								
Private employer	0	0	0.0	1	1	100.0	124	86	69.4	22	16	72.7	0	0	0.0	36	25	69.4	3	3	100.0	186	131	70.4
Private individual	0	0	0.0	2	1	50.0	64	44	68.8	16	13	81.3	1	0	0.0	15	13	86.7	5	4	80.0	103	75	72.8
Medicare	0	0	0.0	0	0	0.0	23	14	60.9	6	5	83.3	0	0	0.0	5	3	60.0	0	0	0.0	34	22	64.7
Medicaid	6	5	83.3	11	9	81.8	1,610	969	60.2	447	293	65.6	5	2	40.0	256	179	69.9	63	42	66.7	2,398	1,499	62.5
Medicare and Medicaid	2	2	100.0	0	0	0.0	55	31	56.4	17	11	64.7	0	0	0.0	17	7	41.2	3	2	66.7	94	53	56.4
Veterans Administration	0	0	0.0	0	0	0.0	7	4	57.1	1	0	0.0	0	0	0.0	3	2	66.7	0	0	0.0	11	6	54.5
Indian Health Service	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Other plan	0	0	0.0	1	0	0.0	64	42	65.6	31	23	74.2	0	0	0.0	20	16	80.0	2	1	50.0	118	82	69.5
No coverage	2	1	50.0	11	8	72.7	554	298	53.8	122	82	67.2	0	0	0.0	79	47	59.5	18	9	50.0	786	445	56.6
Multiple coverages	2	2	100.0	4	4	100.0	170	121	71.2	62	44	71.0	1	0	0.0	30	22	73.3	11	6	54.6	280	199	71.1
Housing status																								
Stable	10	8	80.0	26	20	76.9	2,125	1,294	60.9	562	374	66.6	7	3	42.9	368	263	71.5	85	58	68.2	3,183	2,020	63.5
Temporary	2	2	100.0	5	4	80.0	422	251	59.5	128	87	68.0	1	0	0.0	75	43	57.3	12	4	33.3	645	391	
Unstable	0	0	0.0	0	0	0.0	112	57	50.9	25	17	68.0	0	0	0.0	20	10	50.0	9	6	66.7	166	90	

^a Hispanics/Latinos can be of any race.

^b Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^c Includes hemophilia, blood transfusion, and unknown risk factor.

^d See Technical Notes for the states/territories in each region.

e Because totals were calculated independently of the values for the subpopulations, the values in each column may not sum to the column total.

Table 20a. Retention in care among people who inject drugs (13 and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2014—United States and 3 territories

		can Ind ka Nati			Asian			k/Africa nerican	ın	Hispa	nic/Lati	no ^a		e Haw fic Isla			White		Mul	tiple ra	ces		Total	
		Reta	ined		Reta	ined	_	Retai	ned		Retai	ned		Reta	ained	_	Retai	ned		Reta	ined	_	Retair	ned
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
Age group (yr)			70		110.	70		1101	70		1101	70	1101		70			,,,	110.	.,,,,	70		110.	
13–14	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	1	0	0.0	0	0	0.0	1	0	0.0
15–19	0	0		1	1	100.0	4	3	75.0	2	2	100.0	0	0		1			0	0	0.0	8	7	
20–24	1	1		3	2	66.7	17	9	52.9	14	9	64.3	0	0		40	25	62.5	3	2	66.7	78	48	
25–29	4	2		5	5	100.0	49	34	69.4	57	38	66.7	2	2		160	102	63.8	4	3	75.0	281	186	
30–34	8	6		17	15	88.2	104	80	76.9	175	125	71.4	1	1		312	223	71.5	21	17	81.0	638	467	73.2
35–39	13	11		18	12	66.7	176	125	71.0	330	261	79.1	2	1		374	255	68.2	32	25	78.1	945	690	
40–44	16	10		16	7	43.8	393	304	77.4	532	422	79.3	0	0		609	447	73.4	38	31	81.6	1.604	1.221	76.1
45–49	21	16		14	13	92.9	943	781	82.8	916	748	81.7	5	4		953	751	78.8	77	59	76.6	2,929	2,372	
50-54	33	22		11	10	90.9	1.769	1.442	81.5	1,367	1.185	86.7	6	4		1.265	1,022	80.8	107	87	81.3	4,558	3.772	
55–59	19	14		3	3	100.0	2,336	1,973	84.5	1,065	932	87.5	5	4		955	786	82.3	86	76	88.4	4,469	3,788	
60–64	8	7		4	3	75.0	1,675	1,444	86.2	609	548	90.0	0	0		433	362	83.6	52	43	82.7	2.781	2,407	
≥65	4	3		2	1	50.0	690	587	85.1	263	241	91.6	0	0		138	119	86.2	19	13	68.4	1,116	964	
HHS region ^b																								
Region 1	2	2	100.0	3	2	66.7	608	530	87.2	937	825	88.1	1	1	100.0	692	598	86.4	30	24	80.0	2,273	1,982	87.2
Region 2	7	6		9	8	88.9	1,558	1,335	85.7	2,546	2,227	87.5	1		100.0	590	479	81.2	48	39	81.3	4,759	4,095	
Region 3	0	0		7	6	85.7	2,295	1,942	84.6	502	421	83.9	0	0		712	575	80.8	154	130	84.4	3,670	3,074	
Region 4	17	12		11	10	90.9	1.714	1.447	84.4	311	254	81.7	2	2		907	731	80.6	62	57	91.9	3,024	2,513	
Region 5	13	8		11	9	81.8	781	622	79.6	229	179	78.2	0	0		359	261	72.7	29	19	65.5	1,422	1,098	
Region 6	17	13		9	9	100.0	477	344	72.1	248	176	71.0	1	1		528	366	69.3	17	12	70.6	1,297	921	71.0
Region 7	2	1	50.0	3	3	100.0	34	19	55.9	10	7	70.0	0	0		68	45	66.2	4	3	75.0	121	78	
Region 8	13	10		1	1	100.0	55	49	89.1	53	45	84.9	0	0		177	139	78.5	4	3	75.0	303	247	81.5
Region 9	35	24	68.6	31	18	58.1	452	349	77.2	361	266	73.7	9	6		842	615	73.0	41	25	61.0	1,771	1,303	
Region 10	19	14		6	5	83.3	57	45	79.0	31	28	90.3	7	5		241	193	80.1	19	17	89.5	380	307	80.8
•				Ū	ŭ	00.0	0.	.0	. 0.0	0.		00.0		Ū			.00				00.0	000	00.	00.0
Poverty level																								
0–100%	105	73		64	47	73.4	6,178	5,150	83.4	4,428	3,763	85.0	14	10		3,814	2,943	77.2	339	275	81.1	14,942	12,261	82.1
101–138%	10	10		11	10	90.9	769	667	86.7	358	313	87.4	3	2		512	424	82.8	39	33	84.6	1,702	1,459	
139–250%	8	6		12	10	83.3	581	505	86.9	255	219	85.9	4	4		465	388	83.4	25	21	84.0	1,350	1,153	
251–400%	1	1	100.0	4	3	75.0	222	171	77.0	93	74	79.6	0	0		186	147	79.0	13		100.0	519	409	
>400%	0	0	0.0	2	2	100.0	66	52	78.8	37	33	89.2	0	0	0.0	64	53	82.8	6	2	33.3	175	142	81.1
Health care coverage			400.0	_	_	100.0	40.4	476	07.0	22		0.1.1	_	_	400.0	24-	476	70 -	_	_	00.0	400	446	00.0
Private employer	1	1	100.0	6	6	100.0	194	170	87.6	69	58	84.1	2	2		217	173	79.7	9	8	88.9	498	418	
Private individual	5	3		6	5	83.3	191	157	82.2	78	67	85.9	0	0		173	138	79.8	14	9	64.3	467	379	
Medicare	1	1		2	2	100.0	981	836	85.2	404	346	85.6	1	0		567	476	84.0	37	31	83.8	1,993	1,692	
Medicaid	62	44		42	30	71.4	3,972	3,345	84.2	3,255	2,813	86.4	12	10		2,136	1,691	79.2	212	172	81.1	9,691	8,105	
Medicare and Medicaid	13	11		4	4	100.0	1,010	894	88.5	521	467	89.6	0	0		652	566	86.8	62	53	85.5	2,262	1,995	
Veterans Administration	0	0		0	0	0.0	8	6	75.0	1	1	100.0	0	0		4		100.0	0	0	0.0	13	11	84.6
Indian Health Service	5	3		0	0	0.0	0	0	0.0	0	0	0.0	0	0		1	1	100.0	0	0	0.0	6	4	66.7
Other plan	0	0		1	1	100.0	145	115	79.3	156	115	73.7	1	1		156	105	67.3	5	5	100.0	464	342	
No coverage	15	10		25	17	68.0	1,080	799	74.0	487	368	75.6	2	2		841	572	68.0	50	39	78.0	2,500	1,807	72.3
Multiple coverages	24	19	79.2	6	6	100.0	484	410	84.7	284	232	81.7	3	1	33.3	432	334	77.3	45	36	80.0	1,278	1,038	81.2

Table 20a. Retention in care among people who inject drugs (13 and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2014—United States and 3 territories (cont)

		American Indian/ Alaska Native				Black/African Asian American						Native Hawaiian/ Hispanic/Latino ^a Pacific Islander						White			ces		Total	
	Total	Retained		Total	Retained		Total	Retained		Reta Total			Retained Total		Retained Total		ned	Retained Total			Total	Retained		
	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%	No.	No.	%
Housing status																								
Stable	86	64	74.4	67	53	79.1	6,365	5,390	84.7	4,116	3,595	87.3	17	14	82.4	4,001	3,224	80.6	291	243	83.5	14,943	12,583	84.2
Temporary	19	14	73.7	22	15	68.2	1,107	893	80.7	856	662	77.3	3	1	33.3	781	547	70.0	83	64	77.1	2,871	2,196	76.5
Unstable	20	13	65.0	4	4	100.0	481	366	76.1	274	207	75.6	1	1	100.0	379	273	72.0	53	40	75.5	1,212	904	74.6
Total ^c	127	92	72.4	94	72	76.6	8,156	6,782	83.2	5,330	4,511	84.6	21	16	76.2	5,241	4,093	78.1	439	356	81.1	19,408	15,922	82.0

Note. Data presented in this table represent clients who reported injection drug use as their transmission risk category; data may not be reflective of current injection drug use behavior.

Data are included only for clients with the transmission risk category injection drug use; data do not include those who reported male-to-male sexual contact and injection drug use.

^a Hispanics/Latinos can be of any race.

^b See Technical Notes for the states/territories in each region.

^c Because totals were calculated independently of the values for the subpopulations, the values in each column may not sum to the column total.

Table 20b. Viral suppression among people who inject drugs (aged 13 and older) served by the Ryan White HIV/AIDS Program (non-ADAP), by race/ethnicity and selected characteristics, 2014—United States and 3 territories

	American Indian/ Alaska Native Viral Suppression			Asian Viral Suppression			Black/African American Viral Suppression			Hispanic/Latino ^a			Native Hawaiian/ Pacific Islander			White			Multiple races			Total		
										Viral Suppress			_	Viral Suppression		Viral Suppression			Viral Suppression				Viral Suppression	
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
Age group (yr)																								
13–14	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	
15–19	0	0	0.0	1	1	100.0	5	2	40.0	2	2	100.0	0	0	0.0	3	2	66.7	0	0	0.0	11	7	63.6
20–24	1	1	100.0	3	3	100.0	19	12	63.2	16	12	75.0	0	0		43	26	60.5	2	1	50.0	84	55	
25–29	4	3	75.0	6	5	83.3	55	36	65.5	64	45	70.3	1	0	0.0	172	111	64.5	5	5	100.0	307	205	66.8
30–34	7	5	71.4	17	15		112	76	67.9	180	123	68.3	1	1	100.0	320	233	72.8	23	17	73.9	660	470	
35–39	14	13		19	17	89.5	182	109	59.9	347	239	68.9	2	2	100.0	398	280	70.4	32	25	78.1	994	685	
40–44	16	12	75.0	15	10	66.7	392	288	73.5	547	404	73.9	0	0	0.0	634	484	76.3	38	25	65.8	1,642	1,223	74.5
45-49	22	18	81.8	15	14	93.3	971	736	75.8	953	725	76.1	6	5	83.3	969	798	82.4	78	64	82.1	3,014	2,360	78.3
50–54	30	23	76.7	11	9	81.8	1,817	1,399	77.0	1,384	1,160	83.8	6	6	100.0	1,294	1,117	86.3	108	99	91.7	4,650	3,813	82.0
55–59	21	19	90.5	5	5	100.0	2,358	1,903	80.7	1,077	929	86.3	6	5	83.3	968	856	88.4	85	76	89.4	4,520	3,793	83.9
60-64	9	8	88.9	4	3	75.0	1,673	1,453	86.9	606	520	85.8	0	0	0.0	430	391	90.9	54	45	83.3	2,776	2,420	87.2
≥65	4	3	75.0	2	2	100.0	699	621	88.8	262	234	89.3	0	0	0.0	138	128	92.8	17	15	88.2	1,122	1,003	89.4
HHS region ^b																								
Region 1	2	2	100.0	3	3	100.0	617	520	84.3	940	789	83.9	0	0	0.0	696	613	88.1	30	28	93.3	2,288	1,955	85.4
Region 2	7	5		9	9	100.0	1,616	1,261	78.0	2,607	2,066	79.3	1	1	100.0	601	516	85.9	54	43	79.6	4,895	3,901	79.7
Region 3	0	0	0.0	9	8	88.9	2,246	1,879	83.7	493	409	83.0	0	0	0.0	731	624	85.4	151	130	86.1	3,630	3,050	84.0
Region 4	18	13	72.2	11	8	72.7	1,771	1,384	78.2	314	253	80.6	2	2	100.0	960	771	80.3	67	55	82.1	3,143	2,486	
Region 5	12	9	75.0	10	10		815	664	81.5	240	210	87.5	0	0		376	323	85.9	30	24	80.0	1,483	1,240	
Region 6	18	16		10	10		503	379	75.4	260	190	73.1	1	0		575	434	75.5	19	16	84.2	1,386	1,045	
Region 7	2	1	50.0	3	3		37	29	78.4	10	10	100.0	0	0		80	69	86.3	4	3	75.0	136	115	
Region 8	12	10		1	1	100.0	56	44	78.6	62	55	88.7	0	0		188	148	78.7	4	3	75.0	323	261	80.8
Region 9	35	30		32	24	75.0	432	339	78.5	375	302	80.5	11	9		801	636	79.4	33	29	87.9	1,719	1,369	
Region 10	20	17		6	4	66.7	56	44	78.6	31	25	80.7	7	7		236	194	82.2	19	14	73.7	375	305	
Poverty level																								
0–100%	104	85	81.7	68	58	85.3	6,265	4,969	79.3	4,535	3,620	79.8	15	12	80.0	3,915	3,139	80.2	344	285	82.9	15,246	12,168	79.8
101–138%	11	9		11	11	100.0	789	652	82.6	364	312	85.7	2	2		518	455	87.8	39	34	87.2	1,734	1,475	
139–250%	9	8	88.9	12	9	75.0	610	526	86.2	260	230	88.5	5	5		475	439	92.4	24	24	100.0	1,395	1,241	
251–400%	1	1	100.0	4	3	75.0	232	193	83.2	100	84	84.0	0	0		198	176	88.9	13	11	84.6	548	468	
>400%	0	0	0.0	2	-	100.0	75	56	74.7	49	39	79.6	0	0		68	61	89.7	8	7	87.5	202	165	
Health care coverage																								
Private employer	1	1	100.0	6	6	100.0	205	173	84.4	70	61	87.1	2	2	100.0	219	204	93.2	9	8	88.9	512	455	88.9
Private individual	6	6		6	6		188	168	89.4	79	65	82.3	0	0		187	166	88.8	14	12	85.7	480	423	
Medicare	2	1	50.0	2	2		1,003	847	84.5	399	352	88.2	1	1	100.0	559	494	88.4	36	32	88.9	2,002	1,729	
Medicaid	62	49		42	35	83.3	3,967	3,124	78.8	3,323	2,628	79.1	12	10		2,154	1,761	81.8	209	170	81.3	9,769	7,777	
Medicare and Medicaid	12	11		5	4	80.0	1,032	878	85.1	534	462	86.5	0	0		662	586	88.5	59	54	91.5	2,304	1,995	
	0	0	0.0	0	0	0.0		878	100.0		462	100.0	0	0		662 4	386	100.0	59 0	54 0	0.0	2,304	1,995	
Veterans Administration	6	-		0	0	0.0	8	8	0.0	2	0	0.0	0	0		1	0	0.0	0	0	0.0	8		
Indian Health Service	•	6		1	1			•		•	-		-	-		-	•			•			6	
Other plan	1	1	100.0			100.0	147	121	82.3	167	133	79.6	1	1		167	123	73.7	5	5	100.0	489	385	
No coverage	15	10		28	23	82.1	1,160	851	73.4	520	394	75.8	2	1		917	670	73.1	56	44	78.6	2,698	1,993	
Multiple coverages	23	20	87.0	6	5	83.3	494	407	82.4	295	252	85.4	4	4	100.0	441	372	84.4	51	45	88.2	1,314	1,105	84.′
Housing status																								
Stable	86	73	84.9	69	58	84.1	6,462	5,284	81.8	4,188	3,487	83.3	18	17	94.4	4,073	3,472	85.2	296	261	88.2	15,192	12,652	83.3
Temporary	21	15	71.4	23	21	91.3	1,136	865	76.1	905	673	74.4	3	1	33.3	829	631	76.1	84	68	81.0	3,001	2,274	75.8
Unstable	20	16		5	4	80.0	491	332	67.6	286	181	63.3	1		100.0	392	260	66.3	53	35	66.0	1,248	829	
Total ^c	128	105	82.0	98	84	85.7	8,283	6,635	80.1	5,438	4,393	80.8	22	19	86.4	5,369	4,426	82.4	442	372	84.2	19,780	16,034	81.1

Note. Data presented inthis table represent persons who reported injection drug use as their transmission risk category; data may not be reflective of current injection drug use behavior.

Data are included only for persons with the transmission risk category injection drug use; data do not include those who reported male-to-male sexual contact and injection drug use.

^a Hispanics/Latinos can be of any race.

^b See Technical Notes for the states/territories in each region.

^c Because totals were calculated independently of the values for the subpopulations, the values in each column may not sum to the column total.